Lupin Ltd

Tue 29/04/2025,15:59:30 NSE: LUPIN

₹ 2067.10 -38.30 (-1.82%)

BUY NOW Buy Lupin Ltd Stock

Open Free Demat and Trading account in 15 minutes

Overview
Market Data
Market Depth
Option Chain
News
Fundamental
Shareholding Pattern
Corporate Action
Peers
Company Info
FAQ’s

Home Stock Lupin Ltd

Tue 29/04/2025,16:1:0

NSE

BSE

Lupin Ltd

Tue 29/04/2025,15:59:30 | NSE : LUPIN

₹ 2067.10-38.30 (-1.82%)

Data is delayed. Analysis is best done in real-time! Open a FREE Sharekhan Demat A/c in 15 mins* and continue your analysis with real-time data.

Market Data

Essential tool: analyze, trade, manage, decide.

Open

₹ 2107.70

Previous Close

₹ 2105.40

Volume

1122651

Mkt Cap ( Rs. Cr)

₹94376.56

High

₹ 2115.90

Low

₹ 2053.20

52 Week High

₹ 2402.90

52 Week Low

₹ 1493.30

Book Value Per Share

₹ 342.60

Dividend Yield

0.37

Face Value

₹ 2.00

TTM EPS

62.83

TTM PE

33.55

P/B

6.15

What’s Your Call?

Collective community sentiment on Lupin Ltd

Your Vote -

Buy

48.57%

Hold

12.07%

Sell

39.36%

48.57%

6644 users have voted

Market Depth

How many stocks are available to buy or sell and at what prices.

Buy Order Quantity

100%

Sell Order Quantity

Bid Price

Qty

2067.10

0.00

Bid Total

Bid Price

Qty

0.00

Bid Total

Option Chain

Analyzes market sentiment, predicts Lupin Ltd' movement.

Call Price	Open interest	Strike Price	Put Price	Open interest

News

Media spotlight triggers stock stock attention, sentiment.

Lupin Ltd. - Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS

28 Apr 2025, 3:18PM Intimation regarding allotment of 51495 shares under ESOP.
Lupin Ltd. - Press Release

24 Apr 2025, 10:44AM Lupin Limited has informed the Exchange regarding a press release dated April 24, 2025, titled ""Lupin Receives Approval from U.S. FDA for Tolvaptan T
Lupin receives U.S. FDA approval for Tolvaptan Tablets

24 Apr 2025, 11:20AM Lupin Limited, a leading global pharmaceutical company, has announced that it has received approval from the U.S. Food and Drug Administration (FDA) f
Lupin Ltd. - Announcement under Regulation 30 (LODR)-Press Release / Media Release

24 Apr 2025, 10:46AM Lupin Receives Approval from U. S. FDA for Tolvaptan Tablets.
Lupin Ltd. - Press Release

23 Apr 2025, 10:16AM Lupin Limited has informed the Exchange regarding a press release dated April 23, 2025, titled ""Lupin Diagnostics Achieves NABL Accreditation for All
Lupin Ltd. - Announcement under Regulation 30 (LODR)-Press Release / Media Release

23 Apr 2025, 10:16AM Lupin Diagnostics Achieves NABL Accreditation for All Greenfield Labs.
Lupin Diagnostics secures NABL accreditation across all greenfield labs

23 Apr 2025, 10:25AM Lupin Diagnostics Limited (LDL), a wholly owned subsidiary of global pharmaceutical leader Lupin Limited, has achieved full NABL (National Accreditati
Lupin Ltd. - Press Release

17 Apr 2025, 2:37PM Lupin Limited has informed the Exchange regarding a press release dated April 17, 2025, titled ""Lupin Receives EIR from US FDA for its Injectable Fac
Lupin Ltd. - Announcement under Regulation 30 (LODR)-Press Release / Media Release

17 Apr 2025, 2:37PM Lupin Receives EIR from US FDA for its Injectable Facility in Nagpur.
Lupin Ltd. - News Verification

17 Apr 2025, 9:39AM The Exchange has sought clarification from Lupin Limited with respect to recent news item captioned Lupin, Zydus Life shares fall up to 5% as US court
Lupin Ltd. - The Company Has Informed The Exchange About Court Order In The Matter Of A Patent Case.

16 Apr 2025, 9:41PM The Company has informed the Exchange about court order in the matter of a patent case.
Lupin Ltd. - Pendency of Litigation(s)/dispute(s) or the outcome impacting the Company

16 Apr 2025, 9:37PM Lupin Limited has informed the Exchange about court order in the matter a patent case.
Lupin Ltd. - Rumour Verification - Regulation 30(11)

16 Apr 2025, 8:49PM Lupin Limited has informed the Exchange about Rumour Verification - Regulation 30(11)
Lupin Ltd. - Rumour verification - Regulation 30(11)

16 Apr 2025, 6:14PM Clarification/ confirmation on the news item appearing in www.cnbctv18.com
Lupin Ltd. - News Verification

16 Apr 2025, 3:49PM The Exchange has sought clarification from Lupin Limited with respect to recent news item captioned Lupin, Zydus Life shares fall up to 5% as US court
Lupin Ltd. has submitted to BSE the Shareholding Pattern for the Period Ended March 31, 2025

16 Apr 2025, 5:42PM As of March 2025, 46.92% is owned by Promoters and 53.08% by Public. Among Promoters holding, Indian Promoters holds 46.63% and Fore
Lupin Ltd. - Clarification sought from Lupin Ltd

16 Apr 2025, 4:03PM The Exchange has sought clarification from Lupin Ltd on April 16, 2025, with reference to news appeared in www.cnbctv18.com dated April 16, 2025 quoti
Lupin Ltd. - Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure A

7 Apr 2025, 6:53PM Format of Initial Disclosure to be made by an entity identified as a Large Corporate. <table border='1px'><tr> <td>Sr. No.</td
Lupin Ltd. - Certificate under SEBI (Depositories and Participants) Regulations, 2018

7 Apr 2025, 11:02AM Lupin Limited has informed the Exchange about Certificate under SEBI (Depositories and Participants) Regulations, 2018
Lupin Ltd. - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018

7 Apr 2025, 10:52AM Certificate under Reg. 74(5) of SEBI (Depositories and Participant) Regulations, 2018 for the quarter ended on March 31, 2025.
Lupin Ltd. - Announcement under Regulation 30 (LODR)-Acquisition

2 Apr 2025, 7:13PM Lupin Healthcare (UK) Limited, a wholly owned subsidiary of the Company, has acquired the entire share capital of Renascience Pharma Limited, United
Lupin Ltd. - Acquisition-XBRL

2 Apr 2025, 7:10PM Lupin Limited has informed the Exchange regarding Acquisition
Lupin Ltd. - Acquisition

2 Apr 2025, 7:07PM Lupin Limited has informed the Exchange about Lupin Healthcare (UK) Limited, a wholly owned subsidiary of the Company having acquired the entire share
Lupin Ltd. - Update-Acquisition/Scheme/Sale/Disposal-XBRL

31 Mar 2025, 7:59PM Lupin Limited has informed the Exchange regarding Update-Acquisition/Scheme/Sale/Disposal-XBRL
Lupin Ltd. - Slump Sale-XBRL

31 Mar 2025, 7:53PM Lupin Limited has informed the Exchange regarding Slump Sale
Lupin Ltd. - Announcement under Regulation 30 (LODR)-Restructuring

31 Mar 2025, 7:49PM Modification to the slump sale transaction of transfer of the Over-the-Counter Consumer Healthcare Business.
Lupin Ltd. - Other Restructuring

31 Mar 2025, 7:47PM Lupin Limited has informed the Exchange regarding modification to the slump sale transaction of transfer of the Over-the-Counter Consumer Healthcare B
Lupin Ltd. - Announcement under Regulation 30 (LODR)-Restructuring

31 Mar 2025, 7:44PM Transfer of Company's API R&D Division to Lupin Manufacturing Solutions Limited, wholly owned subsidiary of the Company on slump sale basis.
Lupin Ltd. - Other Restructuring

31 Mar 2025, 7:43PM Lupin Limited has informed the Exchange regarding transfer of Company s API R&D Division to Lupin Manufacturing Solutions Limited, wholly owned subsid
Lupin Ltd. - Board Meeting Outcome for Outcome Of The Board Meeting Held On March 31, 2025.

31 Mar 2025, 7:38PM Outcome of the Board Meeting held on March 31, 2025.
Lupin Ltd. - Outcome of Board Meeting

31 Mar 2025, 7:37PM Lupin Limited has informed the Exchange regarding Outcome of Board Meeting held on March 31, 2025.
Lupin Ltd. - Trading Window-XBRL

28 Mar 2025, 4:41PM LUPIN LIMITED has informed the Exchange about Closure of Trading Window
Lupin Ltd. - Trading Window

28 Mar 2025, 4:40PM Lupin Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015
Lupin Ltd. - Change in Directors/ Key Managerial Personnel/ Auditor/ Compliance Officer/ Share Transfer Agent

28 Mar 2025, 4:18PM LUPIN LIMITED has informed the Exchange about Change in Directors/ Key Managerial Personnel/ Auditor/ Compliance Officer/ Share Transfer Agent
Lupin Ltd. - Retirement

28 Mar 2025, 3:56PM Lupin Limited has informed the Exchange about Retirement of Senior Management Personnel(s).
Lupin Ltd. - Announcement under Regulation 30 (LODR)-Change in Management

28 Mar 2025, 3:54PM Retirement of Senior Management Personnel(s).
Lupin Ltd. - Press Release

22 Mar 2025, 7:54PM Lupin Limited has informed the Exchange regarding a press release dated March 22, 2025, titled ""Lupin Digital Health Introduces Comprehensive Post-Pr
Lupin Ltd. - Announcement under Regulation 30 (LODR)-Press Release / Media Release

22 Mar 2025, 7:53PM Lupin Digital Health Introduces Comprehensive Post-Procedure Home-Based Care Guide in Collaboration with the American College of Cardiology.
Lupin Ltd. - Announcement under Regulation 30 (LODR)-Press Release / Media Release

21 Mar 2025, 4:18PM Nanomi Receives CMO Award for Life Science Leadership in Drug Delivery.
Lupin Ltd. - Press Release

21 Mar 2025, 4:15PM Lupin Limited has informed the Exchange regarding a press release dated March 21, 2025, titled ""Nanomi Receives CMO Award for Life Science Leadership
Lupin Ltd. - Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS

21 Mar 2025, 3:23PM Intimation regarding allotment of 24101 shares under ESOP.
Lupin Ltd. - Alteration Of Capital and Fund Raising-XBRL

21 Mar 2025, 3:19PM LUPIN LIMITED has informed the Exchange regarding Allotment of Securities
Lupin Ltd. - ESOP/ESOS/ESPS

21 Mar 2025, 3:17PM Lupin Limited has informed the Exchange regarding Allotment of 24101 Shares.
Lupin Ltd. - Shareholder Meeting / Postal Ballot-Scrutinizer\s Report

20 Mar 2025, 8:57PM Details of voting results of the business transacted by way of Postal Ballot along with report of the Scrutinizer.
Lupin Ltd. - Shareholders meeting

20 Mar 2025, 8:56PM Lupin Limited has informed the Exchange about details of voting results of the business transacted by way of Postal Ballot along with the report of th
Lupin Ltd. - Press Release

20 Mar 2025, 11:51AM Lupin Limited has informed the Exchange regarding a press release dated March 20, 2025, titled ""Lupin Awarded EcoVadis Silver Medal for Sustainabilit
Lupin awarded EcoVadis silver medal for sustainability excellence

20 Mar 2025, 12:09PM Global pharmaceutical leader Lupin Limited (Lupin) has earned a prestigious Silver Medal from EcoVadis for its exemplary sustainability management acr
Lupin Ltd. - Announcement under Regulation 30 (LODR)-Press Release / Media Release

20 Mar 2025, 11:49AM Lupin Awarded EcoVadis Silver Medal for Sustainability Excellence, Rank Among the Top 15% Globally.
Lupin Ltd. - Update-Acquisition/Scheme/Sale/Disposal-XBRL

18 Mar 2025, 4:39PM Lupin Limited has informed the Exchange regarding Update-Acquisition/Scheme/Sale/Disposal-XBRL
Lupin Ltd. - General Updates

18 Mar 2025, 4:17PM Lupin Limited has informed the Exchange about incorporation of wholly-owned subsidiary in the name and style LUPINLIFE Consumer Healthcare Limited u
Lupin Ltd. - Incorporation Of A Wholly Owned Subsidiary.

18 Mar 2025, 4:14PM The Company has incorporated a wholly owned subsidiary in the name and style 'LUPINLIFE Consumer Healthcare Limited' under Corporate Identification Nu
Lupin Ltd. - Press Release

17 Mar 2025, 10:20AM Lupin Limited has informed the Exchange regarding a press release dated March 17, 2025, titled ""Lupin Receives Tentative Approval from U.S. FDA for A
Lupin Ltd. - Announcement under Regulation 30 (LODR)-Press Release / Media Release

17 Mar 2025, 10:23AM Lupin Receives Tentative Approval from U.S. FDA for Amifampridine Tablets.
Lupin launches Rivaroxaban Tablets USP, 2.5mg in the United States

7 Mar 2025, 4:42PM Global pharmaceutical company Lupin Limited has announced the launch of Rivaroxaban Tablets USP, 2.5 mg, in the U.S. market after receiving final appr
Lupin Ltd. - Press Release

7 Mar 2025, 4:26PM Lupin Limited has informed the Exchange regarding a press release dated March 07, 2025, titled ""Lupin Launches Rivaroxaban Tablets USP, 2.5 mg in the
Lupin Ltd. - Announcement under Regulation 30 (LODR)-Press Release / Media Release

7 Mar 2025, 4:26PM Lupin Launches Rivaroxaban Tablets USP, 2.5mg in the United States.
Lupin Ltd. - Alteration Of Capital and Fund Raising-XBRL

27 Feb 2025, 12:18PM LUPIN LIMITED has informed the Exchange regarding Allotment of Securities
Lupin Ltd. - ESOP/ESOS/ESPS

27 Feb 2025, 12:16PM Lupin Limited has informed the Exchange regarding Allotment of 59940 Shares.
Lupin Ltd. - Press Release

27 Feb 2025, 12:04PM Lupin Limited has informed the Exchange regarding a press release dated February 27, 2025, titled ""Lupin Secures a Place in the Prestigious S&P Globa
Lupin Ltd. - Announcement under Regulation 30 (LODR)-Press Release / Media Release

27 Feb 2025, 12:04PM Lupin Secures a Place in the Prestigious S&P Global Sustainability Yearbook 2025.
Lupin Ltd. - Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS

27 Feb 2025, 12:23PM Intimation regarding allotment of 59940 shares under ESOP.
Lupin Ltd. - Announcement under Regulation 30 (LODR)-Press Release / Media Release

21 Feb 2025, 4:21PM Lupin Receives EIR from U. S. FDA for its Somerset Manufacturing Facility.
Lupin Ltd. - Press Release

21 Feb 2025, 4:20PM Lupin Limited has informed the Exchange regarding a press release dated February 21, 2025, titled ""Lupin Receives EIR from U.S. FDA for its Somerset
Lupin Ltd. - Analysts/Institutional Investor Meet/Con. Call Updates

19 Feb 2025, 5:30PM Lupin Limited has informed the Exchange about Transcript of Q3 FY2025 Earnings Conference Call.
Lupin Ltd. - Analysts/Institutional Investor Meet/Con. Call Updates

19 Feb 2025, 5:15PM Lupin Limited has informed the Exchange about Schedule of meet.
Lupin Ltd. - Copy of Newspaper Publication

19 Feb 2025, 4:35PM Lupin Limited has informed the Exchange about Copy of Newspaper Publication w.r.t. dispatch of Postal Ballot Notice.
Lupin Ltd. - Press Release

19 Feb 2025, 12:49PM Lupin Limited has informed the Exchange regarding a press release dated February 19, 2025, titled ""Lupin Receives A- Leadership Rating from CDP in
Lupin Ltd. - Announcement under Regulation 30 (LODR)-Earnings Call Transcript

19 Feb 2025, 5:32PM Transcript of Q3 FY2025 Earnings Conference Call.
Lupin Ltd. - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

19 Feb 2025, 5:23PM Intimation about participating in the Analyst/Investors Meet.
Lupin Ltd. - Announcement under Regulation 30 (LODR)-Press Release / Media Release

19 Feb 2025, 12:46PM Lupin Receives \A-\ Leadership Rating from CDP in Two Categories - Climate Change and Water Security.
Lupin Ltd. - Notice Of Shareholders Meetings-XBRL

18 Feb 2025, 2:00PM Lupin Limited has informed the Exchange about Notice of Shareholders Meeting for Postal Ballot
Lupin Ltd. - Shareholders meeting

18 Feb 2025, 1:38PM Lupin Limited has informed the Exchange regarding the Notice of Postal Ballot.
Lupin Ltd. - Shareholder Meeting / Postal Ballot-Notice of Postal Ballot

18 Feb 2025, 1:44PM Intimation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 - Postal Ballot Notice.
Lupin Ltd. - Copy of Newspaper Publication

13 Feb 2025, 5:29PM Lupin Limited has informed the Exchange about Copy of Newspaper Publication in respect of Unaudited Financial Results of the Company for the quarter a
Lupin Ltd. - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome

12 Feb 2025, 10:07PM Pursuant to Regulation 30 read with Schedule III Part A Para A(15)(b) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the
Lupin Ltd. - Analysts/Institutional Investor Meet/Con. Call Updates

12 Feb 2025, 9:57PM Lupin Limited has informed the Exchange about Link of Audio recording of the Earnings Call Q3 FY25.
Lupin Ltd. - Press Release (Revised)

12 Feb 2025, 2:59PM Lupin Limited has informed regarding a revised press release dated February 12, 2025, titled ""Lupin Q3 FY2025 Results"".
Lupin Ltd. - Change in Directors/ Key Managerial Personnel/ Auditor/ Compliance Officer/ Share Transfer Agent

12 Feb 2025, 10:31AM LUPIN LIMITED has informed the Exchange about Change in Directors/ Key Managerial Personnel/ Auditor/ Compliance Officer/ Share Transfer Agent
Lupin Ltd. - Incorporation-XBRL

12 Feb 2025, 8:23AM Lupin Limited has informed the Exchange regarding Incorporation
Lupin Ltd. - Slump Sale-XBRL

12 Feb 2025, 8:20AM Lupin Limited has informed the Exchange regarding Slump Sale
Lupin Ltd. - Investor Presentation

12 Feb 2025, 2:40AM Lupin Limited has informed the Exchange about Investor Presentation
Lupin Ltd. - Press Release

12 Feb 2025, 2:20AM Lupin Limited has informed the Exchange regarding a press release dated February 12, 2025, titled ""Lupin Q3 FY2025 Results"".
Lupin Ltd. - Integrated Filing- Financial

12 Feb 2025, 1:40AM Integrated Filing (Financial) for quarter ended December 31, 2024.
Lupin Ltd. - General Updates

12 Feb 2025, 1:34AM Lupin Limited has informed the Exchange about formulation, adoption and implementation of Lupin Employees Stock Option Scheme 2025.
Lupin Ltd. - Incorporation

12 Feb 2025, 1:28AM Lupin Limited has informed the Exchange about Incorporation of a wholly owned subsidiary in the name and style LUPINLIFE Consumer Healthcare Limited
Lupin Ltd. - Other Restructuring

12 Feb 2025, 1:21AM Lupin Limited has informed the Exchange about transfer of the Over-the-Counter ( OTC ) Consumer Healthcare Business of the Company, on a slump sale ba
Lupin Ltd. - Change in Director(s)

12 Feb 2025, 1:16AM Lupin Limited has informed the Exchange regarding Change in Director(s) of the company.
Lupin Ltd. - Outcome of Board Meeting

12 Feb 2025, 1:11AM Lupin Limited has informed the Exchange regarding Outcome of Board Meeting held on February 11, 2025.
Lupin Ltd. - Financial Result Updates

12 Feb 2025, 12:40AM Lupin Limited has submitted to the Exchange, the financial results for the period ended December 31, 2024.
Lupin Ltd. - Announcement under Regulation 30 (LODR)-Press Release / Media Release (Revised)

12 Feb 2025, 2:54PM Lupin Limited has informed regarding a revised Press Release dated February 12, 2025, titled \Lupin Q3 FY2025 Results\.
Lupin Q3 net profit up 7.45% at Rs 984.67 cr

12 Feb 2025, 8:50AM The company reported standalone net profit of Rs 984.67 crore for the quarter ended December 31, 2024 as compared to Rs 916.44 crore in the same perio
Lupin Ltd. - Announcement under Regulation 30 (LODR)-Investor Presentation

12 Feb 2025, 2:43AM Investor Presentation - Q3 FY25
Lupin Ltd. - Integrated Filing (Financial)

12 Feb 2025, 1:42AM Integrated Filing (Financial) for the quarter ended December 31, 2024.
Lupin Ltd. - Formulation, Adoption And Implementation Of Lupin Employees Stock Option Scheme 2025.

12 Feb 2025, 1:31AM Formulation, adoption and implementation of Lupin Employees Stock Option Scheme 2025 for grant of Employee Stock Options to the Eligible Employees of
Lupin Ltd. - Announcement under Regulation 30 (LODR)-Acquisition

12 Feb 2025, 1:24AM Incorporation of a wholly-owned subsidiary in the name and style \LUPINLIFE Consumer Healthcare Limited\ or any other appropriate name, as may be appr
Lupin Ltd. - Announcement under Regulation 30 (LODR)-Restructuring

12 Feb 2025, 1:20AM Transfer of Over-the-Counter Consumer Healthcare Business of the Company, on slump sale basis, to wholly owned subsidiary that is proposed to be incor
Lupin Ltd. - Announcement under Regulation 30 (LODR)-Change in Directorate

12 Feb 2025, 1:13AM Re-appointment of Ms. Vinita Gupta as Chief Executive Officer and re-appointment of Mr. Ramesh Swaminathan as Whole-Time Director of the Company.
Lupin Ltd. - Board Meeting Outcome for Outcome Of Board Meeting - Intimation Under Regulation 30 Of SEBI (Listing Obligations

12 Feb 2025, 1:00AM Outcome of Board Meeting - Intimation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015
Lupin Ltd. - Unaudited Standalone And Consolidated Financial Results Of The Company For The Quarter And Nine-Months Ended Dec

12 Feb 2025, 12:46AM Unaudited Standalone and Consolidated Financial Results of the Company for the quarter and nine-months ended December 31, 2024.
Lupin Ltd. - Press Release

10 Feb 2025, 4:19PM Lupin Limited has informed the Exchange regarding a press release dated February 10, 2025, titled ""Lupin Receives Approval from U.S. FDA for Ipratrop
Lupin Ltd. - Announcement under Regulation 30 (LODR)-Press Release / Media Release

10 Feb 2025, 4:19PM Lupin Receives Approval from U. S. FDA for Ipratropium Bromide Nasal Solution (NASAL Spray), 0.03%
Lupin Ltd. - Press Release

10 Feb 2025, 12:31PM Lupin Limited has informed the Exchange regarding a press release dated February 10, 2025, titled ""Lupin and Natco Receive Approval from U.S. FDA for
Lupin Ltd. - Announcement under Regulation 30 (LODR)-Press Release / Media Release

10 Feb 2025, 12:31PM Lupin and Natco Receive Approval from U. S. FDA for Bosentan Tablets for Oral Suspension.
Lupin Ltd. - Analysts/Institutional Investor Meet/Con. Call Updates

7 Feb 2025, 4:28PM Lupin Limited has informed the Exchange about participating in the Analyst/Institutional Investors Meet.
Lupin Ltd. - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

7 Feb 2025, 4:26PM Intimation about participating in the Analyst/Institutional Investors Meet.
Lupin Ltd. - Intimation Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015.

6 Feb 2025, 11:56AM Intimation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
Lupin Ltd. - Action(s) taken or orders passed

6 Feb 2025, 11:56AM Lupin Limited has informed the Exchange about Action(s) taken or orders passed
Lupin Ltd. - Rumour verification - Regulation 30(11)

4 Feb 2025, 6:56PM Confirmation on the news item appearing in Mainstream Media titled 'Lupin gets USFDA nod for generic HIC drug'.
Lupin Ltd. - Rumour Verification - Regulation 30(11)

4 Feb 2025, 6:53PM Lupin Limited has informed the Exchange about Rumour Verification - Regulation 30(11)
Lupin Ltd. - Action(s) taken or orders passed

3 Feb 2025, 5:09PM Lupin Limited has informed the Exchange about Action(s) taken or orders passed
Lupin Ltd. - Intimation Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015.

3 Feb 2025, 5:08PM Intimation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
Lupin Ltd. - Announcement under Regulation 30 (LODR)-Press Release / Media Release

1 Feb 2025, 9:30PM Lupin Announces Closure of Inspection by U.S. FDA at its Somerset Facility with No Observations.
Lupin Ltd. - Press Release

1 Feb 2025, 9:29PM Lupin Limited has informed the Exchange regarding a press release dated February 01, 2025, titled ""Lupin Announces Closure of Inspection by U.S. FDA
Lupin Ltd. - ESOP/ESOS/ESPS

30 Jan 2025, 3:47PM Lupin Limited has informed the Exchange regarding Allotment of 246462 Shares.
Lupin Ltd. - Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS

30 Jan 2025, 3:38PM Intimation regarding allotment of 246462 shares under ESOP.
Lupin Diagnostics achieves NABL accreditation for all greenfield labs

24 Apr 2025 , 10:05AM Lupin rises over 2% to Rs. 2,132.75 in weak market
Lupin Diagnostics achieves NABL accreditation for All Greenfield Labs.

23 Apr 2025 , 2:14PM Accreditation is a testament to the team's dedication to patient care and our mission to promote healthier lives
Lupin receives EIR from USFDA for its injectable facility in Nagpur

17 Apr 2025 , 2:59PM EIR was issued following an inspection of the facility conducted from June
Lupin gets tentative USFDA approval for Amifampridinetablets

17 Mar 2025 , 11:50AM Amifampridine tablets are used to treat lambert-eaton myasthenic syndrome
Lupin

10 Mar 2025 , 9:00AM Launched Rivaroxaban tablets in the US after receiving final approval for its Abbreviated New Drug Application from the USFDA. The drug is used to reduce the risk of major cardiovascular events. Positive
Lupin

24 Feb 2025 , 9:02AM Lupin: The company received Establishment Inspection Report from USFDA for Somerset Manufacturing Unit. Positive
Lupin

11 Feb 2025 , 8:55AM The company has obtained approval from the U.S. FDA for its Abbreviated New Drug Application for Ipratropium Bromide Nasal Solution.
Lupin

5 Feb 2025 , 12:20PM The company has gotten a US FDA tentative approval for its Abbreviated New Drug Application for generic HIC drug. Product will be manufactured at the Company’s Nagpur facility
Lupin

3 Feb 2025 , 8:54AM Lupin announced closure of Pre- approval inspection of Edaravone Oral Suspension, 105 mg/ 5 mL by USFDA at its Somerset Facility with no observations. Positive
Lupin

27 Jan 2025 , 12:44PM The company has received approval from the US health regulator to market a generic HIV medication in the US market. The company has received tentative approval from the US Food and Drug Administration (USFDA) under the US President's Emergency Plan for AIDS Relief (PEPFAR) for Abacavir, Dolutegravir and Lamivudine tablets. The company's product is a generic equivalent of ViiV Healthcare Company's Triumeq PD tablets for oral suspension.
Lupin

9 Jan 2025 , 10:09AM Received the Establishment Inspection Report (EIR) with satisfactory Voluntary Action Indicated (VAI) classification from the United States Food and Drug Administration (US FDA) for its Pithampur Unit-1 manufacturing facility that manufactures both APIs and finished products. Positive
Lupin

31 Dec 2024 , 9:51AM The company announced the acquisition of Huminsulin in India from Eli Lilly and Company to further enhance its diabetes portfolio. Further delay in approval of Anmeal Proair , would drive earnings upgrade for the company-Positive
Lupin

19 Dec 2024 , 10:44AM The pharma company has received approval from the United States Food and Drug Administration (US FDA) for its Abbreviated New Drug Application (ANDA) for Emtricitabine and Tenofovir Alafenamide tablets, 200 mg/25 mg, to market a generic equivalent of Descovy tablets of Gilead Sciences, Inc, in the US markets. Positive
Lupin

16 Dec 2024 , 1:05PM The company announced the acquisition of anti-diabetes trademarks from Boehringer Ingelheim International GmbH to strengthen its diabetes portfolio in the country. As per the agreement, the trademark rights for these brands will be transferred to Lupin by March next year.
Lupin launches first generic of Pred Forte in the United States

15 Oct 2024 , 12:15PM Lupin launches first generic of Pred Forte (Prednisolone Acetate) in the US
Lupin

1 Oct 2024 , 12:00PM Company signs distribution agreement with scope to commercialise Optase range of products in Mexico.
Lupin signs distribution agreement with SCOPE to commercialise Optase range of products in Mexico

30 Sep 2024 , 2:17PM USFDA Inspection of the Company's Manufacturing Facility at Pithampur Unit-1.
Lupin enters into patent agreement with Takeda Pharma

18 Sep 2024 , 2:02PM Lupin enters into patent agreement with Takeda Pharma to commercialise Vonoprazan Tablets in Indian market.
Lupin

5 Sep 2024 , 10:44AM Lupin has introduced Mirabegron extended-release tablets, 50 mg, in the U.S. market. Mirabegron, a drug used to treat overactive bladder, has estimated annual sales of $1.6 billion in the U.S. Positive
Lupin

30 Aug 2024 , 11:06AM Lupin announced the launch of Doxorubicin Hydrochloride Liposome Injection 20 mg/10 mL (2 mg/mL) and 50 mg/25 mL (2 mg/mL) Single-Dose Vials in the United States, after Lupin’s alliance partner, ForDoz Pharma Corporation, USA (ForDoz) received an approval for its ANDA from the United States Food and Drug Administration (U.S. FDA). (Positive)
Lupin

16 Aug 2024 , 11:21AM Lupin has received tentative approval from the U.S. FDA for its Abbreviated New Drug Application for Brimonidine Tartrate Ophthalmic Solution, 0.025% (OTC), to market a generic equivalent of Lumify® Ophthalmic Solution, 0.025%, of Bausch & Lomb Incorporated. This product will be manufactured at Lupin’s Pithampur facility in India. Brimonidine Tartrate Ophthalmic Solution, 0.025%(OTC) is indicated to relieve redness of the eye due to minor eye irritations. Brimonidine Tartrate Ophthalmic Solution(RLD Lumify®) had an estimated annual sale of USD39million in the U.S. as on IQVIA MAT June2024. (Positive)
Stock Update: Lupin

9 Aug 2024 , 12:54PM Stock Update: Lupin - Strong Q1; complex products to drive growth
Lupin

16 Jul 2024 , 10:14AM Lupin has divested its U.S. Commercial Women’s Health Specialty Business to Evofem Biosciences, Inc. a U.S. biopharmaceutical company focused exclusively on Women’s Health. Lupin’s U.S. Commercial Women’s Health Specialty Business is primarily focused on commercializing SOLOSEC® (secnidazole) 2g oral granules. This FDA-approved single-dose antimicrobial agent provides a complete course of therapy for the treatment of bacterial vaginosis (BV) and trichomoniasis, two common sexual health infections. Under the terms of the deal, Lupin can receive a potential total consideration of up to USD 84 million based on future contingent milestones. (Positive)
Lupin

15 Jul 2024 , 9:15AM Lupin announced that it has received an Establishment Inspection Report (EIR) from the United States Food and Drug Administration (USFDA) for its manufacturing facility in Dabhasa, Gujarat. The said report classified under Voluntary Action Indicated (VAI) status. The facility was inspected from 8 to 12 April 2024. (Positive)
Lupin

9 Jul 2024 , 10:18AM Lupin gets tentative U.S. FDA approval for ANDA of Empagliflozin. Empagliflozin and Metformin Hydrochloride ER Tablets (RLD:Synjardy®XR) had estimated annual sales of USD 357 million in the U.S. (IQVIA MAT November 2020). Positive
Lupin

24 Jun 2024 , 10:26AM Lupin announced that it has received the Establishment Inspection Report (EIR) from the United States Food and Drug Administration (U.S. FDA) for its manufacturing facility in Somerset, New Jersey, with a Voluntary Action Indicated (VAI) status. The facility was inspected from May 7 to May 17, 2024. “We are very pleased to have received the EIR with a satisfactory VAI status for our Somerset facility. This is a significant milestone in building our reputation of being best-in-class in Quality and Compliance,” said Nilesh Gupta, Managing Director, Lupin. (Positive)
Lupin

22 May 2024 , 12:48PM The Company and its subsidiaries are involved in legal proceedings, which are often resolved through settlement agreements with the plaintiffs. The Company and its wholly owned subsidiary Lupin Pharmaceuticals, Inc., USA, entered into a settlement agreement with Health Care Service Corporation and Humana Inc. (collectively, the ‘Plaintiffs’) in connection with ongoing litigation for Glumetza, a drug for treatment of diabetes. While the Company denies the Plaintiffs allegations and maintains that it has robust and meritorious defences to the Plaintiffs claims of liabilities and damages, in order to avoid the costs and uncertainties of continued litigation, the Company decided to settle with the Plaintiffs by entering into a Settlement Agreement for an amount of USD nine million. The settlement agreement is neither an admission of facts nor liability by the Company.
Lupin

16 May 2024 , 9:48AM : Lupin Achieves Significant Milestone with ISO 14001 and ISO 45001 Certification. Lupin Achieves Significant Milestone with ISO 14001 and ISO 45001 Certification Across All its Indian Manufacturing Sites, R&D Center and Corporate Office. Global pharma major Lupin Limited (Lupin) today announced that all 12 of its manufacturing sites, its R&D Center and corporate office in India have successfully completed rigorous audits and been certified by DNV for ISO 14001 — Environment Management Systems (EMS), and ISO 45001 — Occupational Health and Safety Management System (OHSMS). This achievement marks a significant milestone in acknowledging Lupin’s commitment to safe and sustainable operations. Positive
Stock update: Lupin- Mixed Earnings

8 May 2024 , 11:44AM Stock update: Lupin- Mixed Earnings: healthy pipeline of complex products to drive growth.
Lupin

24 Apr 2024 , 10:47AM The company announced that it has received the Establishment Inspection Report (EIR) from the United States Food and Drug Administration (U.S. FDA) for its Aurangabad manufacturing facility. The inspection was conducted from March 6 to March 15, 2024. The U.S. FDA has determined that the inspection classification of the facility is Voluntary Action Indicated (VAI). (Positive)
Lupin

22 Apr 2024 , 9:04AM Lupin - Co announced launch of 25 mg strength of generic Mybetriq or mirabegron in the US market. The 25 mg strength has sales of $1b in the US market. (Positive)
Stock Update: Lupin

16 Apr 2024 , 10:19AM Stock Update: Lupin - gSpiriva on a healthy growth track, headwinds receding.
Lupin

10 Apr 2024 , 10:11AM launch first generic version of Oracea® (Doxycycline Capsules, 40 mg), in the United States, after having received an approval from the United States Food and Drug Administration (U.S. FDA). Doxycycline Capsules, 40 mg is indicated for the treatment of only inflammatory lesions (papules and pustules) of rosacea in adult patients. Doxycy. Doxycycline Capsules had estimated annual sales of USD 128 million in the U.S. (IQVIA MAT February 2024). Positive
Lupin

9 Apr 2024 , 10:07AM Lupin - received approval from the US health regulator to market a generic medication to treat involuntary movements caused by tardive dyskinesia. The company has received approval from the US Food and Drug Administration (USFDA) to market Valbenazine Capsules in strength of 40 mg and 80 mg. Positive
Lupin

18 Mar 2024 , 11:21AM U.S. FDA inspected Lupin’s manufacturing facility at Aurangabad from March 6 to March 15, 2024. The inspection closed with the issuance of a Form-483 with one (1) observation. We are confident of addressing the concern raised by the U.S. FDA and will resolve the same at the earliest. We uphold quality and compliance with utmost importance and are committed to comply with CGMP quality standards across all our facilities. Positive.
Lupin

16 Feb 2024 , 2:38PM Lupin Receives Approval from U.S. FDA for MinzoyaTM (Levonorgestrel and Ethinyl Estradiol Tablets, USP and Ferrous Bisglycinate Tablets) to market a generic equivalent of Balcoltra®(Levonorgestrel and Ethinyl Estradiol Tablets, USP and Ferrous Bisglycinate Tablets) 0.1 mg/0.02 mg and 36.5 mg, of Avion Pharmaceuticals LLC. The product will be manufactured at Lupin’s Pithampur facility in India. MinzoyaTM Tablets are indicated for use by females of reproductive potential to prevent pregnancy. Levonorgestrel and Ethinyl Estradiol Tablets, USP and Ferrous Bisglycinate Tablets (RLD Balcoltra®) had estimated annual sales of USD 42 million in the U.S. (IQVIA MAT December 2023). (Positive)
Lupin gets USFDA nod for Minzoya

16 Feb 2024 , 1:45PM Minzoya Tablets use to prevent pregnancy
Lupin launches Ganirelix Acetate Injection in the United States

15 Feb 2024 , 12:41PM Ganirelix Acetate is used to inhibit of premature luteinizing hormone surges in women
Lupin

14 Feb 2024 , 1:02PM Lupin Launches Bromfenac Ophthalmic Solution, 0.075% in the United States. Bromfenac Ophthalmic Solution, 0.075% is a generic equivalent of BromSite Ophthalmic Solution, 0.075%, of Sun Pharmaceutical Industries Limited. It is indicated for the treatment of postoperative inflammation and prevention of ocular pain in patients undergoing cataract surgery. Bromfenac Ophthalmic Solution 0.075% had estimated annual sales of USD 15 million in the U.S. (IQVIA MAT December 2023). (Positive)
Lupin

8 Feb 2024 , 10:02AM Lupin reported strong set on numbers with beat in our estimates on all front. The company reported sales growth of 20%, EBITDA growth of 98% and PAT growth of 292% .The company reported strong margins where Gross Margin stands at 66% an EBITDA Margin stands at 19.7%. (Positive)
Lupin

7 Feb 2024 , 10:12AM Lupin Receives Approval from U.S. FDA for Bromfenac Ophthalmic Solution, 0.075%. Lupin is the exclusive first-to-file for this product. This product will be manufactured at Lupin’s Pithampur facility in India. Bromfenac Ophthalmic Solution 0.075% (RLD BromSite®) had estimated annual sales of USD 15 million in the U.S. (IQVIA MAT December 2023). (Positive)
Lupin

1 Feb 2024 , 3:37PM Lupin Receives Approval from U.S. FDA for Dronedarone Tablets, USP. Lupin \announced that it has received approval from the United States Food and Drug Administration (U.S. FDA) for its Abbreviated New Drug Application for Dronedarone Tablets USP, 400 mg, to market a generic equivalent of Multaq® Tablets, 400 mg of Sanofi-Aventis U.S. LLC. The product will be manufactured at Lupin’s Goa facility in India. Dronedarone Tablets (RLD Multaq®) had estimated annual sales of USD 510 million in the U.S. (IQVIA MAT December 2023). (Positive)
Lupin

25 Jan 2024 , 10:34AM Lupin Limited (Lupin) today announced that it has received tentative approval from the United States Food and Drug Administration (U.S. FDA) for its Abbreviated New Drug Application for Rivaroxaban Tablets USP, 2.5 mg, 10 mg, 15 mg, and 20 mg, to market a generic equivalent of Xarelto® Tablets, of Janssen Pharmaceuticals, Inc. This product will be manufactured at Lupin’s Pithampur facility in India. Rivaroxaban Tablets USP (RLD Xarelto®) had estimated annual sales of USD 8,249 million in the U.S. (IQVIA MAT November 2023). (Positive)
Lupin

24 Jan 2024 , 10:26AM Lupin Limited (Lupin) today announced that it has received tentative approval from the United States Food and Drug Administration (U.S. FDA) for its Abbreviated New Drug Application for Rivaroxaban Tablets USP, 2.5 mg, 10 mg, 15 mg, and 20 mg, to market a generic equivalent of Xarelto® Tablets, of Janssen Pharmaceuticals, Inc. This product will be manufactured at Lupin’s Pithampur facility in India. Rivaroxaban Tablets USP (RLD Xarelto®) had estimated annual sales of USD 8,249 million in the U.S. (IQVIA MAT November 2023). (Positive)
Lupin

19 Jan 2024 , 10:27AM Lupin Receives Approval from U.S. FDA for Febuxostat Tablets. Febuxostat Tablets, 40 mg and 80 mg, are indicated for the chronic management of hyperuricemia in adult patients with gout who have an inadequate response to a maximally titrated dose of allopurinol, who are intolerant to allopurinol, or for whom treatment with allopurinol is not advisable. Febuxostat Tablets (RLD Uloric) had estimated annual sales of USD 27 million in the U.S. (IQVIA MAT November 2023). (Positive)
Lupin gets USFDA approval For Febuxostat Tablets

19 Jan 2024 , 10:16AM Febuxostat Tablets are used for the chronic management of hyperuricemia in adult patients with gout
Lupin launches Varenicline Tablets in the United States

10 Jan 2024 , 2:20PM Varenicline Tablet is indicated for use as an aid to smoking cessation treatment
Lupin

10 Jan 2024 , 9:52AM Lupin Launches Bromfenac Ophthalmic Solution, 0.07% in the United States. Lupin is the exclusive first-to-file for this product and is eligible for 180-day exclusivity. Bromfenac Ophthalmic Solution, 0.07% is the generic equivalent of Prolensa® Ophthalmic Solution, 0.07%, of Bausch & Lomb Inc. It is indicated for the treatment of postoperative inflammation and reduction of ocular pain in patients who have undergone cataract surgery. Bromfenac Ophthalmic Solution (RLD Prolensa) had estimated annual sales of USD 182 million in the U.S. (IQVIA MAT November 2023). (Positive)
Lupin

5 Jan 2024 , 11:07AM Lupin announced that it has received tentative approval from the United States Food and Drug Administration for its Abbreviated New Drug Application for Dapagliflozin and Saxagliptin Tablets, 5 mg/5 mg and 10 mg/5 mg, to market a generic equivalent of Qtern® Tablets, 5 mg/5 mg and 10 mg/5 mg of AstraZeneca AB. This product will be manufactured at Lupin’s Pithampur facility in India. (Positive)
Stock Update: Lupin

29 Dec 2023 , 11:17AM Stock Update: Lupin - gSpiriva to boost EBITDA margin to 5 years high at 21%
Lupin

18 Dec 2023 , 11:21AM Lupin Receives Approval from U.S. FDA for Allopurinol Tablets USP, 100 mg and 300 mg to market a generic bioequivalent and therapeutically equivalent to the reference listed drug Zyloprim Tablets, 100 mg, and 300 mg, of Casper Pharma, LLC. The product will be manufactured at Lupin’s Pithampur facility in India. Allopurinol Tablets (RLD Zyloprim) had estimated annual sales of USD 88.1 million in the U.S. (IQVIA MAT October 2023). Allopurinol Tablets USP, 100 mg and 300 mg are indicated for the management of adult patients with signs and symptoms of primary or secondary gout (acute attacks, tophi, joint destruction, uric acid lithiasis, and/or nephropathy). (Positive)
Lupin

15 Dec 2023 , 12:35PM Lupin Diagnostics Expands Presence in South India with New Regional Reference Laboratory in Chennai. The newly launched laboratory enhances Lupin Diagnostics’ extensive network which now comprises of 36 laboratories and over 600 collection centers across India. Lupin Diagnostics offers an extensive range of reliable and high-quality diagnostic services, including molecular diagnostics, cytogenetics, flow cytometry, cytology, microbiology, serology, haematology, immunology, routine biochemistry, and more, apart from routine and specialized tests. (Neutral)
Lupin launches new regional reference laboratory in Chennai

14 Dec 2023 , 3:17PM Lupin Diagnostics expands presence in South India with New Regional Reference Laboratory in Chennai
Lupin gets nod from USFDA for Varenicline Tablets

6 Dec 2023 , 10:21AM Lupin gets USFDA ANDA nod for Varenicline Tablets which are used as an aid to smoking cessation treatment
Lupin

24 Nov 2023 , 10:43AM Lupin Receives Approval from U.S. FDA for Bromfenac Ophthalmic Solution, 0.07%. Lupin is eligible for 180-day exclusivity period as it is being the first to file. Bromfenac Ophthalmic Solution (RLD Prolensa®) had estimated annual sales of USD 185 million in the U.S. (IQVIA MAT September 2023). The product will be manufactured at Lupin’s Pithampur facility in India. (Positive)
Lupin

23 Nov 2023 , 11:59AM Lupin launched one of the world’s first fixed-dose triple combination drug under the brand name Vilfuro-G® for the effective management of chronic obstructive pulmonary disease in India. This therapeutic innovation by Lupin brings hope to more than 37 million individuals struggling with COPD in India, a condition that ranks among the leading causes of death and disability in the nation. Positive
Lupin launches fixed-dose triple combination drug

23 Nov 2023 , 10:55AM Vilfuro-G for chronic obstructive pulmonary disease (COPD) management in India
Lupin receives approval from USFDA for Ganirelix Acetate Injection

17 Nov 2023 , 3:12PM It is indicated for inhibition of premature luteinizing hormone surge in women
Lupin signs licensing & supply agreement with Amman Pharma

10 Nov 2023 , 1:45PM Lupin, Amman Pharma sign exclusive licensing and supply agreement for Ranibizumab Biosimilar
Lupin

8 Nov 2023 , 12:52PM Lupin Receives Tentative Approval from U.S. FDA for Canagliflozin and Metformin Hydrochloride Extended-Release Tablets 50 mg/500 mg, 50 mg/1,000 mg, 150 mg/500 mg, and 150 mg/1,000 mg to market a generic equivalent of Invokamet XR® Tablets, 50 mg/500 mg, 50 mg/1,000 mg, 150 mg/500 mg, and 150 mg/1,000 mg, of Janssen Pharmaceuticals, Inc. This product will be manufactured at Lupin’s Pithampur facility in India. Canagliflozin and Metformin Hydrochloride Extended-Release Tablets (RLD Invokamet XR®) had estimated annual sales of USD 28 million in the U.S. (IQVIA MAT July 2023). (Positive)
Lupin

8 Nov 2023 , 12:36PM Lupin Launches Rocuronium Bromide Injection in the United States. Rocuronium Bromide Injection, 50 mg/5 mL (10 mg/mL) and 100 mg/10 mL (10 mg/mL) Multiple-Dose Vials is the generic version of Zemuron® Injection, 50 mg/5 mL and 100 mg/10 mL of Organon USA Inc. and is indicated for inpatients and outpatients as an adjunct to general anesthesia to facilitate both rapid sequence and routine tracheal intubation, and to provide skeletal muscle relaxation during surgery or mechanical ventilation. Rocuronium Bromide Injection (RLD: Zemuron®) had estimated annual sales of USD 54 million in the U.S. (IQVIA MAT August 2023). Positive read through
Lupin gets USFDA tentative nod for ANDA for Selexipag for injection

2 Nov 2023 , 1:40PM Selexipag for injection is used treat pulmonary arterial hypertension
Lupin

1 Nov 2023 , 9:39AM Lupin received Establishment Inspection Report from U.S. FDA for the Company’s Mandideep Unit-2 manufacturing facility. The EIR was issued post the last inspection of the facility conducted from August 7 to August 11, 2023. The inspection closed with the facility receiving an inspection classification of "No Action Indicated" (NAI). (Positive)
Lupin

25 Oct 2023 , 10:41AM Lupin Receives Approval for its Abbreviated New Drug Application for Fluconazole Tablets USP, 50 mg, 100 mg, 150 mg, and 200 mg, to market a generic equivalent of Diflucan® Tablets, 50 mg, 100 mg, 150 mg, and 200 mg, of Pfizer, Inc. This product will be manufactured at Lupin’s Pithampur facility in India. Fluconazole Tablets USP (RLD Diflucan) had estimated annual sales of USD 43 million in the U.S. (IQVIA MAT July 2023).
Lupin

17 Oct 2023 , 11:55AM Lupin Limited have planned to enter into a Business Transfer Agreement (‘BTA’) with Lupin Manufacturing Solutions Limited (‘LMSL’), wholly owned subsidiary of the Company, to carve out two Active Pharmaceutical Ingredients manufacturing sites situate at Dabhasa and Visakhapatnam and select R&D operations, including fermentation, at Lupin Research Park, Pune
Lupin

16 Oct 2023 , 11:59AM Lupin announced that it has received tentative approval from the United States Food and Drug Administration (U.S. FDA) for its Abbreviated New Drug Application for Apalutamide Tablets, 60 mg, to market a generic equivalent of Erleada® Tablets, 60 mg of Janssen Biotech, Inc. Apalutamide Tablets, 60 mg, (RLD Erleada®) had estimated annual sales of USD 1,185.5 million in the U.S.(IQVIA MAT July 2023). (Positive)
Lupin

13 Oct 2023 , 11:29AM Lupin Receives Tentative Approval from U.S. FDA for Calcium, Magnesium, Potassium, and Sodium Oxybates Oral Solution. The net product sales for Calcium, Magnesium, Potassium, and Sodium Oxybates Oral Solution (RLD Xywav) were USD 958.4 million for the year ending December 2022 and USD 604.3 million for the first six months of 2023. (Positive).
Lupin

6 Oct 2023 , 11:21AM Lupin receives tentative approval from U.S. FDA for Tolvaptan tablets. Tolvaptan tablets (RLD Jynarque) had estimated annual sales of USD 287 million in the U.S. (IQVIA MAT August 2023). Lupin received approval for Tolvaptan Tablets, 15 mg, 30 mg, 45 mg, 60 mg, and 90 mg to market a generic equivalent of Jynarque Tablets, 15 mg, 30 mg, 45 mg, 60 mg, and 90 mg, of Otsuka Pharmaceutical Co., Ltd. This product will be manufactured at Lupin’s Nagpur facility in India. View – Lupin is getting approval for big complex products, hence it is positive for the company.
Lupin gets EIR from USFDA for Nagpur Unit-Manufacturing Facility

29 Sep 2023 , 3:35PM USFDA classifies co's Nagpur Unit-1 As Voluntary Action Indicated
Lupin

29 Sep 2023 , 3:14PM Lupin Receives EIR from U.S. FDA for its Nagpur Unit-1 Manufacturing Facility. The EIR was issued post the last inspection of the facility conducted in July 2023. The U.S. FDA has determined that the inspection classification of the facility is Voluntary Action Indicated (VAI), (Positive).
Lupin

22 Sep 2023 , 2:40PM Lupin acquired 5 brands from Menarini for a consideration of Rs 1bn. Menarini is an Italian pharma group and the 5 brands acquired are Piclin (Picosulphate Sodium), Menoctyl (Otilonium Bromide), Sucramal O (Sucralfate + Oxetacaine), Pyridium (Phenazopyridine) and Distaclor (Cefaclor) are being acquired. Lupin has been exclusively marketing these brands in the Indian market since July 2021 under a distribution and promotion agreement with Menarini India Private Limited. The sales of these brands as on FY23 stood at Rs 32.2 crs. This news is neutral as lupin was already selling these drugs in the Indian market from 2021.
Lupin acquires Five Brands from Menarini

22 Sep 2023 , 1:36PM Lupin signs agreement with Italy-based Menarini Group to acquire five brands for Rs. 101 crore
Lupin

7 Sep 2023 , 10:18AM The company has joined hands with Mark Cuban's Cost Plus Drugs and the COPD Foundation to the improve availability and affordability of drugs to treat Chronic Obstructive Pulmonary Disease (COPD) in the US. COPD is a life-threatening condition that affects over 15 million adults in the United States and ranks as the fourth leading cause of death in the country – Positive read through for the stock.
Lupin acquires Ondero & Ondero - Met brands from Boehringer Ingelheim

18 Aug 2023 , 3:25PM Lupin buys brand ONDERO and ONDERO MET to expand Diabetes Portfolio in India
Lupin

17 Aug 2023 , 10:38AM The company has announced the launch of Tiotropium Bromide Inhalation Powder, 18 mcg/capsule, for the treatment of chronic obstructive pulmonary disease (COPD) in the US. Tiotropium Bromide Inhalation Powder, 18 mcg/capsule is a generic equivalent of Spiriva® HandiHaler® (Tiotropium Bromide Inhalation Powder), 18 mcg/capsule of Boehringer Ingelheim Pharmaceuticals, Inc. Positive for the stock.
Lupin

9 Aug 2023 , 10:12AM The company arm receives USFDA Anda approval for Fluocinlone Acetonide Body Oil which used to treat Eczema, a skin condition – Positive read through for the stock
Lupin

2 Aug 2023 , 11:36AM The company announced that its subsidiary, Novel Laboratories Inc. based in Somerset, NJ has received approval from the USFDA for its ANDA for Fluocinolone Acetonide Topical Oil, 0.01% (Scalp Oil), a generic equivalent of Derma-Smoothe/FS Topical Oil, 0.01% (Scalp Oil), of Hill Dermaceuticals, Inc. This product will be manufactured at Lupin’s Somerset facility in the US. Fluocinolone Acetonide Topical Oil (RLD Derma-Smoothe/FS) had estimated annual sales of USD 9 million in the U.S. (IQVIA MAT Mar 2023). Positive for the stock.
Lupin

2 Aug 2023 , 10:39AM Lupin announced that it has received approval from the USFDA for its ANDA for gTurqoz (Norgestrel and Ethinyl Estradiol Tablets USP), a birth control pill of Wyeth Pharmaceuticals LLC, which will be manufactured at Lupin’s Pithampur facility in India. The drug has annual sales of USD 34 million as per IQVIA MAT Mar 2023. Positive for the stock. At the same time, Lupin Pharmaceuticals, the US arm of Lupin Ltd. has issued a voluntary recall of two lots of birth control pills, Tydemy tablets, due to its potential that they were not effective in preventing pregnancy. The company is pulling two lots of Tydemy tablets due to out-of-specification test results at the 12-month stability time point. No adverse effects related to the recall have been reported to date, the company said. Negative read through for the stock.
Lupin

28 Jul 2023 , 11:30AM Lupin informed that it has resolved warning letter for its facilities in Goa and Pithampur Unit 2, Indore as intimated by the USFDA. The warning letter was issued in 2017. It’s a strong positive.
Lupin

27 Jul 2023 , 3:22PM Lupin Ltd. has formed Lupin Manufacturing Solutions Ltd. as a wholly owned subsidiary for undertaking contract development and manufacturing activities. Positive read through.
Lupin

26 Jul 2023 , 3:41PM Lupin Ltd.: The company has announced receipt of approval for Tiotropium 18 micrograms powder for inhalation in capsules for use with LupinHaler, its bioequivalent version of Spiriva from Therapeutic Goods Administration (TGA) of Australia. Tiotropium Bromide Inhalation Powder (Reference Product Spiriva®) had estimated annual sales of USD 10 million in Australia (IQVIA MAT Mar 2023. Positive for the stock.
Lupin

24 Jul 2023 , 1:01PM Lupin Digital Health, the cardiology digital therapeutics (DTx) platform and the American College of Cardiology (ACC) announced a first of its kind collaboration to deliver in home cardiovascular care with Digital therapeutics in India. This collaboration aims to accelerate the application and adoption of DTx platform, Lyfe and also aims to accelerate the application and adoption of DTx in Cardiology in India. Positive.
Lupin collaborates with American College of Cardiology

24 Jul 2023 , 12:56PM Lupin collaborates with American College of Cardiology to deliver in-home cardiovascular care to accelerate application & adoption of DTX in cardiology in India
Lupin

24 Jul 2023 , 12:19PM Lupin Ltd. announced receipt of tentative approval from the USFDA under the US President’s Emergency Plan for AIDS relief for the company’s New Drug Application (NDA) for Dolutegravir Lamivudine and Tenofovir Alafenamide Tablets. Positive for the stock.
Lupin incorporates unit Lupin Atharv ability for neuro-rehabilitation business

21 Jul 2023 , 12:59PM Lupin incorporates Lupin Atharv Ability Ltd., wholly owned subsidiary for neuro rehabilitation business
Lupin

21 Jul 2023 , 12:54PM The company has incorporated Lupin Atharv Ability Ltd., wholly owned subsidiary for neuro rehabilitation business. The multi-disciplined robotic and computer-assisted centre is possibly the only one of its kind in India with a range of rehabilitation programs for post-stroke patients, patients with traumatic brain injury, spinal cord injury, paediatric neurological conditions, Parkinson’s, cerebral palsy, and multiple sclerosis. Each centre would have about 20-odd people including therapists, and services would be tailored to the need of the individual, with prices averaging at about Rs 1,500 for a 45-minute therapy. The company has one centre in Mumbai and plans to add 2 more in 2023. Positive read through.
Lupin

13 Jul 2023 , 11:40AM Lupin Ltd. has received form 483 with 2 observations for its Nagpur oral solid dosage facility from the USFDA. Negative read through for the stock.
Lupin

12 Jul 2023 , 12:20PM Lupin Ltd. has received EIR from the USFDA for its Pithampur Unit – 2 manufacturing facility that manufactures oral solids and ophthalmic dosage forms. The USFDA classifies the inspection as Voluntary Action Indicated (VAI). It will help the company to gain new approvals and launches especially for ophthalmic products. Positive read through for the stock
Lupin gets EIR from USFDA for its Pithampur Unit-2 Manufacturing facility

12 Jul 2023 , 10:56AM Lupin gets EIR from USFDA for its Pithampur Unit-2 Manufacturing facility
Lupin

6 Jul 2023 , 2:39PM Lupin Ltd. informed that its allotment committee of Directors at its meeting held today on July 06, 2003, allotted 16,139 fully paid-up equity shares of Rs. 2 each. These shares have been allotted upon exercising of options granted to the employees under stock options plans of the company. As such the issued and paid-up capital of the company has been increased to Rs. 91 Cr. consisting of 45.51 cr. equity shares of Rs. 2 each. Vs. 45.30 cr equity shares it was in Q4FY23. Neutral read through.
Lupin

5 Jul 2023 , 10:42AM Lupin Ltd. announced that it has received tentative approval for its ANDA, Dolutegravir tablets (RLD Tivicay PD tablets) for oral suspension of ViiV Healthcare. It has annual sales of USD 1 million in the US as per IQVIA MAT Mar 23. Positive for the stock.
Lupin

4 Jul 2023 , 10:42AM Lupin announced that it has received approval from the USFDA for its ANDA for Cyanocobalamin Nasal Spray 500 mcg, / spray a generic equivalent of Nascobal Nasal spray of Par Pharma Inc. It will be manufactured at Lupin’s Somerset facility in the US. The drug has annual sales of USD 69 million in the US (IQVIA MAT Mar 23).
Lupin

30 Jun 2023 , 10:25AM Lupin announced achievement of a key milestone for its novel product MALT1 inhibitor that is partnered with AbbVie inc. towards treatment of haematological cancers. As part of the agreement, Lupin has received USD 25 million from AbbVie for initiation of Phase 1 clinical studies successfully. Lupin had earlier received USD 30 million from AbbVie for achievement of other milestones in the program. Positive for the stock.
Lupin

27 Jun 2023 , 10:53AM Lupin is mulling stake sale in its API business as per market reports. If it fructifies it will be beneficial to its plan to expand margins further. API business contributes 7% of sales and has recovered in FY23 with a 12% rise in sales vs. decline of 28% seen in FY22. Attractive valuations, bright prospects and certified plants make the Indian API sector attractive for Indian and global investors. Apart from the market and the structural factors, a government push for the sector has further lifted the prospects for API players. Sentimentally positive for the stock.
Stock Update: Lupin

26 Jun 2023 , 11:07AM Stock Update: Lupin Ltd. (Company Update): gSpiriva a boost, yet stay on guard
Lupin launches Rufinamide oral suspension in the US

23 Jun 2023 , 12:21PM Rufinamide is used to control seizures in epilepsy patients
Lupin

23 Jun 2023 , 12:14PM Lupin Ltd. announced the launch of Rufinamide oral suspension 40 mg/mL to market generic of Banzel Rufinamide, which had estimated annual sales of USD 72 million in the U.S. (IQVIA MAT April 2023).
Lupin

21 Jun 2023 , 1:30PM Lupin announced that the USFDA has approved ANDA for Tiotropium Bromide Inhalation powder, a generic of Spiriva hand inhaler of Boehringer Ingelheim Pharmaceuticals, Inc. This product will be manufactured at Lupin’s Pithampur facility in India. This is the first generic approval for Spiriva HandiHaler in the U.S., and is also the first DPI approval from India for the U.S. This is an important milestone in its journey of building its respiratory franchise globally. Tiotropium Bromide Inhalation Powder (RLD Spiriva®) had estimated annual sales of USD 1,264 million in the U.S. (IQVIA MAT Mar 2023).
Lupin gets nod from USFDA for Tiotropium Dry Powder Inhaler.

21 Jun 2023 , 1:28PM Lupin becomes first Generic Player to get USFDA approval for gSpiriva
Lupin

19 Jun 2023 , 2:47PM Lupin Ltd. has received EIR from the USFDA for its API manufacturing facility located at Vishakhapatnam, India and received No Action Indicated (NAI) status for the same. Positive read through for the stock.
Lupin

19 Jun 2023 , 11:07AM Lupin Ltd. announced launch of Thiamine Hydrochloride Injection USP, 200 mg/2 mL (100 mg/mL) Multiple-dose Vials, after Lupin’s alliance partner Caplin Steriles Limited (Caplin) received an approval for its ANDA from the United States Food and Drug Administration (U.S. FDA). Thiamine Hydrochloride Injection USP had estimated annual sales of USD 35 million in the U.S. (IQVIA MAT April 2023). Positive read through for both Lupin and Caplin Point as it is an in-licensed product for Lupin and an out licensed one for Caplin Point for the US markets.
Lupin launches Thiamine Hydrochloride injection USP in US

19 Jun 2023 , 10:40AM Lupin launches Thiamine Hydrochloride Injection or vitamin B1 to treat low levels of thiamine in the body
Lupin launches Darunavir tablets in the United States

5 Jun 2023 , 10:21AM Lupin up on launhching Darunavir tablets in US
Lupin

5 Jun 2023 , 10:14AM Lupin has launched Darunavir tablets 600 mg and 800 mg, a generic equivalent of Prezista tablets of Janssen Products LP. The drug has annual sales of USD 308 million in the US as per IQVIA MAT March 2023 report. It’s a limited competition product. Highly positive for the company.
Lupin

2 Jun 2023 , 11:20AM Lupin has received approval from the USFDA for its ANDA for Diazepam Rectal gel Rectal Delivery system 10 mg and 20 mg, a generic of Diastat AcuDial Rectal Delivery system 10 mg and 20 mg of Bausch Health US, LLC. Diazepam Rectal Gel (RLD Diastat AcuDialTM) had estimated annual sales of USD 34 million in the U.S. (IQVIA MAT Mar 2023). Positive read through for the stock. We have a Reduce rating on the shares though.
Lupin

1 Jun 2023 , 10:07AM Lupin has received approval from the USFDA for its ANDA for Obeticholic Acid Tablets a generic of Ocaliva of Intercept Pharma Inc. It will be manufactured in its Nagpur facility. Obeticholic Acid Tablets (RLD Ocaliva) had estimated annual sales of USD 262 million in the U.S. (IQVIA MAT Mar 2023). Strong positive as it will be the first generic of it. We have a Reduce rating on the shares with a PT of Rs. 700.
Lupin

31 May 2023 , 9:52AM Lupin Ltd.: Lupin announced a strategic collaboration with Enzene Biosciences to launch Cetuximab in India, a biosimilar. Positive read-through for the stock. We have a Reduce rating on the shares though.
Lupin

29 May 2023 , 10:02AM The company received approval from Health Canada to market generic version of tiotropium bromide inhalation powder under the name Spiriva for treatment of chronic obstructive pulmonary disease in Canada. Positive read through for the stock.
Lupin

8 May 2023 , 10:29AM Lupin Ltd. announced the acquisition of the entire share capital of the French pharma company called Medisol, which was founded in 2011 and is engaged in generic injectables for France market. The acquisition will enable Lupin to gain access to 7 of Medisol’ s injectables across pain management, anti-inflammatory, cardiovascular diseases, and obstetrics therapies. Positive read through for the stock. However, we have Reduce rating on the shares with a PT of Rs. 660
Lupin Diagnostics launches regional reference laboratory in Bengaluru

13 Apr 2023 , 12:05PM The new laboratory marks a significant step forward in Lupin Diagnostics
Lupin

13 Apr 2023 , 11:02AM In a follow-up to the Form 483 issued on the company’s Pithampur plant at the end of March 23, the media furnishes the observations stating that 4 out of 10 observations are repeat observations. The same plant was given warning letter in Nov 2017. Its sentimentally negative.
Lupin

12 Apr 2023 , 1:49PM Lupin Ltd. announced the launch of its new state of the art Regional Reference Laboratory in Bangalore, Karnataka as a part of the expansion of its diagnostics network. It is in addition to the 25 reference laboratories and 410+ collection centres across India. Positive development.
Lupin

3 Apr 2023 , 1:06PM Lupin receives approval from the USFDA for Tenofovir Alafenamide tablets 25 mg (indicated for hepatitis B) a generic of Vemlidy 25 mg of Gilead Sciences. It will be manufactured at Lupin's Nagpur facility. Tenofovir had estimated annual sales of USD 531 million as of Dec 22 as per IQVIA MAT vs. USD 484 million market size it had in April 22 when Lupin first received the Tentative Approval for it. Highly positive as Lupin will be the first generic manufacturer of the RLD. We have a Hold rating on the stock.
Lupin

31 Mar 2023 , 2:35PM Lupin Ltd. has received approval from the USFDA for its ANDA for Tenofovir Alafenamide tablets 25 mg, a generic equivalent of Vemlidy tablets 25 mg of Gilead Sciences, Inc. This product will be manufactured at Lupin’s Nagpur facility in India. Tenofovir Alafenamide 25 mg had estimated annual sales of USD 531 million in the US (IQVIA MAT December 2022). Positive read through for the stock.
Lupin receives nod from USFDA for Tenofovir Alafenamide Tablets

31 Mar 2023 , 12:50PM Lupin receives USFDA nod for Tenofovir Alafenamide tablets used to treat Chronic Hepatitis B virus
Lupin

31 Mar 2023 , 12:26PM Lupin has informed that its Pithampur Unit 2 manufacturing facility has been inspected by the USFDA and issued form 483 with 10 observations. Negative read through for the stock. We have a Reduce Rating on the shares with a PT of Rs. 660.
Lupin

27 Mar 2023 , 11:05AM Lupin announced successful completion of the inspection for the UK Medicines and Healthcare products Regulatory Agency (UK MHRA) at its Pithampur facilities in India. Positive development for the stock. It has also completed a post marketing Adverse Drug Experience (PADE) inspection of the company's operations, which closed with no observations. Positive development for the stock.
Lupin

27 Mar 2023 , 10:33AM Lupin gets tentative nod from USFDA for Valbenazine Capsules
Lupin gets tentative nod from USFDA for Valbenazine Capsules

27 Mar 2023 , 10:31AM Valbenazine Capsules estimate annual sales of USD 1,235 million in the U.S
Lupin

24 Mar 2023 , 11:57AM Lupin announced that it has received Tentative approval for its ANDA, Obeticholic Acid Tablets 5 and 10 mg to market a generic equivalent of Ocaliva tablets for the same strengths of Intercept Pharmaceuticals Inc. The drug had annual sales of USD 255 million in the US as per IQVIA MAT as of Dec 22. Positive for the company as this ANDA was a Paragraph IV certification filing that can make Lupin as the first generic of the Ocaliva tablets and get 180 days marketing exclusivity for it once Lupin gets the final appro
Lupin gets tentative USFDA approval for Obeticholic Acid Tablets

24 Mar 2023 , 10:12AM Company gets tentative USFDA approval for its Abbreviated new Drug Application
Lupin

21 Mar 2023 , 9:47AM Lupin Limited announced that its alliance partner Caplin Steriles Limited has received final approval from the USFDA for its ANDA, Thiamine Hydrochloride Injection USP, 200 mg/2 mL (100 mg/mL) Multiple-dose Vials, to market a therapeutically equivalent to the reference listed drug (RLD), Thiamine Hydrochloride Injection USP 200 mg/2 mL (100mg/mL) of Fresenius Kabi USA LLC. Thiamine Hydrochloride Injection USP had an annual sale of approximately USD 36 million in the U.S. (IQVIA MAT for the 12-month period ending December 2022). Positive development for the stocks like Lupin and Caplin Point.
Lupin Digital Health unveils results of Digital Therapeutics Study with ACS patients

17 Mar 2023 , 2:22PM Lupin Digital Health unveils results of India’s First Digital Therapeutics Study with ACS Patients
Lupin

17 Mar 2023 , 2:17PM Lupin Digital Health Ltd., a therapeutics platform, has unveiled the results of its study in India, showing the efficacy of Digital Therapeutics (DTx) (Lyf) among patients with acute coronary syndrome (ACS) and post percutaneous coronary intervention. The study findings were presented at the India Live 2023 symposium in Chennai. The patients enrolled in the program demonstrated significant improvement with 90% adhering to the recommended medication, diet, and exercise regimen. Nearly 83.3% of patients maintained their vital signs within normal range and no re-hospitalization occurring during the first 30 days of enrolment. Positive read through for the stock
Lupin

14 Mar 2023 , 9:36AM Lupin Bioresearch Centre completes the 7th consecutive inspection of its Bioresearch centre in Pune, by the USFDA, which conducts BA/BE, PK/CD, In vitro BE, and biosimilar studies. The inspection closed without any observations. Positive read through for the stock.
Lupin

13 Mar 2023 , 12:02PM Lupin completed its pre-approval and GMP inspection by the USFDA of the company's API manufacturing facility at Vishakhapatnam, Vizag. The inspection concluded with no observations. Positive read through for the stock.
Lupin

1 Mar 2023 , 2:43PM Lupin has launched its new Regional Reference Laboratory in Hyderabad, Telangana. It is a part of the company’s strategy to build and strengthen its presence in South India. The addition leads to Lupin’s Diagnostics existing network reaching to 380+ LupiMitra collection centres and 23 labs across India. We have a Reduce rating on the shares.
Lupin

24 Feb 2023 , 11:15AM Lupin’s short term credit rating has been reaffirmed to A+ by ICRA considering its position as one of the leading pharma players in India, its diversified revenue base, and global leadership in several APIs supported by its liquidity and balance sheet position. However, US business continued to remain impacted by price erosion. Neutral to marginally positive read through for the stock.
Lupin

22 Feb 2023 , 9:19AM Lupin Ltd. announced the launch of Lurasidone Hydrochloride tablets, which is a generic of Latuda tablets of Sunovion Pharma Inc. The tablets had an estimated annual sale of USD 4.2 billion in the US (IQVIA MAT Dec 22) It’s a positive read through for the stock.
Lupin launches Lurasidone Hydrochloride tablets in the United States

21 Feb 2023 , 2:29PM Lurasidone Hydrochloride is used to treat certain mental/mood disorders
Lupin

17 Feb 2023 , 10:45AM Lupin Ltd. has received an Establishment Inspection Report (EIR) from the USFDA for its new injectable facility located at Nagpur, India. The EIR was issued post the last inspection of the facility conducted from Oct 17, 2022 – Oct 29, 2022. Positive
Lupin receives EIR from USFDA for its Injectable Facility in Nagpur

17 Feb 2023 , 10:13AM The EIR was issued post the last inspection of the facility conducted from October 17, 2022 to October 29, 2022
Lupin

9 Feb 2023 , 11:14AM Lupin Ltd. announced that it has received approval from the USFDA for its ANDA for Glycopyrrolate Injection USP, a generic equivalent of Robinul Injection, 0.2 mg/ml of Hikma Pharmaceuticals Inc. It is the first such approval from its new injectable facility at Nagpur, India. The approved product had estimated annual sales of USD 39.0 million in the US. (IQVIA MAT December 2022). Positive read through for the stock.
Lupin gets nod from USFDA for Glycopyrrolate Injection, USP

9 Feb 2023 , 10:50AM Lupin gets USFDA nod for Glycopyrrolate Injection USP used to treat ulcers in adults, children
Lupin

6 Feb 2023 , 2:40PM Drug maker Lupin has recalled 5,720 tubes of a cream used in the treatment of various skin conditions, such as dermatitis, eczema and psoriasis, from the US market due to a manufacturing issue, according to the US Food and Drug Administration. The affected lot has been manufactured at the company's Pithampur plant in Madhya Pradesh. Since the company has initiated the Class III nationwide (US) recall of the affected lot on January 23, it is a marginally negative to neutral read through
Lupin

31 Jan 2023 , 12:27PM Lupin Ltd. announced that it has received Tentative Approval from the USFDA under the US’ President’s emergency plan for AIDS relief (PEPFAR) for its New Drug Application (NDA) for Dolutegravir, Emtricitabine, and Tenofovir Alafenamide (DEFTAF) tablets. It will be manufactured at Lupin’s Nagpur facility. Positive read through for the stock.
Lupin arm launches digital therapeutics solution

24 Jan 2023 , 1:48PM Lupin launches LYFE, its Digital Therapeutic Solution for Holistic Heart Care
Lupin

24 Jan 2023 , 1:41PM Lupin Digital Health Ltd., a wholly owned subsidiary of Lupin Ltd. announced the launch of its digital therapeutics’ solution, LYFE. It is a heart care program that can reduce the risk of a heart attack and improve vitals and quality of life for cardiac patients as it will enable monitoring through connected devices. Positive read through for the stock
Lupin

19 Jan 2023 , 9:49AM Lupin Ltd. announced the launch of combination drug Sacubitril and Valsartan under two brands, Valentas and Arnipin in India. It is a generic of Vyamada brand of Novartis
Lupin

16 Jan 2023 , 3:22PM Lupin has received tentative approval for the company’s ANDA for Dolutegravir and Rilpivirine tablets 50 and 25 mg to market a generic of Juluca tablets 50 mg/25 mg of ViiV Healthcare Company. Juluca had estimated annual sales of USD 666 million in the US as per IQVIA MAT Sep 22.
Lupin gets tentative USFDA nod for Dolutegravir & Rilpivirine tablets

16 Jan 2023 , 2:07PM Dolutegravir & Rilpivirine combination is used to treat HIV infection
Lupin

12 Jan 2023 , 10:14AM Lupin has been focusing on optimization of direct and indirect costs such as plant operating expenses, frieght, FTS, and low margin SKUs. The company is investing in the US to maintain leadership position in the US Gx market, is expected to outperform IPM and has a strong growth momentum for emerging markets. The company has respiratory and biologics portfolio of products to drive its growth as well. The company expects to have consolidated sales of USD 2.5 - 3.0 billion by FY25E and consolidated EBITDA of 18-20%. It was mentioned at a JP Morgan Health Conference. Impact: Marginally positive.
Lupin

11 Jan 2023 , 9:35AM Lupin received approval from the USFDA for its ANDA Prasugrel tablets USP, a generic of Effient tablets of Cosette Pharma Inc. with an annual sale of USD 18 million in the US. Our view: Positive as the generic competition is lower in the drug.
Lupin gets USFDA nod for ANDA Prasugrel Tablets

10 Jan 2023 , 2:59PM Prasugrel is used to prevent strokes, heart attacks
Lupin, Exeltis announce reimbursement nod of NaMuscla in Spain

10 Jan 2023 , 12:29PM NaMuscla is the first and only licensed product for this indication in Europe
Lupin

10 Jan 2023 , 11:00AM Lupin and Exeltis Healthcare S.L. got approval from the Spanish Ministry of Health for the reimbursement of Lupin’s NaMuscla drug, for the symptomatic treatment of myotonia (which is a muscle dysfunctioning) in adults. The drug is the first and only licensed product for this indication in Europe and will be marketed by Lupin’s partner Exeltis in Spain. Our view: This is highly positive as myotonic dystrophy market is expected to grow at 7.6% CAGR during CY22-CY28 across the world. Being the indication for rare diseases make them highly costly. Getting a reimbursement from the government will make it more affordable thereby increasing its offtake.
Lupin

9 Jan 2023 , 10:59AM Lupin announced on Friday, post market, that it has received an USFDA approval for its ANDA, Fesoterodine Fumarate Extended-Release tablets, 4 mg, and 8 mg, to market a generic of Toviaz tablets of Pfizer Inc. It will be manufactured at Lupin's Goa facility. It had annual sales of USD 177 million in the US as per IQVIA MAT September 2022. Our view: It is positive as Toviaz tablets has only 4 generic players such as Alkem Labs, Aurobindo, Dr. Reddy’s, and Zydus Pharma, manufacturing it so far.
Lupin

5 Jan 2023 , 12:12PM Lupin Ltd. announced the launch of a novel fixed dose triple drug combination (FDC) of Indacaterol, Glycopyrronium and Mometasone for managing inadequately controlled asthma amongst patients. The product is launched under the brand name DIFIZMA in India. Lupin is the first company to offer this novel FDC dry powder inhalation (DPI) product in India. DIFIZMA is the only FDC product that has been approved by DCGI in India. Our view: Positive development
Lupin launches triple drug combination of Indacaterol, Glycopyrronium & Mometasone

5 Jan 2023 , 11:19AM Difizma is used to treat inadequately controlled asthma
Lupin

22 Dec 2022 , 1:42PM Lupin announced launch of its Regional Reference Laboratory in Indore, Madhya Pradesh as a part of its expansion plan in Central India. Lupin Diagnostics operates over 325 LupiMitra (franchisee collection centers) and 23 laboratories in India. Our view: Positive as it marks the expansion into Central India for diagnostics business. Also Lupin Pharmaceuticals Inc. in the US has been recalling four lots of Quinapril Tablets to the patients due to the presence of a nitrosamine impurity, N-Nitroso-Quinapril, observed in recent testing above the Acceptable Daily Intake (ADI) level. To date, Lupin has received no reports of illness that appear to relate to this issue. Our view: Marginally negative to neutral.
Lupin

21 Dec 2022 , 2:56PM Lupin announced that it has received approval from the USFDA for its ANDA for Brivaracetam tablets 10 mg, 25 mg, 50 mg, 75 mg, and 100 mg, which is a generic equivalent of Briviact Tablets of UCB Inc. The product will be manufactured from Lupin’s Nagpur, India facility. Brivaracetam (RLD: Briviact) had estimated annual sales of USD 420 million in the US as per IQVIA MAT September 2022. Our view: Positive as there was no other generic of Briviact available before it.
Lupin gets USFDA approval for Brivaracetam tablet

21 Dec 2022 , 1:33PM Brivaracetam is used to control partial onset seizures
Lupin launches authorized generic version of PENNSAID in the US

9 Dec 2022 , 2:36PM Pennsaid is used to treat the pain of Osteoarthritis
Lupin

5 Dec 2022 , 2:34PM Lupin announced the launch of Rufinamide Tablets USP 200 mg and 400 mg to market a generic equivalent of Banzel tablets 200 mg and 400 mg of Eisai Inc. Rufinamide tablets (RLD Banzel) had estimated annual sales of USD 138 million in the US as per IQVIA MAT October 2022.
Lupin launches Rufinamide Tablets USP in the United States

5 Dec 2022 , 1:54PM Rufinamide Tablets had an estimated annual sales of $138 m in the US
Lupin

29 Nov 2022 , 12:58PM Lupin: The company launches Formoterol Fumarate inhalation solution in the US used to control wheezing, shortness of breath, and chest tightness caused by Chronic Obstructive Pulmonary Disease (COPD). Formoterol Fumarate inhalation solution had an estimated annual sales of $268mn of the US business – Positive read through for the stock.
Lupin launches Formoterol Fumarate Inhalation Solution in US

29 Nov 2022 , 12:30PM Formoterol Fumarate inhalation solution had est annual sales of $268 m in the US
Lupin

29 Nov 2022 , 10:06AM Brazilian Subsidiary, MedQuimica Acquires Rights to Nine brands from Bausch Health
Lupin

25 Nov 2022 , 10:49AM The USFDA has issued 8 observations for the drug product facility and API facility at Mandideep. The US drug regulator has inspected company's Mandideep unit-1 facility during November 14-23, 2022 – negative read through for the stock
Lupin

22 Nov 2022 , 10:57AM The company has signed a Memorandum of Understanding (MoU) with the Government of Rajasthan to address the prevalence of Cardiovascular Disease (CVD) and Chronic Obstructive Pulmonary Disease (COPD) in the Alwar district of Rajasthan. The collaboration will work towards serving the local communities in Alwar through preventive, curative and support-based solutions focused on curing the diseases in the short term and reducing their prevalence in the long term. The program is planned to be rolled out in a phase-wise manner.
Lupin

20 Oct 2022 , 10:20AM The company’s wholly owned subsidiary Lupin Inc., USA, has signed Definitive Agreement with Sunovion Pharmaceuticals Inc., USA for acquiring Brovana and Xopenex HFA, respiratory brands with an aim to expand its portfolio of Inhalation products. Lupin Inc. will purchase all assets required to manufacture and commercialize Brovana Inhalation Solution and Xopenex HFA Inhalation Aerosol in the United States for a cash consideration of $75 million. Acquisition is expected to be completed 2-3 weeks post signing. IQVIA sales for the two brands combined were approximately $60 Million (MAT August 2022). Additionally, inspection conducted by the USFDA at Lupin’s Biotech manufacturing facility in Pune in October 2022 concluded with the issuance of a Form 483 with seventeen observations. However, 483 letter is not expected to have any material impact on the existing revenues from operations of this facility.
Lupin

7 Oct 2022 , 12:59PM The company has reached an agreement with Unitaid, the Aurum Institute, the Clinton Health Access Initiative (CHAI), and other global procurement agencies to support tuberculosis prevention treatment that will be rolled out to 138 countries, including many low-and middle-income countries with a large burden of TB. Through this agreement, Lupin will introduce two new formulations, a fixed-dose combination of Rifapentine + Isoniazid and Rifapentine 300 mg standalone tablets, at an affordable price. As a global leader in anti-TB medicines, Lupin is committed to ensuring its products are widely available in all countries and there is equitable access to treatment globally.
Lupin partners with global agencies

7 Oct 2022 , 12:16PM Lupin partners with global agencies to increase patient access to Tuberculosis Prevention Treatment
Lupin

7 Oct 2022 , 11:54AM The company announced the appointment of Dr. Shahin Fesharaki as Global Chief Scientific Officer. Dr. Fesharaki will be responsible for Lupin’s global research and development efforts across branded, generics and specialty products. With nearly 30 years' experience in drug development in leading global pharmaceutical companies, Dr. Fesharaki most recently served as the Chief Scientific Officer and Global Head of R&D for Hikma Pharmaceuticals. Prior to that Dr. Fesharaki held various leadership positions in Teva, Allergan/Actavis, Watson Pharmaceuticals and Apotex. Dr. Fesharaki has extensive development experience in both generic and branded pharmaceuticals across a broad range of technologies and dosage forms.
Lupin

4 Oct 2022 , 1:05PM The company has received USFDA nod for Darunavir. Darunavir is used as a pharmacokinetic booster.
Lupin

3 Oct 2022 , 10:36AM The company announced that it has received the Establishment Inspection Report (EIR) from the United States Food and Drug Administration (USFDA) for its Ankleshwar manufacturing facility, located in Gujarat. The inspection of the facility was conducted from August 16-19, 2022 – Positive read through for the stock
Lupin launches Sildenafil in the United States

29 Sep 2022 , 2:45PM Lupin Launches Sildenafil for Oral Suspension in the United States
Lupin gets Health Canada nod for Rymti

13 Sep 2022 , 2:42PM Rymti is used to treat Rheumatoid Arthritis
Lupin introduces generic Suprep Bowel Prep kit in US

9 Sep 2022 , 11:15AM Lupin launches Generic Suprep Bowel Prep Kit in the United States
Lupin, DKSH sign agreement to market 5 biosimilar candidates in Philippines

7 Sep 2022 , 10:54AM Lupin, DKSH sign an exclusive licensing and supply agreement to Market Five Biosimilar Candidates in the Philippines
Lupin

30 Aug 2022 , 10:26AM In partnership with Pharmascience Inc has announced that it has received tentative approval from the USFDA, for its ANDA Dasatinib Tablets in strengths - 20 mg, 50 mg, 70 mg, 80 mg, 100 mg, and 140 mg. The tablet used to treat a certain type of chronic myeloid leukemia as a first treatment. The addressable market size in the US for the tablets is substantial at $1569 mn as per IQVIA MAT June 2022. Given the healthy addressable market size the tentative approval is positive read thru
Lupin

29 Aug 2022 , 11:59AM Launches Desvenlafaxin Extended release tablets strength 25 mg, in the US markets. The tablet Desvenlafaxine is used to treat depression and has an addressable market size of USD 14 mn as per IQVIA MAT June 2022. Though the addressable market size of the drug is relatively small, the launch would widen and product offerings in the US markets; Positive read thru
Lupin gets UK MHRA nod for Tiotropium Bromide inhalation powder

26 Aug 2022 , 12:19PM Lupin announces UK MHRA Approval of Lutio for treatment of COPD
Lupin

26 Aug 2022 , 10:33AM As per media reports the company gets a USFDA approval for its ANDA for Dasatinib Tablet. The tablet is used to treat a certain type of chronic myeloid leukemia, which is a type of cancer of white blood cells as a first line of treatment. Positive
Lupin in exclusive licensing agreement with Japan's I'rom Group for Denosumab

25 Aug 2022 , 12:08PM Lupin and I'rom Enter into an Exclusive Licensing Agreement for Denosumab biosimilar for Japan
Lupin

25 Aug 2022 , 10:13AM The company has announced the acquisition of two brands from Boehringer Ingelheim International GmbH - Ondero and Ondero - Met (including trademark rights associated with the brands). The acquired brands are in the diabetes segment and are used to treat type 2 diabetes. The acquisition is done for a cash consideration of Eur 26 million (~Rs 207 cr). Also Lupin has received USFDA approval for its ANDA Formoterol Fumarate Inhalation Solution strength - 20 mcg/2 mL per Unit-Dose Vial. The drug is used for treatment or prevention or decreasing of breathing problems caused by ongoing lung diseases.
Lupin acquires 'Ondero' & 'Ondero Met' from Boehringer Ingelheim Intl GmbH

25 Aug 2022 , 9:38AM Lupin enters into Deed of Assignment with Boehringer Ingelheim International GmbH for the acquisition of brands Ondero and Ondero
Lupin

19 Aug 2022 , 10:42AM Lupin: Gets USFDA approval for its ANDA - Rufinamide Tablets USP, 100 mg, 200 mg, and 400 mg. The tablets had an annual estimated sales of $164 mn as per IQVIA MAT June 2022. Considering the healthy addressable market size, ANDA approval is positive.
Lupin receives USFDA nod for Rufinamide tablets USP

18 Aug 2022 , 2:57PM Rufinamide tablets are used to control seizures
Lupin receives nod from USFDA for Meclizine Hydrochloride tablets

12 Aug 2022 , 3:33PM Meclizine is an antihistamine that is used to prevent and treat nausea
Lupin

4 Aug 2022 , 10:30AM Lupin: reported a weak performance for Q1FY23 with the operating margins surprising negatively marred by confluence of factors like pricing pressures in the US and remediation cost at its plants. This coupled with the overall cost escalations, resulted in operating margins declining by 1552 bps yoy and consequently the company reported net loss of Rs 89 cr for Q1 as compared to Rs 505 cr profit in Q1FY22, while the sales declined by 12.3% yoy. The results missed estimates
Lupin

26 Jul 2022 , 10:38AM Lupin: The company gets an USFDA approval for ANDA for Azilsartan Kamedoxomil tablets with the strength of 40 mg and 80 mg. The drug is indicated for the treatment of high blood pressures and hypertension and the addressable market size for the tablets is USD 101 mn as of IQVIA MAT March 2022. Given the healthy addressable market size the ANDA approval is positive
Lupin

25 Jul 2022 , 10:05AM The company gets an USFDA approval for Azilsartan Kamedoxomil. The drug is indicated for the treatment of high blood pressures and hypertension. Positive
Lupin

20 Jul 2022 , 10:38AM Lupin Diagnostics has launched its first Reference Laboratory in Ranchi that is equipped a broad spectrum of routine and specialized tests in various fields. People in Jharkhand can now avail preventive health check-ups, home collection and testing centres at 10 locations. In line with its strategy of serving the East India, the company has established the reference lab in Ranchi following the reference labs being set up in Assam, West Bengal and Bihar and the company already has 100 franchise collection centres for East India. Positive read thru
Lupin Diagnostics launches its first reference laboratory in Ranchi

19 Jul 2022 , 2:48PM Lupin Diagnostics will equip doctors with accurate diagnosis in the patient journey
Lupin Somerset manufacturing plant receives EIR from USFDA

7 Jul 2022 , 10:17AM USFDA determines inspection Classification Company’s Somerset facility is Voluntary Action Indicated
Lupin gets approval from USFDA for Paliperidone Extended-Release Tablets

1 Jul 2022 , 10:54AM Paliperidone is mainly used to treat schizophrenia and schizoaffective disorder
Lupin

16 Jun 2022 , 2:32PM The diagnostics arm – Lupin diagnostics has launched its first Regional Reference Laboratory in Patna. The new Regional Reference Laboratory at Patna has capabilities to conduct a broad spectrum of routine and specialized tests across fields. By establishing its presence in the Patna, the company now looks to deeper penetrate Bihar, while earlier it had forayed in Assam and West Bengal. Through upcoming launches of laboratories in Jharkhand (Ranchi) and Orissa (Bhubaneshwar), the company is poised to solidify its position in East India. The company operates 280 centers across India and close to 100 diagnostic centres in East India. Positive read thru
Lupin Diagnostics launches its first Regional Reference Laboratory in Patna

15 Jun 2022 , 4:39PM Expanding diagnostics footprint in East India
Lupin

13 Jun 2022 , 9:45AM As per media reports, The European Medicines Agency has recommended the withdrawal of marketing Authorization in the European Union for amfepramone obesity drug citing safety reasons. This is likely to impact Lupins sales in the EU region, hence negative
Lupin gets tentative USFDA nod for Ivacaftor Tablets

8 Jun 2022 , 2:23PM Lupin receives tentative approval from USFDA for Ivacaftor Tablets
Lupin

6 Jun 2022 , 9:36AM As per media reports more than 300 employees were terminated by the company from the jobs from one of its OSD (Oral Solid Dosages) plants in India, after the USFDA inspection in which the samples were rejected after the agency audit. The sacked employees have lodged a complaint against the company in the local police Station and the management has mentioned that they could consider the released employees for positions as needed from time to time, but we await further clarity on this from the company.
Lupin

9 May 2022 , 9:33AM Gets USFDA approval for its ANDA - lloperidone Tablets in multiple strengths of – 1mg, 2mg, 4mg, 6mg, 8mg, 10mg, and 12mg. The lloperidone Tablets have been indicated for treating mental disorders and the products had estimated US sales of $162 mn in the US as of MAT March 2022. Also Lupin received another approval from USFDA for its ANDA – Pregabalin capsules in the strengths of 25 mg, 50 mg, 75 mg, 100 mg, 150 mg, 200 mg, 225 mg and 300 mg. Pregabalin capsules are used to treat epilepsy and anxiety. The product has an estimated addressable market size of $263 mn in the US as of MAT March 2022. Given the healthy addressable market size, the ANDA approvals are positive.
Lupin

2 May 2022 , 12:52PM Lupin diagnostics has launched a reference Laboratory in Guwahati – North East India. The reference lab has capabilities to conduct a broad spectrum of routine and specialized tests. The expansion is in line with the company’s strategy to expand its presence pan India and there increase access to quality testing in India. Positive read thru
Lupin, Yabao announce Strategic Partnership in China

27 Apr 2022 , 10:28AM Lupin Global enters into a strategic partnership with Chinese co Yabao Pharma, for drugs with Pediatric formulations in Chinese market
Lupin

19 Apr 2022 , 9:55AM Lupin: gets a tentative approval from the USFDA for ANDA Tenofovir Alafenamide Tablets, 25 mg, which is a generic equivalent of Vemlidy tablets. The tablets are used to treat chronic hepatitis B virus infection in adults with compensated liver disease. The tablets had an estimated annual sales of $ 484.2 million in the US, which is a sizeable addressable market size hence positive read thru.
Lupin

8 Apr 2022 , 12:43PM Lupin: has launched Merzee capsules strength - 1 mg/20 mcg, in the US market, under exclusive license, marketing and distribution agreement with Slayback Pharma LLC. Reference listed drug Taytulla had estimated annual sales of $90 million in US, which is sizeable addressable – hence the launch is positive
Lupin Completes Acquisition of Brands from Anglo-French

7 Apr 2022 , 11:28AM Lupin completes acquisition of a portfolio of brands from Anglo-French Drugs & Inds
Lupin

5 Apr 2022 , 3:16PM Lupin: The USFDA has inspected Lupin’s Tarapur manufacturing plant between 22 March 2022 to 4th April 2022. The inspection ended with 4 observations being issued by the USFDA and the management seems confient of addressing the same. However receipt of 4 observations is negative read thru
Lupin

4 Apr 2022 , 12:11PM Lupin: on 18th January 2022, The board of directors of Lupin had approved the acquisition of portfolio of brands from Anglo-French Drugs & Industries Limited and its associates in the Vitamins, Minerals and Supplements and CNS segment. Lupin has now announced that it has entered in to an agreement with Anglo-French Drugs & Industries Limited for the said agreement. The acquisition could strengthen Lupin’s presence in these segments.
Lupin

1 Apr 2022 , 9:54AM Lupin: The USFDA has inspected the company’s manufacturing plant located at Somerset (US) between 7th March 2022 to 30 March 2022. The inspection has ended with 13 observations and the management looks confident of addressing the same. The Somerset plant contributes less than 5 % of the company’s global revenues and the management believes that the observations would not result in any supply disruptions from the plant. However, we believe that the receipt of 13 observations is negative read thru
Lupin receives approval from USFDA for Sildenafil for Oral Suspension

24 Mar 2022 , 1:57PM The product will be manufactured at Lupin's facility in Goa, India
Lupin

14 Mar 2022 , 1:13PM Lupin: Gets USFDA approval for its ANDA - Vigabatrin for Oral Solution USP, strength 500 mg. The product is used to treat infantile spasms in babies and children between the age of 1 month and 2 years. The reference listed drug - Sabril has estimated annual sales of $275 mn in the US as of December 2021. Given the sizeable addressable market size the approval is positive
Lupin

11 Mar 2022 , 12:15PM Lupin diagnostics has launched its first ever reference laboratories in East India Kolkata. The new reference lab has the capabilities to conduct a broad spectrum of routine and specialized tests in the fields of molecular diagnostics, cytogenetics, flow cytometry, histopathology, cytology, microbiology, serology, haematology, immunology and routine biochemistry. Also Lupin Diagnostics is also setting up laboratories in West Bengal, Assam, Bihar, Jharkhand and Orissa to comprehensively cater to the East India region. Setting up of a reference lab in Kolkata would support the geographic expansion in east India for Lupin diagnostics, hence is Positive read thru
Lupin launches its first reference laboratory in East India

11 Mar 2022 , 9:44AM Lupin introduces its First Reference Laboratory in East India establishing its Diagnostics Business in Kolkata
Lupin

3 Mar 2022 , 3:30PM Lupin: gets USFDA approval for its ANDA - Efinaconazole Topical Solution, 10%. The solution is used to treat fungal or yeast infection of toenails. Efinaconazole Topical Solution had estimated annual sales of USD 274 million in the US. Given the strong addressable market size the approval is positive
Lupin receives approval from USFDA for Efinaconazole Topical Solution

3 Mar 2022 , 3:08PM Lupin Global gets USFDA nod for Efinaconazole Topical Solution, used for treatment of fungal or yeast infection of the toenails
Lupin

2 Mar 2022 , 11:32AM Sevelamer Hydrochloride Tablets, 800 mg, a generic equivalent of Renagel. The tablets are used to treat hyperphosphatemia in patients with chronic kidney disease who are on dialysis. Sevelamer Hydrochloride Tablets had estimated annual sales of $75 mn in the US. Given the healthy addressable market size the launch is positive
Lupin

2 Mar 2022 , 11:30AM Sevelamer Hydrochloride Tablets, 800 mg, a generic equivalent of Renagel. The tablets are used to treat hyperphosphatemia in patients with chronic kidney disease who are on dialysis. Sevelamer Hydrochloride Tablets had estimated annual sales of $75 mn in the US. Given the healthy addressable market size the launch is positive
Lupin

18 Feb 2022 , 10:37AM Lupin has announced that the U.S. Food and Drug Administration has approved the company’s supplemental New Drug Application (sNDA) to expand the use of SOLOSEC® (secnidazole) in the treatment of bacterial vaginosis (BV) for female patients 12 years of age and older and in the treatment of trichomoniasis for all patients 12 years of age and older. Positive read through for Lupin
Lupin receives USFDA approval for antibiotic Solosec

18 Feb 2022 , 9:48AM Lupin announces USFDA acceptance for bacterial vaginosis drug
Lupin

10 Feb 2022 , 9:43AM Lupin: has entered into a distribution agreement with Medis for its orphan drug NaMuscla, indicated for he symptomatic treatment of myotonia in adults with non-dystrophic myotonic disorders. NaMuscla is the e first and only licensed product for treating the indication. As per agreement Medis would commercialise the product in Central and Eastern Europe. Positive
Lupin Q3FY2022: Weak quarter

4 Feb 2022 , 9:47AM Lupin Q3FY2022: Weak quarter; Operating performance misses’ estimates
Lupin

28 Jan 2022 , 9:52AM Alongwith Exeltis USA Inc. Lupin announced a promotional agreement for Exeltis to promote SOLOSEC along with Exeltis’ existing line of Women’s Health products. SOLOSEC is indicated for the treatment of Bacterial Vaginosis in adult women and Trichomoniasis in adults. The agreement would enable to expand the reach of Solosec and also improve the accessibility for the patients.
Lupin signs first partnership agreement with Foncoo for China

21 Jan 2022 , 10:11AM Lupin enters into a partnership with Shenzhen Foncoo Pharmaceutical
Lupin

19 Jan 2022 , 11:06AM Lupin: has entered into a partnership with Shenzhen Foncoo Pharmaceutical Co. Ltd, China to launch high quality generic and complex generic medicines in China markets. Foncoo’s successful experiences of importing registration and marketing of the generic formulations and Lupin’s strong capability of making high quality medicines make the partnership a perfect match and points at possible growth opportunities for Lupin. The partnership is in line with Lupin’s strategy of investing in key growth markets including China and hence Positive
Lupin signs first partnership agreement with Foncoo for China

19 Jan 2022 , 10:52AM Lupin enters into a partnership with Shenzhen Foncoo Pharmaceutical (Foncoo)
Lupin

18 Jan 2022 , 3:55PM The board of directors of the company has approved the acquisition of portfolio of brands from Anglo-French Drugs & Industries Limited and its associates in the Vitamins, Minerals and Supplements and CNS segment, which would strengthen Lupin’s presence in these segments.
Lupin launches Molnupiravir under the brand name Molnulup

7 Jan 2022 , 10:08AM Lupin launches Molnupiravir under the brand name Molnulup for the treatment of COVID-19 in adults in India
Lupin

27 Dec 2021 , 11:46AM Lupin: gets USFDA approval for its ANDA - Sevelamer Carbonate for Oral Suspension, 0.8 g and 2.4 g packets. The drug is indicated for control of serum phosphorus in adults and children 6 years of age and older suffering from chronic kidney disease on dialysis. The reference listed drug Renvela had estimated annual sales of USD 51.7 mn MAT in the US as of September 2021 as per IQVIA. Further the product would be manufactured at the Goa plant and consequently is a first product to be approved post receipt of the EIR from the USFDA and hence Positive.
Lupin receives tentative nod from USFDA for Azilsartan Medoxomil Tablets

24 Dec 2021 , 10:33AM The product will be manufactured at Lupin's Nagpur facility in India
Stock Update: Lupin

21 Dec 2021 , 10:56AM Stock Update: Lupin - Goa EIR provides respite; long-term growth levers intact
Stock Update: Lupin

21 Dec 2021 , 10:54AM Stock Update: Lupin - Goa EIR provides respite; long-term growth levers intact
Lupin

14 Dec 2021 , 11:25AM The Goa plant of the company has received an Establishment Inspection Report (EIR)from the USFDA (Plant inspected in September 2021). The USFDA has determined the inspection classification of the facility as VAI (Voluntary Action Indicated). The Goa plant of the company houses key product fillings for the US markets and with the receipt of the EIR the new launch momentum in the US markets is expected to improve and this could partially offset the high competitive pressures and add to the US top-line growth. – Positive
Lupin's Goa manufacturing plant receives EIR from USFDA

14 Dec 2021 , 10:25AM Receives EIR from USFDA with Voluntary Action Indicated classification for our Goa plant
Lupin

13 Dec 2021 , 12:10PM Lupin: US-based arm is recalling 4,113 cartons of generic oral contraceptive tablets from the US markets - Tydemy (drospirenone, ethinyl estradiol & levomefolate calcium tablets, 3 mg/0.03 mg/0.451 mg and levomefolate calcium tablets, 0.451 mg). The company is recalling the lot due to it being "Subpotent Drug" and as per the USFDA, the recall is classified as a Class III recall, hence unlikely to have any material impact on the financial performance of the company
Lupin

10 Dec 2021 , 2:30PM Lupin: Has announced the launch of diagnostic services – Lupin Diagnostics in India, which is a part of its strategy to provide integrated healthcare services. It has established a state-of the-art 45,000 sq. ft National Reference Laboratory in Navi Mumbai with experienced doctors and trained technologists and capability to offer comprehensive range of diagnostic tests. Healthcare services are gaining an increasing importance post the advent of the pandemic and diagnostics services are an integral part of it. Lupin’s entry in the diagnostics space provides a new growth avenue and in the process would diversify the revenue base, hence potentially positive.
Lupin announces launch of its Diagnostics business

10 Dec 2021 , 2:04PM The company establish 45,000 sq.ft National Reference Laboratory in Navi Mumbai
Lupin

6 Dec 2021 , 10:47AM Lupin: The company has entered in to exclusive distribution and marketing agreement with Biomm SA in Brazil. As per the terms of the agreement Biomm SA would distribute and market biosimilar Pegfilgrastim in Brazil. Earlier Lupin had received an approval from the USFDA for the BLA (Biologics License Application) for its proposed biosimilar to Neulasta (pegfilgrastim). The agreement is positive as it could help improve the geographic reach for the biosimilar.
Lupin partners with TTP plc UK for Soft-mist Inhalation Technology Platform

2 Dec 2021 , 11:38AM Lupin subsidary, TTP PLC sign deal to develop soft-mist inhalation technology platform
Lupin launches educational mobile adaptable website for medical students

30 Nov 2021 , 12:57PM Lupin launches Sciflix a mobile-friendly learning platform for post graduate students specializing in pulmonology
Lupin

18 Oct 2021 , 10:48AM Lupin: Has voluntarily recalled all batches of lrbesartan Tablets and lrbesartan and Hydrochlorothiazide Tablets in the US markets due to presence of impurities - N-nitrosolrbesartan, which were found in the API of the medicine. Being a voluntary recall, it is unlikely to have any material impact on the financials of the company.
Lupin

7 Oct 2021 , 1:12PM Gets USFDA tentative approval for its ANDA - Brexpiprazole Tablets strengths - 0.25 mg, 0.5 mg, 1 mg, 2 mg, 3 mg, and 4 mg. The tablets are used to reat the symptoms of schizophrenia as well as is also used with an antidepressant to treat depression. Brexpiprazole Tablets have an estimated annual sales of $1258 mn in the US as per IQVIA MAT July 2021. Given the strong addressable market size for the product, the tentative approval is positive
Lupin receives tentative approval from USFDA for Brexpiprazole Tablets

7 Oct 2021 , 12:32PM Lupin gets tentative approval from the USFDA for its ANDA Brexpiprazole Tablets
Sun Pharma, Lupin

1 Oct 2021 , 9:39AM New Jersey federal judge has invalidated a Sun Pharmas patent on a branded treatment to prevent pain in eye surgery patients post cataract surgery. The suit was a part of intellectual property fight between Sun pharma and Lupin and pertains to Sun pharma’s product bromiside. Lupin has requested approval from the federal government to market a generic version of the brand-name product, which has resulted in Sun Pharma to file suit alleging patent infringement. Though this is sentimentally negative for both Sun pharma and Lupin, we await further clarity on this
Lupin launches Droxidopa capsules in the United States

29 Sep 2021 , 10:56AM Indicates for the treatment of orthostatic dizziness, lightheadedness, or the "feeling that you are about to black out" in adult patients with symptomatic neurogenic orthostatic hypotension (nOH) caused by primary autonomic failure
Lupin falls as USFDA issues seven observation

20 Sep 2021 , 11:06AM Lupin dips by 4% to Rs. 913, after receiving final nod from the USFDA to market Vortioxetine Tablets
Lupin

20 Sep 2021 , 10:22AM Lupin- Gets 7 USFDA Observations at Goa facility unit was earlier inspected by USFDA- Sentimentally negative.
Lupin launches authorized generic version of Duexis in the United States

15 Sep 2021 , 3:24PM Lupin launches the authorised generic version of Duexise tablets, a nonsteroidal anti-inflammatory drug (NSAID) in the US
Lupin

6 Sep 2021 , 1:53PM TB alliance, a non profit drug developer has granted Lupin a non-exclusive license to manufacture the anti-TB drug pretomanid as part of the three-drug regimen. Lupin intends to commercialize the anti-tuberculosis medicine in approximately 140 countries and territories, including many of the highest TB burden countries around the world, hence positive.
Lupin Global, TB Alliance announce commercial partnership for new therapy

6 Sep 2021 , 10:40AM TB Alliance and Lupin announce commercial partnership for new therapy for Highly Drug-Resistant TB
Lupin launches Luforbec for treatment of Asthma & COPD

24 Aug 2021 , 2:10PM Luforbec use for the treatment of asthma and for severe chronic obstructive pulmonary disease
Lupin receives tentative USFDA approval for Brivaracetam tablets

17 Aug 2021 , 12:13PM Brivaracetam Tablets indicates for the treatment of partial-onset seizures in patients four years of age and older
Lupin

17 Aug 2021 , 9:34AM Lupin: Gets tentative approval from the USFDA for its ANDA - Brivaracetam Tablets strengths: 10 mg, 25 mg, 50 mg, 75 mg, and 100 mg. The tablets are indicated for treatment of partial-onset seizures in patients four years of age and older. The reference listed drug – Briviact tablets have an estimated annual sales of $311 mn in the US as of June 2021 – IQVIA MAT. Also Lupin is looking for manufacturing partners in China and plans to enter China markets with few of its respiratory products which have been commercialized in other regulated markets or in pipeline. Both the receipt of tentative approval (due to sizeable addressable market opportunity) and plans to enter the China markets are positive.
Lupin: Stock update

12 Aug 2021 , 11:51AM Lupin: Stock update - long-term growth levers intact
Lupin Q1FY2022

11 Aug 2021 , 10:19AM Lupin Q1FY2022: Operating performance marginally misses estimates
Lupin

30 Jul 2021 , 12:32PM The company’s Australian Subsidiary – Generic health has entered into a definitive agreement under which Lupin will acquire 100% of the shares of Southern Cross Pharma Pty Ltd (SCP), which is engaged in developing, registering, and distributing generic products. Generic Health will gain access to over 60 registered products having sales of over AUD 30 Mn (approximately USD 22 Mn). This will significantly increase Lupin’s value proposition and market share in the Australian market. The acquisition is aligned with Lupin’s strategy to expand and deepen presence in select markets of focus. The transaction is expected to be completed in the 5-6 months time frame. Given the synergies mentioned above, the acquisition is positive
Lupin acquires Southern Cross Pharma in Australia

30 Jul 2021 , 11:37AM Lupin's arm Generic Health to acquire Southern Cross Pharma
Lupin

15 Jul 2021 , 10:45AM As per media news, Vertex Pharmaceuticals has said that Lupins proposed generic version of Kalydeco, which is used for treatment of cystic fibrosis, infringes a patent for the drug. Accordingly Vertex is seeking a court order blocking copies of the drug until the patent expires and has filed a complaint in the feder-al court of Delaware. The Patent for the said drug was issued in May 2020 and expires in August 2029. We await further clarity on this from Lupin.
Lupin launches Tavaborole Topical Solution in the US

13 Jul 2021 , 2:37PM Lupin launches Tavaborole Topical solution in the US market, used to treat onychomycosis of the toenails
Lupin

2 Jul 2021 , 9:41AM Gets USFDA approval for its supplemental New Drug Application (sNDA) to expand the use of SOLOSEC to include the treatment of trichomoniasis in adults. Trichomoniasis is the most common non-viral infection in the U.S affecting an estimated three to five million people every year. The supplemental approval makes SOLOSEC® the first and only single-dose oral prescription antimicrobial agent approved for the treatment of both trichomoniasis and BV (bacterial Vaginosis). The approval of the sNDA is positive and would add to the US topline which accounts for 37% of the overall FY2021 sales
Lupin

30 Jun 2021 , 4:02PM Lupin: The company had received a warning letter from the USFDA for its somerset plant and the warning letter mentions the corrective actions required to be taken at somerset which includes strengthening the cleaning and maintenance procedures, strengthening the manufacturing process validations and a robust quality unit oversight. The company would be working towards addressing the observations, but the warning letter also mentions of repeat violations at multiple sites demonstrates that the company’s oversight and control over manufacturing process is inadequate. Lupin’s other plants at Goa and Indore are already under USFDA scrutiny and these observations could result in a delay in the resolution of the warning letter at these plants as well.
Lupin Global gets tentative USFDA approval for a combination drug to treat HIV

30 Jun 2021 , 10:18AM Lupin receives tentative USFDA nod for Dolutegravir, Lamivudine and Tenofovir Disoproxil Fumarate tablets under PEPFAR
Lupin

28 Jun 2021 , 9:33AM Lupin: Has launched Emtricitabine and Tenofovir Disoproxil Fumarate Tablets Strength - 200 mg/300 mg, which is approved by the USFDA. The Tablets are are the generic equivalent of Truvada tablets and indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection. The reference Listed Drug Truvada tablets had estimated annual sales of USD 2.1 billion in the U.S as of IQVIA MAT March 2021. Given the sizeable addressable market size the product launch is positive.
Lupin

25 Jun 2021 , 10:22AM Otsuka sues Lupin in the court of Delaware (US) over versions of kidney treatment drug - Jynarque proposed by Lupin. Otsuka has claimed that Lupin’s version of the drug infringes two patents for the drug and Otsuka is seeking court order blocking copies of the drug until patents have expired. The patents are set to expire in September 2026 and April 2030. The filling of the legal suit in the Delaware court is negative for Lupin.
Lupin

17 Jun 2021 , 3:23PM Lupin: Gets USFDA approval for Sevelamer Hydrochloride Tablets strength - 400 mg and 800 mg. The Tablets are indicated for the control of serum phosphorus in patients with chronic kidney disease on dialysis. The reference listed drug – Renagel had an estimated annual sales of $ 80 mn in the US as of March 2021 MAT. The approval is positive for Lupin as it would add to the US sales growth
Lupin receives USFDA nod for Sevelamer Hydrochloride Tablets

17 Jun 2021 , 3:20PM Sevelamer Hydrochloride Tablets are indicated for the control of serum phosphorus in patients with chronic kidney disease (CKD) on dialysis
Lupin receives UK marketing authorization for Luforbec

14 Jun 2021 , 1:49PM Luforbec is for regular treatment of asthma and for the symptomatic treatment of patients with severe chronic obstructive pulmonary disease
Lupin

14 Jun 2021 , 10:17AM LUPIN: The USFDA has issued a warning letter to the company’s Somerset (New Jersey, US). The plant was inspected in between September 10, 2020 to November 5, 2020 and earlier was given 13 observations. As per the management the warning letter would be have any impact on the supplies or revenue from operations. However the receipt of the warning letter is negative.
Lupin gets USFDA nod for Emtricitabine & Tenofovir DisoproxilFumarate Tablets

7 Jun 2021 , 2:18PM The product will be manufacture at Lupin's facility in Nagpur, India
Lupin enters digital healthcare space

3 Jun 2021 , 12:43PM Lupin steps into the digital healthcare space with a focus to provide a digital therapeutics platform for doctors and patients in India
Lupin

27 May 2021 , 2:19PM Lupin: Has announced the achievement of key milestones for its MEK inhibitor compound (LNP3794) that is planned for development by Boehringer Ingelheim in combination as potential targeted therapy for patients with difficult-to-treat cancers. As part of the agreement, Lupin has received payment of USD 50 million from Boehringer Ingelheim for achievement of key milestones. In 2019 Lupin and Boehringer Ingelheim inked a licensing, development and commercialization agreement for Lupin’s novel oncology compound to treat KRAS-driven cancers. The receipt of milestone payment of $50 mn is positive and also this provides visibility on the strong product pipeline.
Lupin receives $50 mn from Boehringer Ingelheim

27 May 2021 , 11:50AM Lupin announces achievement of Key Milestones for its Clinical Stage MEK Inhibitor Compound
Lupin

10 May 2021 , 2:56PM Lupin: has signed a royalty-free, limited, non-exclusive voluntary licensing agreement with Eli Lilly for manufacturing and selling of Eli Lilly’s drug Baricitinib in India. Barcitinib has received permission from Central Drugs Standard Control Organization for restricted emergency use in combination with Remdesivir for the treatment of suspect or laboratory-confirmed COVID-19 in hospitalized adults requiring supplemental oxygen, invasive mechanical ventilation, or extracorporeal membrane oxygenation. Baricitinibs timely and restricted emergency use could be an important life saving treatment for Covid 19 patients and with the surge in Covid cases in India, the demand for Barcitinib is expected to be higher, hence the licensing agreement is positive.
Cipla, Lupin, Sun Pharma, Dr Reddys

3 May 2021 , 10:20AM The companies had earlier subscribed to a 20% partnership in ABCD Technologies LLP and pursuant to inclusion of 9 new partners in the company the share of the partnership now stands revised to 6.45% with a corresponding share of profits as well.
Lupin

28 Apr 2021 , 11:45AM Lupin: has settled a lawsuit in the US for cancer drug Evomela with Ligand. Earlier ligand has claimed that Lupin’s purposed generic version of Evomela infringes two patents for Evomela. As per the settlement, Luoin won’t sell its version of Evomela until such date permitted by the settlement agreement.
Lupin

22 Apr 2021 , 11:46AM Lupin: The company has incorporated a wholly owned subsidiary company in the US under the name Lupin Oncology Inc. This wholly owned subsidiary will be engaged in development/co-development and commercialization of multiple oncology Products globally and will also be pursuing partners, financial sponsors
Cadila, Lupin, Sun Pharma, Torrent Pharma

26 Mar 2021 , 10:25AM Each of the companies either directly or through subsidiary companies have subscribed to partnership interest in ABCD Technologies LLP , which is a recently incorporated entity and has not commenced any business activity. The consideration for the said partnership is Rs 40 crore by each of the companies for acquisition of a 20% stake each in ABCD Technologies LLP, which would be renamed as IndoHealth Services LLP. The objective of the partnership is to facilitate, enable and promote efficiency and Good Distribution Practices including digitizing healthcare infrastructure in India, inter alia, in support of the National Digital Health Mission of Government of India. Neutral read thru
Lupin

10 Mar 2021 , 2:55PM Lupin: Has launched the generic version of Alinia tablets strength – 500 mg in the US, which are used to treat diarrhea caused by Giardia lamblia or Cryptosporidium parvum in patients 12 years of age and older. The reference listed drug – Alinia has reported US sales of $ 56 mn as per IQVIA MAT January 2021. The launch is positive as it could help grow the US topline as well as also widen the product offerings.
Lupin launches authorized generic version of Alinia

10 Mar 2021 , 2:53PM Lupin launches generic version of Alinia tablets strength – 500 mg in the US
Lupin's canada arm announces partnership with Endoceutics

9 Mar 2021 , 10:57AM Lupin's canada arm announces partnership with Endoceutics for commercialisation of ‘Intrarosa’
Lupin launches penicillamine tablets USP

2 Mar 2021 , 3:28PM Lupin gets USFDA nod to launch Penicillamine Tablets USP, 250 mg
Lupin

19 Feb 2021 , 5:02PM Lupin: Gets final approval from the USFDA for Droxidopa Capsules, 100 mg, 200 mg and 300 mg. The Droxidopa Capsules are indicated for the treatment of orthostatic dizziness, lightheadedness, in adult patients with symptomatic neurogenic orthostatic hypotension. Droxidopa Capsules reported an estimated annual sales of USD 352 mn in the US as per IQVIA MAT December 2020. The approval is positive as would add to the US sales.
Lupin

17 Feb 2021 , 1:50PM Posaconazole Delayed-Release Tablets, 100 mg after its alliance partner AET Pharma US Inc. got an approval for its ANDA from USFDA. The tablets are indicated for prophylaxis of invasive Aspergillus and Candida infections in patients who are at high risk of developing these infections due to being severely immunocompromised. The reference listed Drug Noxafil reported estimated annual sales of $186 mn in the US as per IQVIA MAT December 2020. The approval is positive for Lupin as it would add to US sales.
Lupin launches Posaconazole Delayed-Release Tablets

17 Feb 2021 , 12:08PM Lupin launches Posaconazole delayed-release tablets, used for the treatment of Invasive Aspergillus & Candida infections
Lupin receives nod for Tavaborole Topical Solution

9 Feb 2021 , 3:28PM Lupin receives USFDA approval for Tavaborole topical solution which used to treat toenail infection caused by fungus
Lupin Q3FY2021

29 Jan 2021 , 10:03AM Lupin Q3FY2021: Strong Operating performance and a low tax leads to PAT beat
Lupin : Multiple growth levers in action

27 Jan 2021 , 10:38AM Lupin : Multiple growth levers in action
Lupin get nod for Sevelamer Carbonate Tablets

25 Jan 2021 , 12:37PM Sevelamer Carbonate Tablets, used for the control of serum phosphorus in adults and children 6 years of age and older with chronic kidney disease on dialysis
Lupin

7 Jan 2021 , 3:44PM Lupin: Gets tentative approval from the USFDA for its Empagliflozin and Metformin Hydrochloride Extended Release Tablets with strengths - 5 mg/1000 mg, 10 mg/1000 mg, 12.5 mg/1000 mg, and 25 rng/1000 mg. The tablets are indicated as an adjunct to diet and exercise, to improve glycemic control in adults with type 2 diabetes mellitus. The reference listed drug – Synjardy XR has an estimated annual sales of $357 mn in the US as per IQVIA MAT November 2020. The tentative approval is positive as it points at a healthy growth potential for the US business of the company
Lupin gets tentative nod for Extended Release tablets from USFDA

7 Jan 2021 , 3:38PM Lupin receives tentative approval for Empagliflozin and Metformin Hydrochloride ER Tablets
Lupin gets USFDA nod to market generic version of Sulfamethoxazole and Trimethoprim

7 Jan 2021 , 10:14AM Lupin receives approval for Sulfamethoxazole and Trimethoprim Oral Suspension USP
Lupin

7 Jan 2021 , 10:01AM Received approval from the USFDA for Sulfamethoxazole and Trimethoprim Oral Suspension USP, 200 mg/40 mg per 5 ml. The drug is indicated for treatment and prevention of a wide variety of bacterial infections (such as middle ear, urine, respiratory, and intestinal infections), and certain type of pneumonia (pneumocystis-type). Reference Listed Drug – Bactrim m) had estimated annual sales of approximately USD 19 million in the US as per IQVIA MAT September 2020. The approval is positive as it would help grow the US sales.
Lupin

6 Jan 2021 , 10:54AM As per media news, The USFDA has issued form 483 to Lupin’s Somerset Facility (New Jersey, US) with around 12 observations. The facility was inspected between 10th September 2020 to November 2020. The plant was earlier classified as OAI (Official Action indicated) by the USFD and was up for re-inspection. The receipt of form 483 is sentimentally negative.
Lupin launches osteoarthritis drug

28 Dec 2020 , 5:16PM reference listed drug Vivlodex reported annual sales of ~ $ 11 million in the US
Lupin gets USFDA nod for toenail drug

28 Dec 2020 , 2:11PM The reference listed drug – Jublia has estimated annual sales of $222.9 million in the US
Lupin gets USFDA nod for toenail drug

28 Dec 2020 , 2:08PM The reference listed drug – Jublia has estimated annual sales of $222.9 million in the US
Lupin

22 Dec 2020 , 9:48AM USFDA approval for Rufinamide Oral Suspension, 40 mg/ml, which is a generic equivalent of Banzel Oral Suspension. The drug is indicated adjunctive treatment of seizures associated with Lennox-Gastaut syndrome in pediatric patients 1 year of age and older, and in adults. Banzel had an estimated annual sales of USD 124.5 million in the US as per IQVIA MAT September 2020. The approval is positive as it would add to the US sales.
Lupin gets approval for Colesevelam Hydrochloride Tablets

21 Dec 2020 , 3:16PM Lupin received approval for its Colesevelam Hydrochloride Tablets, 625 mg, from the USFDA
Lupin

21 Dec 2020 , 9:53AM Lupin: Gets approval for its Colesevelam Hydrochloride Tablets, 625 mg from the USFDA. The medicine is a generic equivalent of Welchol Tablets. The medicine is indicated to reduce the Cholesterol levels (LDL – C). The generic equivalent tablet has reported an annual sale of approximately USD 159 million in the US as per IQVIA MAT September 2020. The approval is positive as it would add to the US sales
Lupin

16 Dec 2020 , 3:11PM Has announced that it has amicably settled a dispute with the sellers in the Gavis / Novel transaction and to the satisfaction of all involved parties. Back in March 2016 Lupin had completed the acquisition of the US based Gavis Pharmaceuticals LLC and Novel Laboratories, which had strengthened its presence in the Us generic markets and had complemented its portfolio in the dermatology business. The settlement of dispute is positive as it would remove the overhang
Lupin receives approval for Penicillamine Tablets USP

1 Dec 2020 , 2:31PM Lupin gets USFDA nod for Penicillamine Tablets, indicates in the treatment of Wilson’s disease, Cystinuria, and in patients with severe, active x who have failed to respond to an adequate trial of conventional therapy
Lupin

25 Nov 2020 , 1:43PM Lupin: Alliance partner - Concord Biotech Limited has received an approval from the USFDA for Tacrolimus Capsules USP – Strength 0.5 mg, 1 mg, and 5 mg. Consequently, Lupin has launched the medicine in the US. The capsules are indicated for prophylaxis of organ rejection, in adult patients receiving allogeneic kidney transplant, liver transplant, and heart transplant, and in pediatric patients receiving allogeneic liver transplants, in combination with other immunosuppressants. Tacrolimus Capsules had an annual sales of approximately USD 303 million in the U.S as per IQVIA MAT September 2020. The launch is positive as it would aid the growth in the US sales.
Lupin launches Tacrolimus Capsules USP

25 Nov 2020 , 1:42PM Lupin launches immunosuppressive drug, Tacrolimus capsule in the US market
Lupin

17 Nov 2020 , 9:44AM As per media news, the USFDA has accepted Lupin’s Supplemental New Drug Application for Solosec, which is a drug indicated for the treatment of trichomoniasis in adults and adolescents. The FDA has assigned a target date of June 30, 2021. If approved for trichomoniasis, Solosec could be the only single-dose oral prescription treatment for the infection.
Lupin's alliance partner concord receives USFDA approval for Tacrolimus Capsules USP

12 Nov 2020 , 3:37PM Tacrolimus Capsules USP indicates for the prophylaxis of organ rejection in adult and pediatric patients
Lupin Q2FY2021: Weaker quarter

5 Nov 2020 , 11:30AM Lupin Q2FY2021: Weaker quarter; higher tax rate leads to PAT decline
Lupin

6 Oct 2020 , 1:44PM Lupin: Gets USFDA approval for Dimethyl Fumarate Delayed-Release Capsules, 120 mg and 240 mg for the US markets. The medicine is are indicated for the treatment of patients with relapsing forms of multiple sclerosis. Reference listed drug – Tecfidera had annual sales of approx. $ 3788 mn in the US as of June 2020 as per IQVIA MAT. Lupin is expected to launch the product shortly. The Approval is positive as it would fuel the US revenues.
Lupin receives approval for Dimethyl Fumarate Delayed-Release Capsules

6 Oct 2020 , 12:43PM Lupin gets USFDA nod for Dimethyl Fumarate delayed-release capsules, used to treat relapsing multiple Sclerosis
Lupin launches Lapatinib tablets

1 Oct 2020 , 10:00AM Lupin launches generic metastatic breast cancer drug in US
Lupin

28 Sep 2020 , 3:37PM Launches Fosaprepitant for Injection, 150 mg Single-Dose Vial. The drug is indicated for treatment of Acute and delayed nausea and vomiting associated with moderate and high emetogenic cancer chemotherapy (MEC). The reference listed drug Emend – has an annual sales of $136 mn in the US on MAT July 2020. Also the company has launched Atorvastatin Calcium Tablets USP, 10 mg, 20 mg, 40 mg, and 80 mg. The tablets are indicated to lower cholesterol in blood for adults and children over 10 years of age and also is indicated to lower the risk of heart attack and stroke. The reference listed drug Liptor reported US sales of $559 mn as of July 2020 MAT. The launch is positive and would result in higher topline in the US business.
Lupin launches Atorvastatin calcium tablets USP

28 Sep 2020 , 1:37PM Lupin launches Atorvastatin calcium tablets, used to lower cholesterol in blood for adults and children above 10 yrs
Lupin

22 Sep 2020 , 5:12PM Gets USFDA approval for Divalproex Sodium Extended-Release (ER) Tablets USP, 250 mg and 500 mg. The drug is indicated for treatment of manic or mixed episodes associated with bipolar disorder, seizures and Prophylaxis of migraine headaches. The reference Listed drug – Depakote ER has annual sales of USD 130 mn in US as per QVIA MAT July 2020. The approval is positive as it would enable grow the company’s US revenues.
Lupin gets USFDA approval for Divalproex tablets

22 Sep 2020 , 3:43PM Lupin launches Divalproex sodium extended-release tablets, used for treatment of bipolar disorder
Lupin hit 52-week high

18 Sep 2020 , 10:32AM Lupin rises by 9% to Rs. 1,110 in the current market
Cipla, Lupin

18 Sep 2020 , 9:59AM As per media reports, Perrigo Company plc announced a voluntary U.S. nationwide recall of albuterol sulfate inhalation aerosol to the retail level. The drug has US market size of around ~$850-900mn. Cipla and Lupin are the closest competitors to Perrigo in the albuterol sulphate market and hence are likely to be benefit from this
Lupin

3 Sep 2020 , 12:17PM Launches Leflunomide Tablets USP, 10 mg and 20 mg, after it received an approval from the USFDA. The drug is a generic equivalent of Arava tablets of Sanofi-Aventis U.S. and is indicated for the treatment of adults with active rheumatoid arthritis. Arava tablets had an annual sales of ~ $42 million in the US MAT June 2020. The launch is positive as this would help improve the US business.
Lupin launches Leflunomide tablets USP

2 Sep 2020 , 4:04PM Lupin launches anti-rheumatic drug, Leflunomide tablet in the US market
Lupin, Mylan launch Nepexto, biosimilar Etanercept in Germany

26 Aug 2020 , 3:25PM Lupin, Mylan launch Nepexto, biosimilar etanercept, in the German market
Lupin receives approval for Generic Albuterol Sulphate MDI

25 Aug 2020 , 10:22AM Lupin gets approval from the US drug regulator for its Albuterol Sulfate inhalation aerosol
Lupin

25 Aug 2020 , 9:43AM Lupin gets approval for generic Albuterol Sulphate MDI Albuterol Sulfate Inhalation Aerosol, 90 mcg (base)/actuationm indicated for the treatment of acute episodes of bronchospasm or prevention of asthmatic symptoms; total Albuterol Sulfate Inhalation Aerosol market had U.S. sales of approximately US$2.9 bn – positive for Lupin
Lupin

21 Aug 2020 , 9:19AM ForDoz Pharma partners with Lupin on development of two complex injectable products in advanced development stage at ForDoz, in US and its territories; the products are in the Oncology and Anti-infective therapeutic areas which when approved, will provide affordable alternatives to patients and healthcare professionals – positive read thru as strategic addition to its Complex Injectables pipeline would bolster its Institutional business offerings
Lupin

20 Aug 2020 , 11:01AM Lupin: Stock update: Uncertainties yet to subside
Lupin

17 Aug 2020 , 9:58AM Plans to submit a supplemental New Drug Application for Solosec to the USFDA for the treatment of trichomoniasis later this year. The company announced results from its pivotal Phase 3 clinical trial to assess efficacy and safety of single-dose Solosec (secnidazole) 2g oral granules in female patients with trichomoniasis in the US markets. The trial results showed a clinically and statistically significant response rate, or microbiological cure, in patients. Positive for Lupin, If the drug gets final approval as it would help to grow the US business.
Lupin

10 Aug 2020 , 11:59AM Lupin: Q1FY2021 Result Update - Weak quarter; uncertainties yet to subside
Lupin

10 Aug 2020 , 10:08AM Is recalling 11,688 bottles of Lisinopril tablets USP, 10 mg, which is used to treat high blood pressure, in the US market. The recall is due to presence of foreign tablets in specific number of bottles. Lisinopril tablets USP, (20 mg) were found in a 1,000 count bottle of Lisinopril Tablets USP (10 mg). The USFDA has classified this has a type II recall and hence this is unlikely to have any material impact on the financial performance of the company
Lupin

7 Aug 2020 , 12:12PM Wholly-owned subsidiary Lupin Inc. has entered into an agreement with ForDoz Pharma Corp for granting Lupin the exclusive rights to market and distribute 2 complex injectable assets, which are in advanced stages of development in US and its territories. The assets are in the Oncology and Anti-infective therapeutic areas and when approved would provide affordable alternatives to patients and healthcare professionals. The assets will be made at the Fordoz’s plant in the US and Fordoz would be be responsible for the development, and obtaining the necessary regulatory approvals while Lupin would be responsible for marketing and distribution. If the assets are approved by the regulator, The agreement is positive for Lupin as it would offer new growth opportunities in the US.
Lupin

7 Aug 2020 , 11:20AM Lupin Q1FY2021: Weaker than expected performance
Lupin

6 Aug 2020 , 5:06PM In alliance with concord Biotech has announced the receipt of approval from USFDA for Mycophenolate Mofetil Tablets USP - 500 mg, to market a generic version of Cell Cept Tablets of Roche. Mycophenolate Mofetil Tablets are indicated for the prophylaxis of organ rejection in recipients of allogeneic kidney, heart or liver transplants, in combination with other immunosuppressants. The reference Listed drug – cellcept had annual sales in the US to the tune of $ 96 mn as per IQVIA – MAT March 2020. The approval is positive as it could add to the topline growth of the US business
Lupin's alliance partner gets USFDA nod to market CellCept Tablets

6 Aug 2020 , 3:32PM Lupin's alliance partner concord receives USFDA approval for Mycophenolate Mofetil Tablets USP
Lupin

5 Aug 2020 , 12:32PM Lupin: Has launched Favipiravir in India under the brand name “Covihalt” for the treatment of mild to moderate COVID-19. Favipiravir has received authorization from the Drug Controller General of India for emergency use. Covihalt’s dosage strength has been developed keeping in mind convenience of administration. It is available as 200 mg tablets in the form of a strip of 10 tablets, and priced at Rs. 49 per tablet and is competitively priced. Given the increase in Covid cases in India, the demand for the medicine could surge and aid topline growth.
Lupin launches Favipiravir Drug Covihalt for treatment of mild to moderate COVID-19

5 Aug 2020 , 11:29AM Favipiravir in India under the brand name Covihalt for the treatment of mild to moderate COVID-19
Lupin receives tentative USFDA nod for Empagliflozin tablets

4 Aug 2020 , 2:46PM Empagliflozin Tablets indicates as an adjunct to diet and exercise to improve glycemic control in adults
Lupin

3 Aug 2020 , 11:47AM As per media news, Lupin is recalling 35,928 bottles of a generic antibiotic drug – Cefdinir in the US market following unfavourable result in retention samples. The lot has been manufactured at Lupin's Mandideep (Madhya Pradesh) manufacturing facility. The recall is for a specific lot and is due to Out of Specification results. The recall is classified as a Class – II recall, Voluntary one and hence is unlikely to have a material impact.
Lupin gets tentative nod from USFDA

24 Jul 2020 , 10:38AM Lupin receives tentative approval for Empagliflozin and Linagliptin Tablets
Lupin

24 Jul 2020 , 9:41AM Gets tentative approval from the U.S. FDA for its Empagliflozin and Linagliptin tablet. The approval is to market a generic version of Glyxambi tablets of Boehringer Ingelheim Pharma. The drug is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type-2 diabetes mellitus. The approval is positive as it would help improve the US business of the company
Lupin

15 Jul 2020 , 10:07AM As per media reports, Lupin has shut one of its manufacturing plants in Gujarat as around 17 employees at the site tested positive for COVID-19. The pant manufactures tuberculosis drugs and was shut on 12 July 2020.
Lupin

8 Jul 2020 , 11:58AM Subsidiary company Lupin Pharmaceuticals Inc. is voluntarily recalling all batches of Metformin Hydrochloride Extended-Release Tablets USP, 500mg and 1000mg in the US. The recall is on the back of additional analysis by USFDA that revealed certain tested batches which were above the Acceptable Daily Intake Limit for the impurity Nitrosodimethylamine (NDMA). Company has not received any reports of adverse events related to this recall. Lupin has stated that it expect to re-introduce the updated Metformin Hydrochloride Extended-Release Tablet in the U.S. in the current quarter.
Lupin voluntarily recalls Metformin Hydrochloride 500 mg-1g in US

8 Jul 2020 , 10:17AM Lupin voluntarily recalls its Metformin Hydrochloride Extended-Release tablets USP, 500 mg & 1,000 mg products in the US
Lupin

22 Jun 2020 , 12:43PM The company is voluntarily recalling 4,224 bottles of a product – Lisinopril, in the US. The medicine is used to treat high blood pressure conditions. This is a class II recall on account of a product mix up where Lisinopril 10 mg tablets were found in Lisinopril 5 mg 1000-count bottle. Being a class II recall, it is unlikely to have any material impact on the performance of the company.
Lupin

15 Jun 2020 , 12:22PM Plans to approach the USFDA for re-inspection of their facilities in Goa, Pithampur and Somerset (US). The Goa and Pithampur unit 2 is under USFDA Warning letter since November 2017, while the Somerset plant is under OAI. The management expects the Goa plant and then the Pithampur plant to be ready for inspection over the next couple of months and expects Somerset to be ready before Goa. The resolution of the regulatory hurdles is critical and would be an overhang on the stock until fully resolved. We have a Hold recommendation on the stock.
Lupin

12 Jun 2020 , 11:35AM Got approval from the USFDA for Albendazole Tablets USP, 200 mg. The medicine is an generic equivalent of Albenza Tablets of Impax Laboratories Inc. The drug is indicated for the treatment of Parenchymal neurocysticercosis due to active lesions caused by larval forms of the pork tapeworm and also for Cystic hydatid disease of the liver, lung, and peritoneum. The generic equivalent had an annual sales of USD 34 Mn MAT as per IQVIA as on April 2020. Positive as this would help improve the US business.
Lupin receives approval for Albendazole Tablets USP

12 Jun 2020 , 10:05AM Pharma major announces that it has receive approval for its Albendazole Tablets USP
Lupin

11 Jun 2020 , 1:03PM As per media news, the company is voluntarily recalling one lot of Metformin Hydrochloride Extended-Release Tablets USP, 500mg. USFDA analysis revealed that this lot had acceptable limits of NDMA, which is a carcinogenic substance. As the recall is voluntary one and is only for a specific lot, it is unlikely to have any material impact on the performance of Lupin.
Lupin

10 Jun 2020 , 10:08AM US subsidiary company – Lupin Pharmaceuticals Inc signs marketing pact with Ceek womens health a leading company in the gynaecological care. As per the agreement lupin would market Ceek’s products alongside its women's health flagship product, Solosec (secnidazole) 2g oral granules, indicated for the treatment of bacterial vaginosis (BV). This is positive for Lupin as it would widen the product offerings in the US
USFDA grants Mexiletine Orphan drug designation

8 Jun 2020 , 10:47AM USFDA grants ODD to mexiletine hydrochloride for the treatment of myotonic disorders
USFDA grants Mexiletine Orphan drug designation

8 Jun 2020 , 10:46AM USFDA grants ODD to mexiletine hydrochloride for the treatment of myotonic disorders
Lupin

5 Jun 2020 , 9:12AM European Commission has granted marketing authorization to Lupin and Mylan for Nepexto, a biosimilar to Enbrel (etanercept). The drug is indicated for rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, axial spondyloarthritis, plaque psoriasis and paediatric plaque psoriasis. The authorization follows the adoption of a positive opinion by the Committee for Medicinal Products for Human Use in March this year and the authorization applies to all member countries of the European Nation. As per IQVIA, Enbrel had global sales of approximately $ 9.6 bn for the 12 months ending December 2019. Positive as this would substantially boost topline.
Lupin

3 Jun 2020 , 11:47AM Lupin has entered in to distribution agreement with three companies in the EU region – Exeltis Healthcare (Spain and Portugal), Cresco Pharma B.V (Netherlands) and Macure Pharma ApS (Nordic Countries), for its orphan drug NaMuscla (mexiletin). The drug is indicated for symptomatic treatment of myotonia in adults with non-dystrophic myotonic (NDM) disorders. Under the agreement the companies would commercialise the drug in EU region, while Lupin would continue to commercialize the drug in Germany and UK and would launch the product in Australia and France later this year. The move is positive as this would enable the company to address the needs of patients suffering from NDM in EU and Australia and thus aid revenue growth.
Lupin signs distribution agreement in Key EU Territories for Orphan Drug NaMuscla

3 Jun 2020 , 11:10AM Lupin global signs cs in key EU territories for orphan drug Namuscla
Lupin receives approval for Meloxicam capsules

3 Jun 2020 , 9:44AM The drug is a generic equivalent of Vivlodex Capsules manufactured by Zyla Life Sciences US
Lupin

3 Jun 2020 , 9:18AM Gets USFDA approval for Meloxicam Capsules, 5 mg and 10 mg. The drug is a generic equivalent of Vivlodex Capsules manufactured by Zyla Life Sciences US. The drug is indicated for indicated for management of osteoarthritis pain. The generic equivalent had an annual sale of approximately USD 14 million in the U.S as per IQVIA MAT. This is Positive as approval would help the improve the US business.
Lupin

1 Jun 2020 , 12:21PM Lupin Limited: Q4FY2020 Result Update – Regulatory Overhang Stays
Lupin

29 May 2020 , 10:00AM Lupin Q4FY2020: Weak operating performance; low tax & high other income leads to PAT beat
Lupin

29 May 2020 , 9:51AM As per media reports, the company gets USFDA approval for azithromycin tablets. The medicine is an antibiotic and is used to treat bacterial infections. Positive as this would help improving the US business.
Lupin

22 May 2020 , 2:34PM Gets USFDA approval for Trientine Hydrochloride Capsules USP - 250 mg. The medicine is a generic equivalent of Syprine Capsules of Bausch Health US. The drug is indicated for treatment of patients with Wilson's disease who are intolerant of penicillamine. The product would be manufactured at Lupin’s Nagpur (unit 1) facility. The drug has reported an annual US sales of USD 86 mn, as per IQVIA MAT March 2020. Positive as this would add to the US business growth
Lupin receives approval for Trientine Hydrochloride Capsules USP

22 May 2020 , 2:00PM Lupin gets USFDA nod for Trientine Hydrochloride Capsules USP - 250 mg
Lupin launches authorized generic version of Apriso

19 May 2020 , 11:42AM Launch of authorized generic version of Bausch Health’s Apriso
Lupin

14 May 2020 , 10:19AM Gets Establishment Inspection Report (EIR) from the USFDA for its Vizag unit, inspected between January 13 to January 17, 2020. The unit manufactures API (Active Pharmaceutical Ingredients). This is positive as the receipt of the EIR indicates successful closure of the inspection.
Lupin's Vizag API facility receives EIR from USFDA

14 May 2020 , 10:06AM Lupin's Vizag API facility receives establishment inspection report from USFDA
Lupin

11 May 2020 , 10:44AM The UK’s regulator MHRA (Medicines and Healthcare products Regulatory Agency) has successfully closed the inspection process at the company’s manufacturing plant at Pithampur – unit I,II and III. The inspection was conducted in January 2020. Successful closure of the inspection is positive.
Lupin Pithampur plant completes successful UK MHRA

11 May 2020 , 10:04AM Lupin's pithampur facilities complete successful UK MHRA inspection
Lupin

5 May 2020 , 9:11AM Has announced a positive top-line result from its phase 3 clinical trial to assess efficacy and safety of single dose Solosec (Secnidazole) 2g oral granules. The drug is used to treat Trichomoniasis. Based on the data, the company plans to file Supplemental New Drug Application (sNDA) with the USFDA in the 2H2020. Trichomoniasis impacts 3 to 5 mn people in the US, hence points at substantial size of opportunity for the US business; Positive
Lupin

5 May 2020 , 9:10AM Has announced a positive top-line result from its phase 3 clinical trial to assess efficacy and safety of single dose Solosec (Secnidazole) 2g oral granules. The drug is used to treat Trichomoniasis. Based on the data, the company plans to file Supplemental New Drug Application (sNDA) with the USFDA in the 2H2020. Trichomoniasis impacts 3 to 5 mn people in the US, hence points at substantial size of opportunity for the US business; Positive
Lupin's Pithampur Unit-1 facility receives EIR from USFDA

30 Apr 2020 , 9:45AM USFDA issues Establishment Inspection Report for Lupin Global's Pithampur Unit-1
Lupin gets tentative nod for Arformoterol Tartrate Inhalation Solution 15 mcg (base)/2 mL

29 Apr 2020 , 2:31PM Drug indicates treatment of bronchoconstriction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysem
Lupin

29 Apr 2020 , 2:17PM The company has received a tentative approval from the USFDA to market Arformoterol Tartrate Inhalation Solution 15 mcg (base)/2 mL, Unit-dose Vials. The drug is indicated for treatment of bronchoconstriction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema. The drug has an annual sales of USD 489 mn in the US as per IQVIA MAT Feb 2020. Positive read thru as this would improve the US business.
Lupin

23 Apr 2020 , 9:51AM As per media news, Solosec oral granules have received preferred coverage effective immediately on the Express Scripts National Preferred, Flex, and Basic commercial formularies. Sentimentally Positive
Lupin's Mandideep Unit II facility receives EIR from USFDA

15 Apr 2020 , 9:48AM Lupin's Mandideep Unit II gets establishment inspection report from USFDA
Lupin contributes Rs. 21 crore towards COVID-19 relief efforts

13 Apr 2020 , 9:44AM Pharma major announces contribution of Rs. 21 crore for relief efforts directed towards mitigating the COVID-19 crisis
Lupin

8 Apr 2020 , 9:38AM Lupin gets USFDA approval for Drospirenone, Ethinyl Estradiol tablets, which is combination birth control pill. Positive as this would widen the company’s product offering in the US
Lupin

7 Apr 2020 , 12:39PM Launches Mycophenolic Acid Delayed-Release Tablets USP - 180 mg and 360 mg. Lupin’s partner Concord Biotech Limited (Concord) had received an approval from the USFDA. The drug is indicated for of Prophylaxis of organ rejection in adult patients receiving kidney transplants and in pediatric patients at least 5 years of age and older who are at least 6 months post kidney transplant. This is also Used in combination with cyclosporine and corticosteroids. The drig had an annula sales of $156 mn in US as per IQVIA MAT – February 2020. Positive
Lupin launches Mycophenolic Acid Delayed-Release Tablets USP

7 Apr 2020 , 9:34AM Pharma major announces the launch of Mycophenolic Acid Delayed-Release Tablets USP, 180 mg and 360 mg
Lupin's Aurangabad facility receives EIR from USFDA

3 Apr 2020 , 9:39AM Pharma major gets EIR from USFDA for Aurangabad facility
Lupin

30 Mar 2020 , 12:14PM Lupin announced that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the approval of Nepexto, a biosimilar to Enbrel (etanercept), for all indications of the reference product including rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, axial spondyloarthritis, plaque psoriasis and paediatric plaque psoriasis. The positive opinion will now be considered by the European Commission (EC). Once approved, the EC would grant a central marketing authorization for member countries of the EU. The authorization is likely to come in May 2020. This would be positive for Lupin as it would enable it to market the drug in the EU region.
Lupin's inhalation research center, Florida gets EIR from USFDA

30 Mar 2020 , 10:57AM Lupin gets EIR from the USFDA for its inhalation Research Center located at Coral Springs, Florida
Lupin appoints Ramesh Swaminathan as CFO and head corporate affairs

27 Mar 2020 , 2:28PM Appointment of Ramesh Swaminathan as chief financial officer and head corporate affairs
Lupin

23 Mar 2020 , 11:47AM launched Betamethasone Dipropionate Ointment USP (Augmented), 0.05%, to be manufactured at Pithampur (Unit Ill) facility, India. Ointment is the generic equivalent of Diprolene Ointmentof Merck Sharp and Dohme Corp. It is a corticosteroid indicated for relief of the inflammatory and pruritic manifestations of corticosteroid -responsive dermatoses in patients 13 years of age and older. Diprolene (Reference Listed drug) had an annual sales of approximately USD 21 million in US as per (IQVIA MAT January 2020). Positive
Lupin introduces generic version of Vimovo tablets

6 Mar 2020 , 12:34PM Lupin launches authorized generic version of Vimovo
Lupin

6 Mar 2020 , 10:58AM The company announced the launch of the authorized generic tablet for Horizon Therapeutics PLC's Vimovo delayed release tablets in the U.S. The product is a combination of naproxen, and esomeprazole magnesium, a proton pump inhibitor (PPI) indicated in adult and adolescent patients 12 years of age and older requiring naproxen for symptomatic relief of arthritis and esomeprazole magnesium to decrease the risk of developing naproxen-associated gastric ulcers. The tablet had annual sales of approximately USD 400 million in the U.S. as of January 2020 - IQVIA MAT. Positive as this would add to the topline.
Lupin

25 Feb 2020 , 1:00PM As per media news, USFDA has approved Perrigo's ANDA for generic Albuterol Sulfate - inhalation aerosol, the first AB-rated generic version of ProAir. Lupin too had filed for the drug and would not get an approval as the company has received a complete response letter from the USFDA, consequently new approvals are withheld. Negative
Lupin

17 Feb 2020 , 12:16PM Has launched Moxifloxacin Ophthalmic Solution USP, 0.5%. The drug is the AT2 rated generice equivalent of Moxeza of Novartis. The drug is indicated for treatment of bacterial conjunctivitis caused by susceptible strains of certain organisms. The drug has annual sales of approximately USD 10 million in the U.S. as per IQVIA MAT December 2019. Given the comparatively small size of the market for the drug, it is unlikely to materially boost the topline.
USFDA completes inspection of Lupin's Aurangabad facility with Zero observation

17 Feb 2020 , 10:41AM Aurangabad facility inspection concludes without any observation
Lupin

13 Feb 2020 , 11:41AM Lupin: Q3FY2020 Result Update - Regulatory hurdles point to tough revival
USFDA completes inspection of Lupin's Pithampur (Unit-I) facility

12 Feb 2020 , 3:31PM The inspection for the Pithampur (Unit-I) facility closes with two 483 observations
Lupin

7 Feb 2020 , 11:44AM Lupin Q3FY2020: Weak performance
Lupin

6 Feb 2020 , 11:01AM The company has received an approval from the USFDA for Leflunomide Tablets USP, 10 mg and 20 mg, to market a generic equivalent of Arava Tablets of Sanofi Aventis. The product would be manufactured at Lupin's Pithampur (Unit 1) facility. Leflunomide Tablets are indicated for the treatment of adults with active rheumatoid arthritis. Leflunomide Tablets USP had annual sales of approximately USD 44 million in the U.S as IQVIA MAT December 2019. Positive as this would add to Lupins topline
Lupin

27 Jan 2020 , 11:09AM The successful completion of the inspection carried out by the UK Medicines and Healthcare products Regulatory Agency, the regulatory agency of the United Kingdom at its three manufacturing units in Pithampur (India). The inspection for the three units at Pithampur closed with no critical observation and one major observation. The nature of one major observation received is not known and could have an adverse impact on the stock. We have a reduce recommendation.
Lupin

20 Jan 2020 , 10:21AM The company’s Vizag API facility was inspected by the US-FDA between 13 Jan 2020 to 17 Jan 2020. The inspection closed with five observations. The nature of observations is not known. Negative read thru
Lupin

13 Jan 2020 , 2:11PM The company gets 2 observations from USFDA for Nagpur facility – negative read through for the stock
Lupin falls after USFDA observation

13 Jan 2020 , 11:45AM USFDA classifies the inspection of Lupin's Tarapur facility as OAI
Lupin Ankleshwar facility bags Par Excellence Award

13 Jan 2020 , 10:21AM Lupin's Ankleshwar facility wins par excellence award at 33rd National Convention on quality concept
Lupin

10 Jan 2020 , 10:41AM As per media reports, the company received US FDA approval for Famotidine, a drug used to decrease stomach acid production. Positive read thru
Lupin's Ankleshwar facility wins gold award from American society

10 Jan 2020 , 10:29AM Pharma major received gold award at the 9th Annual Conference on Quality Management
Lupin receives approval for Betamethasone Dipropionate Ointment USP

20 Dec 2019 , 3:10PM Pharma major gets USFDA nod to market a generic equivalent of Diprolene Ointment
Lupin

20 Dec 2019 , 3:04PM Receives USFDA approval for Betamethasone Dipropionate Ointment USP (Augmented), 0.05%. This is a generic equivalent of Diprolene Ointment of Merck Sharp and Dohme Corp. The drug would be manufactured at Lupin’s Pithampur plant (unit 3) and is indicated for relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses in patients 13 years of age and older. As of September 2019 IQVIA MAT data the drug had an annual sales of approximately USD 22 mn. Positive read thru
Lupin

20 Dec 2019 , 1:11PM In alliance with Concord Biotech receives USFDA approval for Mycophenolic Acid delayed release tablets, which is a generic version of Myfortic delayed release tablets of Novartis – Positive read thru for Lupin
Lupin completes divestment in Kyowa to Unison

17 Dec 2019 , 12:05PM Lupin announces completion of Kyowa divestiture to Unison
Lupin launches Hydrocortisone Valerate Cream

22 Nov 2019 , 3:22PM Lupin's Hydrocortisone Valerate Cream is the generic equivalent of Westcort Cream of Sun Pharmaceutical Industries Inc
Lupin launches Hydrocortisone Valerate Cream

22 Nov 2019 , 3:20PM Lupin's Hydrocortisone Valerate Cream is the generic equivalent of Westcort Cream of Sun Pharmaceutical Industries Inc
Lupin launches Adhero to support treatment of Respiratory Disease

22 Nov 2019 , 2:05PM Lupin launches Adhero to support treatment of Respiratory Disease
Lupin

20 Nov 2019 , 11:52AM Announced the launch of Potassium Chloride (KCI) for Oral Solution USP, 20 mEq, having received an approval from the US-FDA. The drug is the generic equivalent of Pharma Research Software Solution, LLC's Potassium Chloride for Oral Solution USP, 20 mEq, and is indicated for the treatment and prophylaxis of hypokalemia with or without metabolic alkalosis in patients for whom dietary management with potassium-rich foods or diuretic dose reduction is insufficient. Potassium Chlorise had an annual sales of approximately USD 90 mn in the US. The news has come before the close of market hours yesterday. Positive read thru
Lupin

13 Nov 2019 , 10:45AM Entered into a definitive agreement for the sale of its entire stake in its Japanese subsidiary Kyowa Pharmaceutical Industry Co., Ltd. (‘Kyowa’) to Unison Capital Partners IV, LPS and Unison Capital Partners IV (F). L.P. Under the terms of the agreement, Lupin’s subsidiary Nanomi B.V. will divest its entire stake (99.82%) in Kyowa to Unison’s entity Plutus Ltd. for an enterprise value of JPY 57,361 million (Rs 3702.4 cr). This would generate a post tax cash flow of Rs 2103.9 cr. This is likely to strengthen the company’s balance sheet position as the proceeds are likely to be utilised to repay debts. Net debt of the Company will stand at Rs 1129 cr compared to Rs 4361.8 cr as on September 30, 2019. The deal done at 2x EV/Sales and 11.5x EV/EBITDA, Kyowa Pharmaceutical contributes 10% of Lupin revenues, the deal will be EPS accretive and also bring down the debts. Postive read-thru
Lupin

13 Nov 2019 , 10:25AM Lupin enters into agreement to divest its stake in Kyowa to Unison
Lupin

11 Nov 2019 , 12:23PM Has received approval for its Zileuton Extended-Release Tablets, 600 mg, from US FDA, to market a generic equivalent of Zyflo CR Extended-Release Tablets, 600 mg, of Chiesi USA, Inc. The medicine is indicated for prophylaxis and chronic treatment of asthma in adults and children 12 years of age and older. Zileuton Extended-Release Tablets, 600 mg had annual sales of approximately USD 43 million in the U.S Positive read thru
Lupin gets USFDA nod for Zileuton Extended-Release Tablets

11 Nov 2019 , 10:25AM Pharma major gets approval from USFDA to market a generic equivalent of Zyflo CR® Extended-Release Tablets
Lupin

7 Nov 2019 , 11:04AM As per media news, Lupin gets US FDA approval for Zileuton, which is used to prevent and control symptoms such as wheezing and shortness of breath caused by asthma. Positive read thru
Lupin

6 Nov 2019 , 3:46PM Lupin Q2FY2020: Operating performance marginally ahead of estimates, Adjusted PAT beat estimates lead by lower tax
Lupin receives sANDA approval from USFDA for Levothyroxine Sodium Tablets USP

1 Nov 2019 , 2:58PM Pharma major gets ANDA nod from USFDA to market a generic equivalent of LEVOXYL
Lupin

1 Nov 2019 , 10:11AM Lupin: As per media news, Lupin is in advanced talks to sell its Japanese generics subsidiary Kyowa Pharmaceuticals for an enterprise value of $600 million to a local player as it steps up efforts to significantly cut operations in Japan. Pricing pressures in Japan and the recent decline in growth and impending further declines have led to re-evaluate the market and investment. The company has been reviewing its global footprint and the decision to scale down Japan is part of that exercise. The company has already moved a lion’s share of the japense manufacturing plant to its Goa facility. The move is positive as the slow growing Japanese business is a drag on profitability
Lupin's Nagpur facility receives EIR from the USFDA

18 Oct 2019 , 2:40PM Lupin global's Nagpur unit get EIR by USFDA, indicating closure of inspection
Lupin

14 Oct 2019 , 10:51AM Company plans to file Etanercept (Pegfilgrastim) biosimilars in US by Q4FY20 – Sentimentally positive read thru.
Lupin receives GMP certificate from PMDA

9 Oct 2019 , 12:40PM Japan's PMDA issues GMP Certificate to Lupin's Unit II Mandideep facility
Lupin launches Mycophenolate Mofetil Capsules USPV

7 Oct 2019 , 10:41AM Pharma major announces the launch of Mycophenolate Mofetil Capsules
Lupin appoints Johnny Mikell as Global Head of Quality

3 Oct 2019 , 12:43PM Pharma major appoints Johnny Mikell as President and Global Head of Quality
Lupin

3 Oct 2019 , 12:14PM Lupin: USFDA finds repeat violations at Lupin’s multiple manufacturing sites including Mandideep Plant; Repeated failures at multiple sites demonstrate oversight and control over drugs are inadequate. Company should assess global manufacturing operations, indicating longer timelines for resolution – Negative
Lupin gets USFDA nod for Extended Phenytoin Sodium Capsules USP

1 Oct 2019 , 3:21PM Lupin receives USFDA approval for generic equivalent of Dilantin, used for the prevention & treatment of seizures
Lupin

1 Oct 2019 , 12:29PM Japan’s PMDA completed inspection of the company’s Goa facility with no critical or major observations. The company has completed the sale of Japanese arm’s sale of injectables business and related assets to the Neopharma Group – Positive read thru.
Lupin launches Sildenafil Tablets USP

30 Sep 2019 , 3:27PM Pharma major introduces Sildenafil Tablets USP getting nod from USFDA
Lupin appoints Jon Stelzmiller as President of US Specialty Business

25 Sep 2019 , 12:13PM Pharma major appoints Jon Stelzmiller as the President of its US Specialty business
Lupin's arm signs Commercial Agreement with Creso Pharma

26 Aug 2019 , 4:07PM Lupin's subsidiary in South Africa announces Commercial Agreement with Creso Pharma for hemp oil based cannaQIX
Lupin launches Fluoxetine Tablets USP

22 Aug 2019 , 3:25PM Lupin launches Fluoxetine Tablets receives approval from USFDA
Lupin divests Kyowa Criticare to Neopharma group

22 Aug 2019 , 11:31AM Lupin's Japanese arm enters into agreement for sale of injectables business
Lupin gets USFDA nod for generic of Westcort cream

16 Aug 2019 , 3:37PM Lupin receives USFDA approval for Hydrocortisone Valerate Cream
Lupin Q1FY2020: Mixed bag performance

7 Aug 2019 , 2:48PM Lupin Q1 net profit rises by 49.4% to Rs. 303 crore
Lupin's Aurangabad facility receives EIR from USFDA

5 Aug 2019 , 10:40AM Lupin gets EIR from USFDA from USFDA for its Aurangabad facility
Lupin's Nagpur facility wins ENR global best project award

22 Jul 2019 , 10:55AM Pharma major secures ENR global best project award of Merit in the Manufacturing category
Lupin launches Imatinib Mesylate Tablets

9 Jul 2019 , 4:03PM Pharma major introduces lmatinib Mesylate tablets, 100 mg and 400 mg
Lupin receives USFDA approval for Phenylephrine & Ketorolac Intraocular Solution

3 Jul 2019 , 2:55PM Lupin's Phenylephrine and Ketorolac Intraocular Solution, 1%/0.3%, is the generic version of Omidria Intraocular Solution
Lupin receives tentative USFDA approval for Mirabegron ER Tablets

28 Jun 2019 , 10:56AM Lupin's Mirabegron ER Tablets, 25 mg and 50 mg, is a generic version of Myrbetriq Extended Release Tablets
Japan’s PMDA completed inspection of its Mandideep facility

6 Jun 2019 , 10:43AM Lupin: Japan’s PMDA completed inspection of its Mandideep facility with no critical or major observations; inspection was conducted between May 14-19, 20109 – Neutral.
USFDA classifies the inspection of Lupin's Goa facility as OAI

27 May 2019 , 10:24AM Lupin: USFDA classifies inspection of Lupin's Goa facility as OAI (Official Action Indicated (OAI); Negative; USFDA may not approve products filed from this plant until issies resloved. Ongoing operations not affected but new approvals may get delayed.
USFDA classifies the inspection of Lupin's Goa facility as OAI

27 May 2019 , 10:20AM Lupin gets communication from the USFDA classifying the inspection conducted at its Goa facility
Lupin launches Budesonide Inhalation Suspension

22 May 2019 , 3:35PM Lupin global launches Budesonide Inhalation Suspension in the US market
USFDA completes inspection of Lupin's Aurangabad facility

16 May 2019 , 10:09AM Lupin's inspection at the Aurangabad facility closes with three observations
Lupin launches Clobazam Tablets

10 May 2019 , 1:02PM Lupin's Clobazam tablets is the generic version of Lundbeck Pharms, LLts Onfi Tablets, 10 mg and 20 mg
Lupin, Aptissen enters into distribution agreement Synolis VAfor Canada

9 May 2019 , 10:42AM Lupin and Aptissen announce exclusive distribution agreement of Synolis VAfor Canada
USFDA classifies the inspection of Lupin's Pithampur facility as OAI

24 Apr 2019 , 10:27AM USFDA classifies Pithampur facility as OAI
Lupin surges on Morgan Stanley upgrades

23 Apr 2019 , 1:07PM Lupin rises over 4% to Rs. 868.5, after Morgan Stanley upgrades its rating on the stock to overweight
Lupin gets USFDA nod for Fluoxetine Tablets

16 Apr 2019 , 2:36PM Pharma major receives FDA approval for Fluoxetine Tablets USP
Lupin launches Testosterone Gel

12 Apr 2019 , 12:23PM Lupin launch Testosterone Gel, 1.62% for which, USFDA approval was received earlier
Lupin receives FDA approval for Testosterone Gel

11 Apr 2019 , 1:00PM Lupin receives approval for its Testosterone Gel from USFDA to market a generic version of AndroGel
Lupin launches Fluoxetine Tablets USP

10 Apr 2019 , 2:27PM Lupin launches Fluoxetine Tablets USP, 60mg, gets an approval from the USFDA
Lupin Bioresearch Centre completes fifth successful USFDA inspection

3 Apr 2019 , 10:42AM Lupin successful completes the USFDA inspection at its Lupin Bioresearch Centre
Lupin gets EIR from USFDA

3 Apr 2019 , 9:45AM Lupin: Company receives Establishment Inspection Report (EIR) from the USFDA for its Pithampur facility (Unit-3) in Madhya Pradesh; Unit-3 facility is involved in the manufacture of metered dose inhalers (MDIs), dry powder inhalers (DPIs) and topical formulations for the regulated markets – Positive; Company continues to grapple with USFDA at other key sites like Somerset, Mandideep; We have a reduce rating on stock with TP under review.
Lupin Pithampur Unit-3 receives EIR from USFDA

2 Apr 2019 , 11:09AM Lupin Pithampur Unit-III receives establishment inspection report from the USFDA
Lupin US facility somerset gets form 483

1 Apr 2019 , 9:59AM Lupin: Company’s US facility Somerset (in New Jersey) receives form 483 with 6 obs – Negative.
Lupin Company recalls 3200 bottles of Testosterone Topical Solutins in US

1 Apr 2019 , 9:19AM Lupin: Company recalls 3,200 bottles of Testosterone Topical Solution in the US on the back of repetitive complaints of container indicating faulty pump – Negative read thru.
Lupin, YL Biologics gets nod to market rheumatoid arthritis drug in Japan

26 Mar 2019 , 1:13PM Lupin and YL Biologics receives PMDA approval for Etanercept biosimilar in Japan
Lupin gets USFDA nod for generic of Viagra tablets

25 Mar 2019 , 12:26PM Lupin global gets USFDA nod for leading anti-erectile dysfunction drug
Lupin launches generic Levothyroxine Sodium Tablets USP

22 Mar 2019 , 12:59PM Pharma major receives USFDA nod to launch Levothyroxine Sodium Tablets USP
Lupin falls after USFDA letter for New Jersey plant

18 Mar 2019 , 1:15PM Lupin slips over 5% to Rs. 741.35, after USFDA classifies the inspection of its Somerset facility as Official Action Indicated
USFDA classifies inspection of Lupin’s arm Novel Labs

18 Mar 2019 , 10:46AM Lupin: USFDA classifies inspection of Lupin’s arm Novel Labs’ US facility as Official Action Indicated (OAI) – Negative; second OAI within a week; fear of a companywide regulatory issue
Lupin gets OAI letter from USFDA for MP plant

14 Mar 2019 , 10:31AM USFDA classifies the inspection at the Company's Mandideep (Unit 1) facility as OAI
Lupin receives FDA approval for Atorvastatin Calcium Tablets USP

8 Mar 2019 , 10:59AM Pharma major received approval for its Atorvastatin Calcium Tablets
Lupin, Natco get FDA nod for Imatinib Mesylate tablets

5 Mar 2019 , 2:19PM Lupin in alliance with Natco receives FDA approval for Imatinib Mesylate Tablets
Lupin gets FDA nod for Azacitidine for Injection

28 Feb 2019 , 3:34PM Pharma major receives FDA approval for Azacitidine for Injection, 100 mg Single-Dose Vial
Lupin launches generic Ranolazine ER Tablets in US

28 Feb 2019 , 11:31AM Pharma major announces the exclusive launch of its Ranolazine Extended-Release (ER) Tablets
Lupin launches Minocycline Hydrochloride ER tablets

26 Feb 2019 , 2:59PM Pharma major introduces generic Minocycline Hydrochloride ER Tablets USP 55mg
Lupin receives USFDA approval for methylprednisolone tablets

25 Feb 2019 , 5:01PM Pharma major gets USFDA nod to market a generic version of Pharmacia and Upjohn Company's Medrol tablets
Lupin launches Clobazam Oral Suspension

15 Feb 2019 , 2:48PM Pharma major launches Clobazam Oral Suspension, 2.5mg/mL in the US market
Lupin launches Tadalafil Tablets USP

12 Feb 2019 , 3:32PM Pharma major announces the launch of Tadalafil Tablets USP 20 mg
Lupin gets USFDA approval for Tadalafil Tablets USP, 20 mg

7 Feb 2019 , 10:39AM Pharma major receives USFDA nod for Tadalafil Tablets
USFDA completes inspection of Lupin's Pithampur Unit 2

28 Jan 2019 , 11:01AM Lupin: USFDA completed inspection of Lupin’s Pithampur Unit 2 (unit under warning letter) with six observations – sentimentally negative; clarification on nature of observations awaited
Lupin gets FDA nod for Levothyroxine Sodium Tablets

22 Jan 2019 , 10:53AM Lupin receives FDA approval for Levothyroxine Sodium Tablets; used to treat thyroid – Positive; one of the key product approval expected; could contribute ~ $30-40 mn of sales; successful resolution of warning letter issued to two sites will be next trigger to watch for.
Lupin voluntarily recalls 55,000 vials

21 Jan 2019 , 12:05PM Lupin voluntarily recalls 55,000 vials and over 1.6 lakh boxes of anti-bacterial drug Ceftriaxone for injection; manufactured at the company's facility in Mandideep – Negative; ongoing voluntary nationwide recall has been classified as Class-I recall, meaning dangerous or defective products that predictably could cause serious health problems.
Lupin gets nod for treatment of Myotonia

8 Jan 2019 , 11:02AM Orphan Drug NaMuscJa receives European Commission approval for the Treatment of Myotonia in Non-Dystrophic Myotonic Disorders
Lupin gets USFDA nod for generic schizophrenia drug

7 Jan 2019 , 3:17PM Lupin receives FDA approval for Lurasidone Hydrochloride Tablets, 20 mg, 40 mg, 60 mg, 80 mg & 120 mg
Lupin gets USFDA nod for Clobazam Oral Suspension

1 Jan 2019 , 11:58AM Lupin received USFDA approval for Clobazam Oral Suspension; generic version of Lundbeck Pharma’s Onfi Oral Suspension for treatment of seizures in patients two years of age or older – Positive
Lupin partnership with AbbVie for novel oncology drug

24 Dec 2018 , 11:34AM Lupin partnership with AbbVie for novel oncology drug
Lupin gets USFDA nod for Apixaban Tablets

11 Dec 2018 , 9:51AM Lupin receives tentative US FDA approval for Apixaban Tablets, 2.5 mg and 5 mg.
Lupin's Pithampur Unit-3 receives EIR from USFDA

10 Dec 2018 , 2:38PM Lupin gets EIR report for its Pithampur (Unit 3) facility
USFDA issues observations for Lupin global's Mandideep Unit

5 Dec 2018 , 1:46PM Lupin completes inspections carried out at its Mandideep location
Lupin's CFO resigns

28 Nov 2018 , 11:29AM Lupin: Ramesh Swaminathan resigns as the Chief Financial Officer of the company – sentimentally negative for the stock
Lupin's Tarapur facility receives EIR from USFDA

27 Nov 2018 , 12:57PM Lupin's Tarapur facility receives Establishment Inspection Report (EIR) from USFDA
Lupin receives FDA approval for KCl for Oral Solution 20 mEq

27 Nov 2018 , 10:35AM Lupin's Potassium Chloride for Oral Solution USP, 20 mEq is the generic version of Pharma Research Software Solution
Lupin receives USFDA approval for Clomipramine HCl Capsules

27 Nov 2018 , 10:29AM Lupin gets nod for its Clomipramine Hydrochloride Capsule to market a generic version of SpecGx LLC's Anafranil Capsules
Lupin launches generic Tetrabenazine Tablets

21 Nov 2018 , 11:29AM Lupin launches generic Tetrabenazine tablets in the US market
Lupin gets FDA nod for Budesonide Inhalation Suspension

13 Nov 2018 , 11:51AM Lupin receives FDA approval for Budesonide Inhalation Suspension, 0.5 mg/2 mL
Lupin's Nagpur facility receives EIR from USFDA

12 Nov 2018 , 10:33AM Lupin gets EIR report post the completion of a Pre-Approval Inspection (PAI) for its Phenytoin Sodium Extended Release 100 mg capsules
Lupin pithampur unit 3 gets form 483

30 Oct 2018 , 11:25AM Lupin: Pithampur unit 3 gets Form 483 with 5 obs in a pre-approval inspection; company says obs procedural in nature; Unit 2 is under warning letter – Sentimentally negative for Lupin
Lupin's pithampur Unit-3 inspect by USFDA

19 Oct 2018 , 2:52PM Lupin completes USFDA inspection carried out at its Pithampur Unit-3 (Indore) facility
Lupin gets FDA nod for Lurasidone Hydrochloride Tablets

15 Oct 2018 , 3:09PM Lupin receives tentative FDA approval for generic Lurasidone Hydrochloride Tablets, 20 mg, 40 mg, 60 mg, 80 mg and 120 mg
Lupin launches generic Clobetasol Propionate Ointment USP in US

9 Oct 2018 , 3:30PM Lupin's Clobetasol Propionate Ointment USP, 0.05% is the generic equivalent of Fougera Pharmaceuticals Inc.'s Temovate Ointment, 0.05%
Lupin enters into partnership with Lilly

1 Oct 2018 , 11:33AM Lupin and Lilly partner for improved access to diabetes treatment in India
Lupin gets nod for Atovaquone Oral Suspension USP

14 Sep 2018 , 10:13AM Lupin received approval for its Atovaquone Oral Suspension USP, 750 mg/5 ml from US FDA. It is indicated for prevention and acute oral treatment of mild-tomoderate Pneumocystis carinii pneumonia (PCP) in patients intolerant to trimethoprim-sulfamethoxazole. Positive for Stock
Lupin's Tarapur API manufacturing facility inspect by USFDA

4 Sep 2018 , 11:37AM Lupin announces the completion of a cGMP inspection carried out by the USFDA at its Tarapur facility
Lupin gets USFDA nod to market generic version of Genus Lifesciences

31 Aug 2018 , 2:52PM Lupin receives USFDA approval for generic Potassium Chloride Oral Solution USP
Lupin gets FDA nod for Gabapentin Tablets

28 Aug 2018 , 12:36PM Lupin receives FDA approval for generic Gabapentin Tablets USP, 600 mg and 800 mg.
Lupin gets FDA nod for generic equivalent tablets

27 Aug 2018 , 12:17PM Lupin launches generic Drospirenone, Ethinyl Estradiol, Levomefolate Calcium Tablets and Levomefolate Calcium Tablets, 3 mg/0.02 mg/0.451 mg and 0.451 mg
Lupin gets EIR from USFDA

24 Aug 2018 , 2:15PM Lupin's Nagpur facility receives Establishment Investigation Report (EIR) from US FDA
Lupin up after receiving approval for generic tablets

23 Aug 2018 , 10:17AM Lupin rises over 3% to Rs916.85, after receiving US drug regulator's tentative approval for generic Nudovra tablets
Lupin gets USFDA nod for Hydrocortisone Butyrate Lotion

21 Aug 2018 , 11:50AM Lupin gets final approval for its Hydrocortisone Butyrate Lotion, 0.1% from USFDA to market a generic version of PreCision Dermatology
Lupin: Disappointing performance continues

10 Aug 2018 , 12:43PM Lupin: Disappointing performance continues; Maintain Reduce with PT under review
Lupin gets FDA nod for its Nitrofurantoin Capsules USP

12 Jul 2018 , 2:33PM Lupin receives final approval for its Nitrofurantoin Capsules USP (Macrocrystals), 50 mg and 100 mg from the United States Food and Drug Administration
Lupin gets USFDA nod for generic malaria drug

10 Jul 2018 , 12:08PM Lupin receives approval from the US health regulator for Hydroxychloroquine Sulfate tablets, which is used to treat malaria
Lupin Company launches generic Tobramycin Inhalation Solution

14 Jun 2018 , 10:42AM Positive read through for Lupin.
Lupin receives USFDA approval for Nystatin

5 Jun 2018 , 11:02AM Positive read through for Lupin.
Lupin reports disappointing performance

16 May 2018 , 11:16AM Maintain Reduce with PT under review.
Lupin submits new drug application for Etanercept biosimilar

9 May 2018 , 10:14AM Long term positive read through for Lupin.
Lupin gets FDA nod for generic Temovate ointment

8 May 2018 , 11:33AM Lupin gets final approval for its Clobetasol Propionate Ointment USP, 0.05% from the United States Food and Drug Administration
Lupin receives USFDA approval for gTemovate ointment

8 May 2018 , 11:09AM Positive read through for Lupin.
USFDA to inspect Lupin’s formulation facility at Nagpur

7 May 2018 , 10:40AM Lupin stock to remain in focus.
Lupin gets USFDA tentative nod for testosterone gel

18 Apr 2018 , 2:14PM Lupin gets USFDA tentative nod for testosterone gel
Pithampur unit 1 gets EIR from USFDA

6 Apr 2018 , 1:58PM Sentimentally positive for Lupin.
Lupin gets EIR from USFDA for Pithampur facility; stk up

6 Apr 2018 , 11:59AM Lupin rises over 7% at Rs842.45, after Pithampur Unit 1 facility receives establishment investigation report from the US drug regulator
Lupin's goa facility successfully compeletes inspection

3 Apr 2018 , 11:39AM Lupin rises by 3% at Rs798.1, after the UK drug regulator successfully completes its inspection of the company's Goa facility
Lupin's Goa facility successfully completes UKMHRA inspection with no critical or major observations

3 Apr 2018 , 11:19AM Sentimentally positive;
Lupin's Pithampur unit gets Health Canada clearance

2 Apr 2018 , 2:29PM Lupin announces that its Pithampur unit 2 manufacturing facility located in Indore has been cleared by Health Canada after a review
Lupin successfully gets reviewed by Health Canada

2 Apr 2018 , 12:14PM Sentimentally positive; stock is up by 2%+
Lupin gets USFDA nod for psoriasis treatment spray

19 Mar 2018 , 3:36PM Lupin secures US drug regulator's approval for a generic drug indicated for the treatment of plaque psoriasis in patients 18 years of age or older
Lupin signs agreement with CSIR-NCL and DST

8 Mar 2018 , 3:31PM Lupin signs an agreement with CSIR-NCL, Pune and DST, Delhi for conducting research on a continuous purification process development of a biosimilar monoclonal antibody therapeutic
Lupin reports disappointing performance

7 Feb 2018 , 2:27PM Downgrade to Reduce with our PT under review.
Lupin gets USFDA nod for launching generic lotion

2 Feb 2018 , 12:22PM Lupin announces the launch of its Clobetasol Propionate Lotion 0.05% having received an approval from USFDA earlier
Lupin to launch regular products every 3-4 months

16 Jan 2018 , 9:19AM Positive read through for Lupin as it plans to come up with regular product launches every 3-4 months and aims to be present across all the major OTC product categories.
Lupin gets USFDA nod for generic psoriasis treatment solution

29 Dec 2017 , 10:24AM Lupin receives final approval from the USFDA to market a generic version of Dovonex scalp solution
USFDA approves Lupin for generic dovonex scal solution

29 Dec 2017 , 9:40AM Stocks to remain in focus as Lupin and its peers receive USFDA approval
Lupin receives USFDA approval

29 Dec 2017 , 9:27AM Positive read through as Lupin receives USFDA approval for generic Dovonex Scalp Solution
Lupin promoters buy 1 lakh shares

1 Dec 2017 , 2:20PM 1 lakh shares have been bought from 28-29 November 2017.
Yes Bank and IndusInd Bank to replace Lupin and Cipla

20 Nov 2017 , 8:46AM Positive news for Yes bank and IndusInd as they would be replacing Lupin and Cipla in Sensex Index with effect from 18th December 2017
Lupin gets warning letter for two plants

8 Nov 2017 , 12:45PM Owing to a lack of clarity and uncertainty over the outcome of the USFDA warning letters, we expect considerable de-rating of the stock.
Lupin gets combined warning letter from USFDA

7 Nov 2017 , 2:10PM Negative news for Lupin as it gets combined warning letter from USFDA for its formulation manufacturing facilities at Goa and Pithampur unit – 2
Teva slumps as it cut its growth guidance

3 Nov 2017 , 9:18AM Sentimentally negative news for Indian generic player (like Lupin, Sun Pharma, Glenmark, Cadila etc) as it reflects continued pricing and regulatory pressure on generic companies in US markets.
Lupin launches generic Acticlate tablets in US

3 Nov 2017 , 8:56AM Positive news for Lupin as it launches generic Acticlate tablets in US.
Lupin's Q2 results report decline in total sales

31 Oct 2017 , 11:48AM Lupin Limited (Lupin) reported a 7.9% decline in its total sales (including operating income) to Rs.3, 952 crore (lower than our expectation of Rs.4, 167 crore) for 2QFY2018.
Lupin Q2 results display mixed performance

30 Oct 2017 , 3:46PM Lupin's sales number are below expectation due to steep decline in US sales whereas profit is above expectation due to higher other income.
Lupin gets USFDA final approval for carbidopa tablets

25 Oct 2017 , 12:10PM Lupin gets USFDA final approval for its carbidopa tablets 25 mg (gLodosyn tablets) used in treatment of symptoms of idiopathic Parkinson’s disease, postencephalitic Parkinson’s and symptomatic Parkinsonism - approved drug has sales of ~Rs 140 crore.
Lupin gets USFDA final approval for carbidopa tablets - positive

25 Oct 2017 , 8:51AM Lupin gets USFDA final approval for its carbidopa tablets 25 mg (gLodosyn tablets) used in treatment of symptoms of idiopathic Parkinson’s disease, postencephalitic Parkinson’s and symptomatic Parkinsonism - Positive for stock; approved drug has sales of ~Rs 140 crore.
Lupin bags approval for Nadolol Tablets

10 Oct 2017 , 9:54AM Lupin receives final approval for its Nadolol Tablets USP, 20 mg, 40 mg, and 80 mg from the USFDA to market a generic version
Lupin receives USFDA nod for gCorgard Tablets

10 Oct 2017 , 8:55AM Lupin receives USFDA final approval for gCorgard Tablets; used to treat chest pain & hypertension. Positive for Lupin.
Lupin gets USFDA nod for skin treatment lotion

26 Sep 2017 , 9:04AM Lupin: gets USFDA approval for Clobetasol propionate topical lotion, used to treat a variety of skin conditions (e.g., eczema, dermatitis, allergies, rash) – Positive for Lupin
Lupin gets USFDA approval for Doxycycline Hyclate

11 Sep 2017 , 2:30PM Lupin gets USFDA approval for Doxycycline Hyclate tablets, – Positive for Lupin; stock is up 1%+
Lupin receives EIR for Aurangabad plant

22 Aug 2017 , 8:39AM Lupin gets Establishment Inspection Report (EIR) for Aurangabad plant – Sentimentally positive for Lupin.
Lupin: Disappointing performance and weak guidance

4 Aug 2017 , 9:11AM Lupin: Disappointing performance and weak guidance; Downgrade to Reduce with downward revised TP of Rs.950.
Lupin's sales performance for Q1FY2018 disappoints

4 Aug 2017 , 9:08AM Disappointing performance and weak guidance; Downgrade to Reduce with downward revised TP of Rs.950.
Lupin reports disappointing Q1FY2018 performance

2 Aug 2017 , 2:50PM Lupin reports disappointing Q1FY2018 performance.
Relief from skin inflammation as Lupin gets USFDA nod for gLidex

2 Aug 2017 , 9:54AM Lupin gets USFDA approval for gLidex ointment, used for relief of skin diseases causing inflammation.
Lupin gains after FDA nod for Ancobon Capsules

10 Jul 2017 , 3:31PM Lupin rises over 3% to Rs1156, after company receives approval from the US health regulator for generic Ancobon Capsules

Key fundamentals

Evaluate the intrinsic value of Lupin Ltd stock

Name	March-24	March-23	March-22	March-21	March-20
Assets	20621.22	19025.32	18940.66	18864.51	17478.8
Liabilities	20621.22	19025.32	18940.66	18864.51	17478.8
Equity	91.14	91	90.9	90.74	90.6
Gross Profit	3459.06	1082.66	275.71	2044.06	1907.61
Net Profit	2326.09	425.21	-188.7	1258.62	727.55
Cash From Operating Activities	2504.13	1793.99	151.03	1570.08	2219.49
NPM(%)	15.85	3.77	-1.6	11.38	6.59
Revenue	14666.5	11258.83	11771.67	11055.93	11025.66
Expenses	11207.44	10176.17	11495.96	9011.87	9118.05
ROE(%)	14.87	2.71	-1.2	8.04	4.65

Name	March-24	March-23	March-22	March-21	March-20
Assets	17043.36	16786.87	16066.14	16923.67	16867.19
Liabilities	17043.36	16786.87	16066.14	16923.67	16867.19
Equity	91.14	91	90.9	90.74	90.6
Gross Profit	3810.52	1798.12	287.22	2566.88	2354.8
Net Profit	1914.48	430.08	-1528.04	1216.53	-269.39
Cash From Operating Activities	3648.36	1897.24	367.31	1821.76	1468.84
NPM(%)	9.56	2.58	-9.31	8.02	-1.75
Revenue	20010.82	16641.66	16405.48	15162.96	15374.76
Expenses	16200.3	14843.54	16118.26	12596.08	13019.96
ROE(%)	12.23	2.74	-9.76	7.77	-1.72

Shareholding Pattern

Corporate Action

XD-Date	Dividend-Amount	Dividend-%	Dividend Yield(%GE)	Price on that day
16 Jul 2024	8	400	0.39	1679.65
14 Jul 2023	4	200	0.39	750.2
14 Jul 2022	4	200	0.39	683.3
27 Jul 2021	6.5	325	0.39	1178.45
03 Aug 2020	6	300	0.39	869.8
29 Jul 2019	5	250	0.39	782.15
30 Jul 2018	5	250	0.39	818.15
24 Jul 2017	7.5	375	0.39	1228.5
14 Jul 2015	7.5	375	0.39	1689.5
21 Jul 2014	3	150	0.39	990
13 Feb 2014	3	150	0.39	921.8
29 Jul 2013	4	200	0.39	730.8
13 Jul 2012	3.2	160	0.39	522.15
18 Jul 2011	3	150	0.39	424.2
19 Jul 2010	13.5	135	0.39	1819.45
20 Jul 2009	12.5	125	0.39	783.3
11 Jul 2008	10	100	0.39	581.75
10 Jul 2007	5	50	0.39	710.35
07 Jul 2006	6.5	65	0.39	1239.55
15 Jul 2005	6.5	65	0.39	607.2
13 Jul 2004	6.5	65	0.39	806.95
15 Jul 2003	5	50	0.39	168.5
14 Aug 2002	0	25	0.39	109.1
24 Jan 2002	0	25	0.39	92.8
29 Aug 2001	0	35	0.39	13.2
12 Oct 2000	0	10	0.39	23.2
	0	10	0.39	25.4

From Year	To Year	Class of Share	Authorized Capital(Crores)	Issued Capital(Crores)	Paid Up Shares(NOS)	Paid Up Face Value	Paid Up Capital(Crores)
2023	2024	Equity Share	200.00	91.14	455678908.00	2	91.14
2022	2023	Equity Share	200.00	91.00	454981335.00	2	91.00
2021	2022	Equity Share	200.00	90.90	454475014.00	2	90.90
2020	2021	Equity Share	200.00	90.74	453680133.00	2	90.74
2019	2020	Equity Share	200.00	90.60	452998121.00	2	90.60
2018	2019	Equity Share	200.00	90.50	452493697.00	2	90.50
2017	2018	Equity Share	200.00	90.42	452082850.00	2	90.42
2016	2017	Equity Share	200.00	90.32	451576869.00	2	90.32
2015	2016	Equity Share	200.00	90.12	450582969.00	2	90.12
2014	2015	Equity Share	100.00	89.90	449488335.00	2	89.90
2013	2014	Equity Share	100.00	89.68	448375804.00	2	89.68
2012	2013	Equity Share	100.00	89.51	447529493.00	2	89.51
2011	2012	Equity Share	100.00	89.33	446641681.00	2	89.33
2010	2011	Equity Share	100.00	89.24	446201189.00	2	89.24
2009	2010	Equity Share	100.00	88.94	88943833.00	10	88.94
2008	2009	Equity Share	100.00	82.82	82819550.00	10	82.82
2007	2008	Equity Share	100.00	82.08	82080895.00	10	82.08
2006	2007	Equity Share	100.00	80.34	80344564.00	10	80.34
2005	2006	Equity Share	50.00	40.14	40141134.00	10	40.14
2004	2005	Equity Share	50.00	40.14	40141134.00	10	40.14
2003	2004	Equity Share	50.00	40.14	40141134.00	10	40.14
2002	2003	Equity Share	50.00	40.14	40141134.00	10	40.14
2001	2002	Equity Share	50.00	40.14	40141134.00	10	40.14
2000	2001	Equity Share	50.00	2.83	2830086.00	10	2.83
1999	2000	Equity Share	50.00	33.55	33550865.00	10	33.55
1998	1999	Equity Share	50.00	33.55	33550865.00	10	33.55
1997	1998	Equity Share	50.00	33.55	33550865.00	10	33.55
1996	1997	Equity Share	50.00	33.55	33550865.00	10	33.55
1995	1996	Equity Share	50.00	33.55	33550865.00	10	33.55
1994	1995	Equity Share	50.00	33.55	33550865.00	10	33.55
1993	1994	Equity Share	50.00	33.55	33550865.00	10	33.55
1992	1993	Equity Share	50.00	22.15	22150865.00	10	22.15
1991	1992	Equity Share	50.00	22.15	22150865.00	10	22.15

Announcement Date	Price	Bonus Ratio	Record Date
05 May 2010	1819.45	Stock split from Rs. 10/- to Rs. 2/-	30 Aug 2010
17 May 2006	1239.55	Bonus issue in the ratio of 1:1	14 Aug 2006

Fund	Market Value(CR)	% Hold
Tata NifMidSmHealth (G)	11.96	9.47
Tata NifMidSmHealth (I)	11.96	9.47
Tata NifMidSmHealth (I-Rein)	11.96	9.47
Tata NifMidSmHealthD (G)	11.96	9.47
Tata NifMidSmHealthD (I)	11.96	9.47
Tata NifMidSmHealthD (I-Rein)	11.96	9.47
MotilalNifMidSmHea (G)	2.09	8.88
MotilalNifMidSmHeaDP (G)	2.09	8.88
Nippon Pharma (B)	587.73	7.27
Nippon Pharma (G)	587.73	7.27
Nippon Pharma (I)	587.73	7.27
Nippon Pharma DP (B)	587.73	7.27
Nippon Pharma DP (G)	587.73	7.27
Nippon Pharma DP (I)	587.73	7.27
NipponInd NiftyPharm (G)	55.84	6.52
ICICI PruNifPharma (G)	5.22	6.48
ICICI PruNifPharma (I)	5.22	6.48
ICICI PruNifPharmaDP (G)	5.22	6.48
ICICI PruNifPharmaDP (I)	5.22	6.48
MiraeAsset Health (G)	165.31	6.20
MiraeAsset Health (I)	165.31	6.20
MiraeAsset Health DP (G)	165.31	6.20
MiraeAsset Health DP (I)	165.31	6.20
Tata IndiaPharma (G)	74.95	6.19
Tata IndiaPharma (I)	74.95	6.19
Tata IndiaPharma (I-Rein)	74.95	6.19
Tata IndiaPharma DP (G)	74.95	6.19
Tata IndiaPharma DP (I-Payo)	74.95	6.19
Tata IndiaPharma DP (I-Rein)	74.95	6.19
AxisNifHealthcareETF (G)	1.11	5.84
ITI Pharma&HeaCare (G)	12.35	5.78
ITI Pharma&HeaCare (I)	12.35	5.78
ITI Pharma&HeaCareDP (G)	12.35	5.78
ITI Pharma&HeaCareDP (I)	12.35	5.78
WhiteOakPar&Health (G)	16.93	5.58
WhiteOakPar&HealthDP (G)	16.93	5.58
HDFC Pharma&Health (G)	88.67	5.43
HDFC Pharma&Health (I)	88.67	5.43
HDFC Pharma&HealthDP (G)	88.67	5.43
HDFC Pharma&HealthDP (I)	88.67	5.43
ICICI NiftyHealthETF (G)	7.06	5.40
AdityaBSL NifHealthC (G)	1.91	5.40
DSP NiftyHealthcaETF (G)	0.53	5.40
SBI HealthcareOpp (G)	174.76	4.96
SBI HealthcareOpp (I)	174.76	4.96
SBI HealthcareOpp (IDCWR)	174.76	4.96
SBI HealthcareOppDP (G)	174.76	4.96
SBI HealthcareOppDP (I)	174.76	4.96
SBI HealthcareOppDP (IDCWR)	174.76	4.96
AdityaBSL Phar&Hea (G)	39.79	4.88
AdityaBSL Phar&Hea (I)	39.79	4.88
AdityaBSL Phar&HeaDP (G)	39.79	4.88
AdityaBSL Phar&HeaDP (I)	39.79	4.88
ICICI Pru PHD (G)	232.32	4.73
ICICI Pru PHD (I)	232.32	4.73
ICICI Pru PHD DP (G)	232.32	4.73
ICICI Pru PHD DP (I)	232.32	4.73
SBI Quant (G)	163.61	4.59
SBI Quant (I)	163.61	4.59
SBI Quant DP (G)	163.61	4.59
SBI Quant DP (I)	163.61	4.59
EdelNifMC150M50 (G)	34.60	4.31
EdelNifMC150M50 (I)	34.60	4.31
EdelNifMC150M50DP (G)	34.60	4.31
EdelNifMC150M50DP (I)	34.60	4.31
Kotak NifMid150Mom (G)	4.13	4.31
Kotak NifMid150Mom (I)	4.13	4.31
Kotak NifMid150MomDP (G)	4.13	4.31
Kotak NifMid150MomDP (I)	4.13	4.31
TataNifMid150MoM50 (G)	30.01	4.31
TataNifMid150MoM50 (I)	30.01	4.31
TataNifMid150MoM50 (I-Rein)	30.01	4.31
TataNifMid150Mom50DP (G)	30.01	4.31
TataNifMid150Mom50DP (I)	30.01	4.31
TataNifMid150Mom50DP (I-Rein)	30.01	4.31
HDFC MNC (G)	23.73	4.25
HDFC MNC (I)	23.73	4.25
HDFC MNC DP (G)	23.73	4.25
HDFC MNC DP (I)	23.73	4.25
ICICI BSEMidcapSeETF (G)	3.16	4.12
SBI LongTermAdSIVDP (G)	8.32	3.99
SBI LongTermAdSIVDP (I)	8.32	3.99
SBI LongTermAdvSIV (G)	8.32	3.99
SBI LongTermAdvSIV (I)	8.32	3.99
Motilal BSEHealthETF (G)	1.10	3.95
Bandhan BSEHealthC (G)	0.69	3.95
Bandhan BSEHealthCDP (G)	0.69	3.95
InvescoManufacturiDP (G)	28.10	3.77
InvescoManufacturiDP (I)	28.10	3.77
InvescoManufacturing (G)	28.10	3.77
InvescoManufacturing (I)	28.10	3.77
UTI NifAlpLovVol30 (G)	2.93	3.75
UTI NifAlpLovVol30DP (G)	2.93	3.75
ICICI NifAlpLow30ETF (G)	62.34	3.73
BandhanNiAlpLowV30 (G)	0.30	3.72
BandhanNiAlpLowV30DP (G)	0.30	3.72
Nippon NifAlpLV30 (G)	46.04	3.71
Nippon NifAlpLV30 (I)	46.04	3.71
Nippon NifAlpLV30DP (G)	46.04	3.71
Nippon NifAlpLV30DP (I)	46.04	3.71
EdelweissNifAlpV30 (G)	4.74	3.70
EdelweissNifAlpV30 (I)	4.74	3.70
EdelweissNifAlpV30DP (G)	4.74	3.70
EdelweissNifAlpV30DP (I)	4.74	3.70
Edel MSCI DomWH45 (G)	5.73	3.58
Edel MSCI DomWH45 (I)	5.73	3.58
Edel MSCI DomWH45 DP (G)	5.73	3.58
Edel MSCI DomWH45 DP (I)	5.73	3.58
Axis Quant (G)	34.81	3.57
Axis Quant (I)	34.81	3.57
Axis Quant DP (G)	34.81	3.57
Axis Quant DP (I)	34.81	3.57
Kotak Healthcare (G)	14.60	3.55
Kotak Healthcare (I)	14.60	3.55
Kotak Healthcare DP (G)	14.60	3.55
Kotak Healthcare DP (I)	14.60	3.55
SBI InnovativeOppr (G)	262.78	3.53
SBI InnovativeOppr (I)	262.78	3.53
SBI InnovativeOpprDP (G)	262.78	3.53
SBI InnovativeOpprDP (I)	262.78	3.53
HSBC Midcap (G)	356.39	3.44
HSBC Midcap (I)	356.39	3.44
HSBC Midcap (IDCWR)	356.39	3.44
HSBC Midcap DP (G)	356.39	3.44
HSBC Midcap DP (I)	356.39	3.44
AdityaBSL Quant (G)	80.67	3.41
AdityaBSL Quant (I)	80.67	3.41
AdityaBSL Quant DP (G)	80.67	3.41
AdityaBSL Quant DP (I)	80.67	3.41
ICICI Pru FocusEq (G)	334.89	3.19
ICICI Pru FocusEq (I)	334.89	3.19
ICICI Pru FocusEq (IDCWR)	334.89	3.19
ICICI Pru FocusEq DP (G)	334.89	3.19
ICICI Pru FocusEq DP (I)	334.89	3.19
ICICI Pru FocusEq DP (IDCWR)	334.89	3.19
MotilaNif500M50ETF (G)	4.09	3.09
Motilal Nif500Mo50DP (G)	16.58	3.08
Motilal Nifty500Mo50 (G)	16.58	3.08
BandhanNif500Mom50 (G)	0.60	3.08
BandhanNif500Mom50DP (G)	0.60	3.08
NipponNif500Mom50 (G)	21.15	3.08
NipponNif500Mom50 (I)	21.15	3.08
NipponNif500Mom50DP (G)	21.15	3.08
NipponNif500Mom50DP (I)	21.15	3.08
Mirae Asset Midcap (G)	450.43	3.02
Mirae Asset Midcap (I)	450.43	3.02
Mirae Asset MidcapDP (G)	450.43	3.02
Mirae Asset MidcapDP (I)	450.43	3.02
Axis NiftyMidcap50 (G)	12.13	2.99
Axis NiftyMidcap50 (I)	12.13	2.99
Axis NiftyMidcap50DP (G)	12.13	2.99
Axis NiftyMidcap50DP (I)	12.13	2.99
Kotak NifMidcap50 (G)	1.46	2.99
Kotak NifMidcap50 (I)	1.46	2.99
Kotak NifMidcap50DP (G)	1.46	2.99
Kotak NifMidcap50DP (I)	1.46	2.99
Kotak NiftyMidcap50 (G)	1.59	2.99
Tata Nif200Alpha30 (G)	5.21	2.93
Tata Nif200Alpha30 (I)	5.21	2.93
Tata Nif200Alpha30 (I-Rein)	5.21	2.93
Tata Nif200Alpha30DP (G)	5.21	2.93
Tata Nif200Alpha30DP (I)	5.21	2.93
Tata Nif200Alpha30DP (I-Rein)	5.21	2.93
Tata Mid Cap Gro RP (G)	124.83	2.87
Tata Mid Cap Gro RP (I)	124.83	2.87
Tata Mid Cap Gro RP (IDCWR)	124.83	2.87
Tata MidCap GrowthDP (G)	124.83	2.87
Tata MidCap GrowthDP (I)	124.83	2.87
Tata MidCap GrowthDP (IDCWR)	124.83	2.87
ICICIPruInnovation (G)	172.50	2.74
ICICIPruInnovation (I)	172.50	2.74
ICICIPruInnovationDP (G)	172.50	2.74
ICICIPruInnovationDP (I)	172.50	2.74
BaroBNPNif200Mom30 (G)	0.61	2.68
BaroBNPNif200Mom30DP (G)	0.61	2.68
BandhanNif200Mom30 (G)	3.10	2.63
BandhanNif200Mom30 (I)	3.10	2.63
BandhanNif200Mom30DP (G)	3.10	2.63
BandhanNif200Mom30DP (I)	3.10	2.63
HDFC Nif200Mom30ETF (G)	2.13	2.63
HDFC Nif200Momen30 (G)	17.59	2.63
HDFC Nif200Momen30DP (G)	17.59	2.63
UTI Nifty200 Mom30 (G)	193.44	2.63
UTI Nifty200 Mom30DP (G)	193.44	2.63
AdityaNif200M30ETF (G)	1.13	2.63
Motilal Nif200M30ETF (G)	3.03	2.63
ICICI Nift200M30ETF (G)	14.91	2.63
Motilal Nif200M30I (G)	21.94	2.62
Motilal Nif200M30IDP (G)	21.94	2.62
Kotak Nif200Mom30 (G)	9.20	2.62
Kotak Nif200Mom30 (I)	9.20	2.62
Kotak Nif200Mom30DP (G)	9.20	2.62
Kotak Nif200Mom30DP (I)	9.20	2.62
ICICINif200M30Indx (G)	12.80	2.62
ICICINif200M30Indx (I)	12.80	2.62
ICICINif200M30IndxDP (G)	12.80	2.62
ICICINif200M30IndxDP (I)	12.80	2.62
UTI NIfMidsmall400 (G)	1.04	2.60
UTI NIfMidsmall400DP (G)	1.04	2.60
MiraeNifMS400MQ100 (G)	7.82	2.60
Edelweiss BusinCyc (G)	43.61	2.57
Edelweiss BusinCyc (I)	43.61	2.57
Edelweiss BusinCycDP (G)	43.61	2.57
Edelweiss BusinCycDP (I)	43.61	2.57
Sundaram Mid Cap (G)	273.84	2.42
Sundaram Mid Cap (I)	273.84	2.42
Sundaram Mid Cap (I-Rein)	273.84	2.42
Sundaram Mid Cap-DP (G)	273.84	2.42
Sundaram Mid Cap-DP (I)	273.84	2.42
Sundaram Mid Cap-DP (IDCWR)	273.84	2.42
Tata BusinessCycle (G)	64.16	2.34
Tata BusinessCycle (I)	64.16	2.34
Tata BusinessCycle (I-Rein)	64.16	2.34
Tata BusinessCycleDP (G)	64.16	2.34
Tata BusinessCycleDP (I)	64.16	2.34
Tata BusinessCycleDP (I-Rein)	64.16	2.34
UTI Healthcare (G)	24.34	2.34
UTI Healthcare (I)	24.34	2.34
UTI Healthcare (I-Rein)	24.34	2.34
UTI Healthcare DP (G)	24.34	2.34
UTI Healthcare DP (I)	24.34	2.34
HSBC ExportOpportu (G)	36.07	2.21
HSBC ExportOpportu (I)	36.07	2.21
HSBC ExportOpportuDP (G)	36.07	2.21
HSBC ExportOpportuDP (I)	36.07	2.21
BarBNP Midcap (G)	43.60	2.20
BarBNP Midcap (I)	43.60	2.20
BarBNP Midcap DP (G)	43.60	2.20
BarBNP Midcap DP (I)	43.60	2.20
Axis Midcap (G)	606.92	2.14
Axis Midcap (I)	606.92	2.14
Axis Midcap (I-Rein)	606.92	2.14
Axis Midcap DP (G)	606.92	2.14
Axis Midcap DP (I)	606.92	2.14
ITI Multi Cap (G)	23.83	2.13
ITI Multi Cap (I)	23.83	2.13
ITI Multi Cap DP (G)	23.83	2.13
ITI Multi Cap DP (I)	23.83	2.13
TataNif500MulManuf (G)	2.43	2.11
TataNif500MulManuf (I)	2.43	2.11
TataNif500MulManuf (I-Rein)	2.43	2.11
TataNif500MulManufDP (G)	2.43	2.11
TataNif500MulManufDP (I)	2.43	2.11
TataNif500MulManufDP (I-Rein)	2.43	2.11
BOI MidCapTaxS2 (G)	0.63	2.09
BOI MidCapTaxS2 (I)	0.63	2.09
BOI MidCaTaxS2DP (G)	0.63	2.09
BOI MidCaTaxS2DP (I)	0.63	2.09
Sundaram Multi Cap (G)	54.62	2.09
Sundaram Multi Cap (I)	54.62	2.09
Sundaram Multi Cap (IDCWS)	54.62	2.09
Sundaram Multi CapDP (G)	54.62	2.09
Sundaram Multi CapDP (I)	54.62	2.09
Sundaram Multi CapDP (IDCWR)	54.62	2.09
Sundaram Multi CapDP (IDCWS)	54.62	2.09
Tata FocusedEquity (G)	36.34	2.09
Tata FocusedEquity (I)	36.34	2.09
Tata FocusedEquity (I-Rein)	36.34	2.09
Tata FocusedEquityDP (G)	36.34	2.09
Tata FocusedEquityDP (I)	36.34	2.09
Tata FocusedEquityDP (I-Rein)	36.34	2.09
Edelweiss Mid Cap (G)	179.91	2.08
Edelweiss Mid Cap (I)	179.91	2.08
Edelweiss Mid Cap (I-Rein)	179.91	2.08
Edelweiss Mid Cap DP (G)	179.91	2.08
Edelweiss Mid Cap DP (I)	179.91	2.08
SBI Long Term Eq (G)	559.20	2.05
SBI Long Term Eq (I)	559.20	2.05
SBI Long Term Eq (IDCWR)	559.20	2.05
SBI Long Term Eq-DP (G)	559.20	2.05
SBI Long Term Eq-DP (I)	559.20	2.05
SBI Long Term Eq-DP (IDCWR)	559.20	2.05
BOI MidCapTaxS1 (G)	1.16	2.04
BOI MidCapTaxS1 (I)	1.16	2.04
BOI MidCaTaxS1DP (G)	1.16	2.04
BOI MidCaTaxS1DP (I)	1.16	2.04
ICICI Pru Quant (G)	2.54	2.03
ICICI Pru Quant (I)	2.54	2.03
ICICI Pru Quant DP (G)	2.54	2.03
ICICI Pru Quant DP (I)	2.54	2.03
SBI BSESensexNxt50 (G)	0.41	2.02
WhiteOak MidCap (G)	55.27	2.01
WhiteOak MidCap (I)	55.27	2.01
WhiteOak MidCapDP (G)	55.27	2.01
WhiteOak MidCapDP (I)	55.27	2.01
ITI Mid Cap (G)	21.66	1.98
ITI Mid Cap (I)	21.66	1.98
ITI Mid Cap DP (G)	21.66	1.98
ITI Mid Cap DP (I)	21.66	1.98
SBI MagGlobal (G)	124.83	1.98
SBI MagGlobal (I)	124.83	1.98
SBI MagGlobal (IDCWR)	124.83	1.98
SBI MagGlobal DP (G)	124.83	1.98
SBI MagGlobal DP (I)	124.83	1.98
SBI MagGlobal DP (IDCWR)	124.83	1.98
Motilal NifMid100ETF (G)	10.74	1.98
LICNifMidcap100ETF (G)	12.58	1.96
NipponETFBSESenNxt50 (G)	0.86	1.96
UTI BSESenNext50ETF (G)	0.48	1.96
Kotak Quant (G)	12.90	1.92
Kotak Quant (I)	12.90	1.92
Kotak Quant DP (G)	12.90	1.92
Kotak Quant DP (I)	12.90	1.92
HDFC LargeCap (G)	683.22	1.89
HDFC LargeCap (I)	683.22	1.89
HDFC LargeCap (IDCWR)	683.22	1.89
HDFC LargeCap DP (G)	683.22	1.89
HDFC LargeCap DP (I)	683.22	1.89
HDFC LargeCap DP (IDCWR)	683.22	1.89
ICICI Pru MNC (G)	29.43	1.84
ICICI Pru MNC (I)	29.43	1.84
ICICI Pru MNC DP (G)	29.43	1.84
ICICI Pru MNC DP (I)	29.43	1.84
HSBC Large&Mid Cap (G)	68.91	1.83
HSBC Large&Mid Cap (I)	68.91	1.83
HSBC Large&MidCapDP (G)	68.91	1.83
HSBC Large&MidCapDP (I)	68.91	1.83
Tata Large & MidCap (G)	145.63	1.83
Tata Large&MidCap (I)	145.63	1.83
Tata Large&MidCap (IDCWR)	145.63	1.83
Tata Large&MidCap DP (G)	145.63	1.83
Tata Large&MidCap DP (I)	145.63	1.83
Tata Large&MidCap DP (IDCWR)	145.63	1.83
DSP Quant (G)	17.68	1.81
DSP Quant (I)	17.68	1.81
DSP Quant DP (G)	17.68	1.81
DSP Quant DP (I)	17.68	1.81
Bandhan Innovation (G)	24.98	1.80
Bandhan Innovation (I)	24.98	1.80
Bandhan InnovationDP (G)	24.98	1.80
Bandhan InnovationDP (I)	24.98	1.80
AdityaBSL Midcap (G)	97.52	1.77
AdityaBSL Midcap (I)	97.52	1.77
AdityaBSL Midcap (IDCWR)	97.52	1.77
AdityaBSL Midcap DP (G)	97.52	1.77
AdityaBSL Midcap DP (I)	97.52	1.77
AdityaBSL Midcap DP (IDCWR)	97.52	1.77
Axis Momentum (G)	22.29	1.76
Axis Momentum (I)	22.29	1.76
Axis Momentum DP (G)	22.29	1.76
Axis Momentum DP (I)	22.29	1.76
Nippon Quant (B)	1.62	1.76
Nippon Quant (G)	1.62	1.76
Nippon Quant (I)	1.62	1.76
Nippon Quant (I-Rein)	1.62	1.76
Nippon Quant - DP (B)	1.62	1.76
Nippon Quant - DP (G)	1.62	1.76
Nippon Quant - DP (I)	1.62	1.76
MiraeAss Multicap (G)	57.53	1.73
MiraeAss Multicap (I)	57.53	1.73
MiraeAss Multicap DP (G)	57.53	1.73
MiraeAss Multicap DP (I)	57.53	1.73
HSBC Tax Saver Eq DP (G)	3.87	1.71
HSBC Tax Saver Eq DP (I)	3.87	1.71
HSBC TaxSaver Equity (G)	3.87	1.71
HSBC TaxSaver Equity (I)	3.87	1.71
BarBNP Value (G)	22.31	1.70
BarBNP Value (I)	22.31	1.70
BarBNP Value DP (G)	22.31	1.70
BarBNP Value DP (I)	22.31	1.70
HSBC Large Cap (G)	30.42	1.70
HSBC Large Cap (I)	30.42	1.70
HSBC Large Cap (IDCWR)	30.42	1.70
HSBC Large Cap DP (G)	30.42	1.70
HSBC Large Cap DP (I)	30.42	1.70
HSBC Large Cap DP (IDCWR)	30.42	1.70
EdelweissLar&MiCap (G)	60.55	1.68
EdelweissLar&MiCap (I)	60.55	1.68
EdelweissLar&MiCap (I-Rein)	60.55	1.68
EdelweissLar&MiCapDP (G)	60.55	1.68
EdelweissLar&MiCapDP (I)	60.55	1.68
Union Midcap (G)	22.12	1.68
Union Midcap (I)	22.12	1.68
Union Midcap DP (G)	22.12	1.68
Union Midcap DP (I)	22.12	1.68
Tata Multicap (G)	48.06	1.64
Tata Multicap (I)	48.06	1.64
Tata Multicap (I-Rein)	48.06	1.64
Tata Multicap DP (G)	48.06	1.64
Tata Multicap DP (I)	48.06	1.64
Tata Multicap DP (I-Rein)	48.06	1.64
Sundaram L&MidCap (G)	104.28	1.63
Sundaram L&MidCap (I)	104.28	1.63
Sundaram L&MidCap (IDCWR)	104.28	1.63
Sundaram L&MidCapDP (G)	104.28	1.63
Sundaram L&MidCapDP (I)	104.28	1.63
Sundaram L&MidCapDP (IDCWR)	104.28	1.63
HSBC MulAssetAllco (G)	32.18	1.61
HSBC MulAssetAllco (I)	32.18	1.61
HSBC MulAssetAllcoDP (G)	32.18	1.61
HSBC MulAssetAllcoDP (I)	32.18	1.61
BarodaNifMidcap150 (G)	0.13	1.58
BarodaNifMidcap150DP (G)	0.13	1.58
Nippon Growth (B)	517.61	1.56
Nippon Growth (G)	517.61	1.56
Nippon Growth (I)	517.61	1.56
Nippon Growth (IDCWR)	517.61	1.56
Nippon Growth - IP (I)	517.61	1.56
Nippon Growth - IP (I-Rein)	517.61	1.56
Nippon Growth DP (B)	517.61	1.56
Nippon Growth DP (G)	517.61	1.56
Nippon Growth DP (I)	517.61	1.56
Nippon NiftyMid150 (G)	30.35	1.56
SBI NifMidcap150 (G)	11.20	1.56
SBI NifMidcap150 (I)	11.20	1.56
SBI NifMidcap150DP (G)	11.20	1.56
SBI NifMidcap150DP (I)	11.20	1.56
Zerodha Nifty Mid150 (G)	0.99	1.56
ICICI NifMidca150ETF (G)	6.40	1.55
MiraeNifMidcap150ETF (G)	14.40	1.55
AdityaBSLNifMid150 (G)	4.90	1.55
AdityaBSLNifMid150 (I)	4.90	1.55
AdityaBSLNifMid150DP (G)	4.90	1.55
AdityaBSLNifMid150DP (I)	4.90	1.55
ICICINifMid150IndeDP (G)	9.73	1.55
ICICINifMid150IndeDP (I)	9.73	1.55
ICICINifMid150Index (G)	9.73	1.55
ICICINifMid150Index (I)	9.73	1.55
Motilal Midcap 150 (G)	30.83	1.55
Motilal MidCap 150DP (G)	30.83	1.55
Bandhan NifMidC150 (G)	0.34	1.55
Bandhan NifMidC150DP (G)	0.34	1.55
HDFC NifMidcap150ETF (G)	1.17	1.55
HDFC NiftyMid150 (G)	4.52	1.55
HDFC NiftyMid150DP (G)	4.52	1.55
Navi NifMidcap150 (G)	3.54	1.55
Navi NifMidcap150DP (G)	3.54	1.55
Nippon NifMidca150 (G)	24.01	1.55
Nippon NifMidca150 (I)	24.01	1.55
Nippon NifMidca150DP (G)	24.01	1.55
Nippon NifMidca150DP (I)	24.01	1.55
UTI NifMidcap150 (G)	0.71	1.55
UTI NifMidcap150DP (G)	0.71	1.55
UTI NifMidcap150ETF (G)	0.14	1.55
KotakNifMid150Indx (G)	0.11	1.54
KotakNifMid150Indx (I)	0.11	1.54
KotakNifMid150IndxDP (G)	0.11	1.54
KotakNifMid150IndxDP (I)	0.11	1.54
EdelweissConsumpti (G)	4.75	1.51
EdelweissConsumpti (I)	4.75	1.51
EdelweissConsumptiDP (G)	4.75	1.51
EdelweissConsumptiDP (I)	4.75	1.51
Mirae Nif200Alp30ETF (G)	5.69	1.50
Union Multicap (G)	15.63	1.50
Union Multicap (I)	15.63	1.50
Union Multicap DP (G)	15.63	1.50
Union Multicap DP (I)	15.63	1.50
KotakNifMid150ETF (G)	0.01	1.48
Mirae Lar&Midcap (G)	538.67	1.48
Mirae Lar&Midcap (I)	538.67	1.48
Mirae Lar&Midcap (I-Rein)	538.67	1.48
Mirae Lar&Midcap DP (G)	538.67	1.48
Mirae Lar&Midcap DP (I)	538.67	1.48
TRUSTMF Flexi Cap (G)	13.37	1.46
TRUSTMF Flexi Cap (I)	13.37	1.46
TRUSTMF Flexi Cap DP (G)	13.37	1.46
TRUSTMF Flexi Cap DP (I)	13.37	1.46
Union BusinesCycle (G)	7.97	1.45
Union BusinesCycle (I)	7.97	1.45
Union BusinesCycleDP (G)	7.97	1.45
Union BusinesCycleDP (I)	7.97	1.45
Edelweiss LarCap (G)	16.56	1.43
Edelweiss LarCap (I)	16.56	1.43
Edelweiss LarCap (I-Rein)	16.56	1.43
Edelweiss LarCap B (G)	16.56	1.43
Edelweiss LarCap B (I)	16.56	1.43
Edelweiss LarCap B (I-Rein)	16.56	1.43
Edelweiss LarCap C (G)	16.56	1.43
Edelweiss LarCap C (I)	16.56	1.43
Edelweiss LarCap C (I-Rein)	16.56	1.43
Edelweiss LarCapDP (G)	16.56	1.43
Edelweiss LarCapDP (I)	16.56	1.43
Mirae NifIndManufETF (G)	2.87	1.42
UTI NifManufacturi (G)	0.27	1.41
UTI NifManufacturiDP (G)	0.27	1.41
FranklinELSSTaxSav (G)	87.19	1.37
FranklinELSSTaxSav (I)	87.19	1.37
FranklinELSSTaxSav (I-Rein)	87.19	1.37
FranklinELSSTaxSavDP (G)	87.19	1.37
FranklinELSSTaxSavDP (I)	87.19	1.37
Union Retirement (G)	2.07	1.34
Union Retirement (I)	2.07	1.34
Union Retirement DP (G)	2.07	1.34
Union Retirement DP (I)	2.07	1.34
Navi NifManufIndex (G)	0.70	1.31
Navi NifManufIndexDP (G)	0.70	1.31
Tata Hybrid Eq DP (G)	52.01	1.30
Tata Hybrid Eq DP (I)	52.01	1.30
Tata Hybrid Eq DP (I-Mont)	52.01	1.30
Tata Hybrid Eq DP (IDCWR)	52.01	1.30
Tata Hybrid Eq DP (MIDCWR)	52.01	1.30
Tata Hybrid Eq RP (G)	52.01	1.30
Tata Hybrid Eq RP (I)	52.01	1.30
Tata Hybrid Eq RP (I-Mont)	52.01	1.30
Tata Hybrid Eq RP (IDCWR)	52.01	1.30
Tata Hybrid Eq RP (MIDCWR)	52.01	1.30
Bajaj Healthcare (G)	3.97	1.29
Bajaj Healthcare (I)	3.97	1.29
Bajaj Healthcare DP (G)	3.97	1.29
Bajaj Healthcare DP (I)	3.97	1.29
Invesco Bal Adv (G)	12.19	1.29
Invesco Bal Adv (I)	12.19	1.29
Invesco Bal Adv DP (G)	12.19	1.29
Invesco Bal Adv DP (I)	12.19	1.29
Nippon Eq Hybrid (G)	47.66	1.29
Nippon Eq Hybrid (I)	47.66	1.29
Nippon Eq Hybrid (I-Mont)	47.66	1.29
Nippon Eq Hybrid (I-Quar)	47.66	1.29
Nippon Eq Hybrid (I-Rein)	47.66	1.29
Nippon Eq Hybrid (M)	47.66	1.29
Nippon Eq Hybrid (Q)	47.66	1.29
Nippon Eq HybridDP (G)	47.66	1.29
Nippon Eq HybridDP (I)	47.66	1.29
Nippon Eq HybridDP (I-Mont)	47.66	1.29
Nippon Eq HybridDP (I-Quar)	47.66	1.29
Nippon EqHyb SP1 (G)	47.66	1.29
Nippon EqHyb SP1 (I)	47.66	1.29
Nippon EqHyb SP1 (I-Mont)	47.66	1.29
Nippon EqHyb SP1 (I-Quar)	47.66	1.29
Nippon EqHyb SP1 DP (G)	47.66	1.29
Nippon EqHyb SP1 DP (I)	47.66	1.29
Nippon EqHyb SP1 DP (I-Mont)	47.66	1.29
Nippon EqHyb SP1 DP (I-Quar)	47.66	1.29
Tata Ethical DP (G)	41.61	1.28
Tata Ethical DP (I)	41.61	1.28
Tata Ethical DP (IDCWR)	41.61	1.28
Tata Ethical RP (G)	41.61	1.28
Tata Ethical RP (I)	41.61	1.28
Tata Ethical RP (IDCWR)	41.61	1.28
HDFC Value Fund RP (G)	86.02	1.26
HDFC Value Fund RP (I)	86.02	1.26
HDFC Value Fund RP (IDCWR)	86.02	1.26
HDFC Value Fund DP (G)	86.02	1.26
HDFC Value Fund DP (I)	86.02	1.26
HDFC Value Fund DP (IDCWR)	86.02	1.26
Quantum ELSSTaxSav (G)	2.62	1.25
Quantum ELSSTaxSav (I)	2.62	1.25
Quantum ELSSTaxSavDP (G)	2.62	1.25
Quantum ELSSTaxSavDP (I)	2.62	1.25
BandhanSterlingVal (G)	116.61	1.24
BandhanSterlingVal (I)	116.61	1.24
BandhanSterlingVal (IDCWR)	116.61	1.24
BandhanSterlingValDP (G)	116.61	1.24
BandhanSterlingValDP (I)	116.61	1.24
InvescoInd Contra (G)	211.67	1.23
InvescoInd Contra (I)	211.67	1.23
InvescoInd Contra (I-Rein)	211.67	1.23
InvescoInd Contra DP (G)	211.67	1.23
InvescoInd Contra DP (I)	211.67	1.23
InvescoInd Contra DP (IDCWR)	211.67	1.23
Nippon RetWeathCre (B)	37.52	1.23
Nippon RetWeathCre (G)	37.52	1.23
Nippon RetWeathCre (I)	37.52	1.23
Nippon RetWeathCreDP (B)	37.52	1.23
Nippon RetWeathCreDP (G)	37.52	1.23
Nippon RetWeathCreDP (I)	37.52	1.23
Franklin Flexi Cap (G)	212.47	1.22
Franklin Flexi Cap (I)	212.47	1.22
Franklin Flexi CapDP (G)	212.47	1.22
Franklin Flexi CapDP (I)	212.47	1.22
HDFC Large&MidCap (G)	283.91	1.21
HDFC Large&MidCap (I)	283.91	1.21
HDFC Large&MidCap (IDCWR)	283.91	1.21
HDFC Large&MidCap DP (G)	283.91	1.21
HDFC Large&MidCap DP (I)	283.91	1.21
HDFC Large&MidCap DP (IDCWR)	283.91	1.21
HDFC BalanceAdva DP (G)	1141.85	1.20
HDFC BalanceAdva DP (I)	1141.85	1.20
HDFC BalanceAdva DP (IDCWR)	1141.85	1.20
HDFC BalanceAdva RP (G)	1141.85	1.20
HDFC BalanceAdva RP (I)	1141.85	1.20
HDFC BalanceAdva RP (IDCWR)	1141.85	1.20
Quantum LTE Value-DP (G)	13.24	1.18
Quantum LTE Value-DP (I)	13.24	1.18
Quantum LTE Value-RP (G)	13.24	1.18
Quantum LTE Value-RP (I)	13.24	1.18
Quantum LTE Value-RP (I-Rein)	13.24	1.18
ICICI PruValDisco (G)	572.57	1.17
ICICI PruValDisco (I)	572.57	1.17
ICICI PruValDisco (IDCWR)	572.57	1.17
ICICI PruValDisco DP (G)	572.57	1.17
ICICI PruValDisco DP (I)	572.57	1.17
ICICI PruValDisco DP (IDCWR)	572.57	1.17
Union Large&Mid (G)	9.29	1.15
Union Large&Mid (I)	9.29	1.15
Union Large&Mid DP (G)	9.29	1.15
Union Large&Mid DP (I)	9.29	1.15
HSBC Flexi Cap (G)	49.38	1.09
HSBC Flexi Cap (I)	49.38	1.09
HSBC Flexi Cap (IDCWR)	49.38	1.09
HSBC Flexi Cap DP (G)	49.38	1.09
HSBC Flexi Cap DP (I)	49.38	1.09
HSBC Flexi Cap DP (IDCWR)	49.38	1.09
Bandhan ELSSTaxSav (G)	70.98	1.08
Bandhan ELSSTaxSav (I)	70.98	1.08
Bandhan ELSSTaxSav (IDCWR)	70.98	1.08
Bandhan ELSSTaxSavDP (G)	70.98	1.08
Bandhan ELSSTaxSavDP (I)	70.98	1.08
ITI Large&Midcap (G)	8.31	1.06
ITI Large&Midcap (I)	8.31	1.06
ITI Large&Midcap DP (G)	8.31	1.06
ITI Large&Midcap DP (I)	8.31	1.06
Nippon Flexi Cap (G)	86.19	1.04
Nippon Flexi Cap (I)	86.19	1.04
Nippon Flexi Cap DP (G)	86.19	1.04
Nippon Flexi Cap DP (I)	86.19	1.04
Axis ELSS TaxSaver (G)	345.16	1.00
Axis ELSS TaxSaver (I)	345.16	1.00
Axis ELSS TaxSaver (I-Rein)	345.16	1.00
Axis ELSS TaxSaverDP (G)	345.16	1.00
Axis ELSS TaxSaverDP (I)	345.16	1.00
Axis Growth Oppo (G)	132.00	0.98
Axis Growth Oppo (I)	132.00	0.98
Axis Growth Oppo DP (G)	132.00	0.98
Axis Growth Oppo DP (I)	132.00	0.98
HSBC ELSSTaxsaver (G)	37.76	0.98
HSBC ELSSTaxsaver (I)	37.76	0.98
HSBC ELSSTaxsaver (IDCWR)	37.76	0.98
HSBC ELSSTaxSaverDP (G)	37.76	0.98
HSBC ELSSTaxSaverDP (I)	37.76	0.98
HSBC ELSSTaxSaverDP (IDCWR)	37.76	0.98
ICICI PruExp&Ser (G)	12.98	0.98
ICICI PruExp&Ser (I)	12.98	0.98
ICICI PruExp&Ser (IDCWR)	12.98	0.98
ICICI PruExp&Ser DP (G)	12.98	0.98
ICICI PruExp&Ser DP (I)	12.98	0.98
ICICI PruExp&Ser DP (IDCWR)	12.98	0.98
Edelweiss FlexiCap (G)	23.41	0.97
Edelweiss FlexiCap (I)	23.41	0.97
Edelweiss FlexiCapDP (G)	23.41	0.97
Edelweiss FlexiCapDP (I)	23.41	0.97
Edelweiss MultiCap (G)	24.16	0.96
Edelweiss MultiCap (I)	24.16	0.96
Edelweiss MultiCapDP (G)	24.16	0.96
Edelweiss MultiCapDP (I)	24.16	0.96
Axis India Manufac (G)	52.66	0.95
Axis India Manufac (I)	52.66	0.95
Axis India ManufacDP (G)	52.66	0.95
Axis India ManufacDP (I)	52.66	0.95
Bandhan BalanceAdv (G)	20.97	0.95
Bandhan BalanceAdv (I)	20.97	0.95
Bandhan BalanceAdv (IDCWR)	20.97	0.95
Bandhan BalanceAdvDP (G)	20.97	0.95
Bandhan BalanceAdvDP (I)	20.97	0.95
Bandhan BalanceAdvDP (IDCWR)	20.97	0.95
Bandhan Large Cap (G)	16.77	0.95
Bandhan Large Cap (I)	16.77	0.95
Bandhan Large Cap (IDCWR)	16.77	0.95
Bandhan Large Cap DP (G)	16.77	0.95
Bandhan Large Cap DP (I)	16.77	0.95
Samco DynAssetAllo (G)	4.81	0.95
Samco DynAssetAllo (I)	4.81	0.95
Samco DynAssetAlloDP (G)	4.81	0.95
Samco DynAssetAlloDP (I)	4.81	0.95
Mahindra SmallCap (G)	32.62	0.94
Mahindra SmallCap (I)	32.62	0.94
Mahindra SmallCapDP (G)	32.62	0.94
Mahindra SmallCapDP (I)	32.62	0.94
Union Flexi Cap (G)	20.28	0.94
Union Flexi Cap (I)	20.28	0.94
Union Flexi Cap (IDCWR)	20.28	0.94
Union Flexi Cap DP (G)	20.28	0.94
Union Flexi Cap DP (I)	20.28	0.94
Union Flexi Cap DP (IDCWR)	20.28	0.94
UTI Mid Cap (G)	99.78	0.94
UTI Mid Cap (I)	99.78	0.94
UTI Mid Cap (I-Rein)	99.78	0.94
UTI Mid Cap DP (G)	99.78	0.94
UTI Mid Cap DP (I)	99.78	0.94
DSP EqOpport (G)	127.91	0.93
DSP EqOpport (I)	127.91	0.93
DSP EqOpport (IDCWR)	127.91	0.93
DSP EqOpport DP (G)	127.91	0.93
DSP EqOpport DP (I)	127.91	0.93
DSP EqOpport DP (IDCWR)	127.91	0.93
Edelweiss ElssTaxSav (G)	3.56	0.93
Edelweiss ElssTaxSav (I)	3.56	0.93
Edelweiss ElssTaxSav (I-Rein)	3.56	0.93
Edelweiss ElssTaxSDP (G)	3.56	0.93
Edelweiss ElssTaxSDP (I)	3.56	0.93
HDFC Manufacturing (G)	105.13	0.91
HDFC Manufacturing (I)	105.13	0.91
HDFC ManufacturingDP (G)	105.13	0.91
HDFC ManufacturingDP (I)	105.13	0.91
HSBC Multi Cap (G)	38.88	0.91
HSBC Multi Cap (I)	38.88	0.91
HSBC Multi Cap DP (G)	38.88	0.91
HSBC Multi Cap DP (I)	38.88	0.91
Union MulAssetAllo (G)	7.18	0.90
Union MulAssetAllo (I)	7.18	0.90
Union MulAssetAlloDP (G)	7.18	0.90
Union MulAssetAlloDP (I)	7.18	0.90
HDFC BusinessCycle (G)	24.60	0.89
HDFC BusinessCycle (I)	24.60	0.89
HDFC BusinessCycleDP (G)	24.60	0.89
HDFC BusinessCycleDP (I)	24.60	0.89
Bandhan AggrHybrid (G)	7.24	0.88
Bandhan AggrHybrid (I)	7.24	0.88
Bandhan AggrHybrid (IDCWR)	7.24	0.88
Bandhan AggrHybridDP (G)	7.24	0.88
Bandhan AggrHybridDP (I)	7.24	0.88
Bandhan AggrHybridDP (IDCWR)	7.24	0.88
Edelweiss AggHy (G)	21.47	0.86
Edelweiss AggHy (I)	21.47	0.86
Edelweiss AggHy DP (G)	21.47	0.86
Edelweiss AggHy DP (I)	21.47	0.86
Edelweiss AggHyPlanB (G)	21.47	0.86
Edelweiss AggHyPlanB (I)	21.47	0.86
Union Balanced Advan (G)	11.72	0.86
Union Balanced Advan (I)	11.72	0.86
Union Balanced AdvDP (G)	11.72	0.86
Union Balanced AdvDP (I)	11.72	0.86
HSBC Aggre Hybrid (AIDCWR)	41.83	0.83
HSBC Aggre Hybrid (G)	41.83	0.83
HSBC Aggre Hybrid (I)	41.83	0.83
HSBC Aggre Hybrid (I-Annu)	41.83	0.83
HSBC Aggre Hybrid (IDCWR)	41.83	0.83
HSBC Aggre Hybrid DP (AIDCWR)	41.83	0.83
HSBC Aggre Hybrid DP (G)	41.83	0.83
HSBC Aggre Hybrid DP (I)	41.83	0.83
HSBC Aggre Hybrid DP (I-Annu)	41.83	0.83
ICICI PruMultAsset (G)	446.87	0.81
ICICI PruMultAsset (I)	446.87	0.81
ICICI PruMultAsset (IDCWR)	446.87	0.81
ICICI PruMultAssetDP (G)	446.87	0.81
ICICI PruMultAssetDP (I)	446.87	0.81
ICICI PruMultAssetDP (IDCWR)	446.87	0.81
UTI MultiAssetAllo (G)	42.48	0.80
UTI MultiAssetAllo (I)	42.48	0.80
UTI MultiAssetAllo (I-Rein)	42.48	0.80
UTI MultiAssetAlloDP (G)	42.48	0.80
UTI MultiAssetAlloDP (I)	42.48	0.80
Bandhan NifAlpha50 (G)	2.87	0.79
Bandhan NifAlpha50 (I)	2.87	0.79
Bandhan NifAlpha50DP (G)	2.87	0.79
Bandhan NifAlpha50DP (I)	2.87	0.79
Kotak NiftAlpha50ETF (G)	4.38	0.79
MahiManu MidCap (G)	26.74	0.79
MahiManu MidCap (I)	26.74	0.79
MahiManu MidCap DP (G)	26.74	0.79
MahiManu MidCap DP (I)	26.74	0.79
EdelNifLar&Midcap (G)	1.88	0.78
EdelNifLar&Midcap (I)	1.88	0.78
EdelNifLar&MidcapDP (G)	1.88	0.78
EdelNifLar&MidcapDP (I)	1.88	0.78
HDFC NifLarMC250 (G)	3.46	0.78
HDFC NifLarMC250DP (G)	3.46	0.78
Mirae NifLarMid250 (G)	0.12	0.78
Mirae NifLarMid250 (I)	0.12	0.78
Mirae NifLarMid250DP (G)	0.12	0.78
Mirae NifLarMid250DP (I)	0.12	0.78
ICICI NifLarMid250 (G)	1.47	0.78
ICICI NifLarMid250 (I)	1.47	0.78
ICICI NifLarMid250DP (G)	1.47	0.78
ICICI NifLarMid250DP (I)	1.47	0.78
Zerodha ELSSTaxSavDP (G)	1.37	0.78
Zerodha NifLarMid DP (G)	6.41	0.78
Edelweiss BalAdv (G)	94.01	0.77
Edelweiss BalAdv (I)	94.01	0.77
Edelweiss BalAdv (I-Mont)	94.01	0.77
Edelweiss BalAdv (I-Rein)	94.01	0.77
Edelweiss BalAdv DP (G)	94.01	0.77
Edelweiss BalAdv DP (I)	94.01	0.77
Edelweiss BalAdv DP (I-Mont)	94.01	0.77
WhiteOak MultiCap (G)	12.11	0.77
WhiteOak MultiCap DP (G)	12.11	0.77
Union AggreHybrid (G)	4.66	0.75
Union AggreHybrid (I)	4.66	0.75
Union AggreHybrid DP (G)	4.66	0.75
Union AggreHybrid DP (I)	4.66	0.75
WhiteOak EquitySav (G)	0.26	0.75
WhiteOak EquitySavDP (G)	0.26	0.75
Bandhan Retirement (G)	1.27	0.74
Bandhan Retirement (I)	1.27	0.74
Bandhan RetirementDP (G)	1.27	0.74
Bandhan RetirementDP (I)	1.27	0.74
Sundaram Agg Hyb (I-Mont)	39.55	0.70
Sundaram Agg Hyb (MIDCWR)	39.55	0.70
Sundaram Agg HybDP (G)	39.55	0.70
Sundaram Agg HybDP (I-Mont)	39.55	0.70
Sundaram Agg HybDP (MIDCWR)	39.55	0.70
Sundaram Agg HyEq (G)	39.55	0.70
UTI Quant (G)	10.30	0.70
UTI Quant DP (G)	10.30	0.70
Nippon MulAssetAll (G)	35.49	0.67
Nippon MulAssetAll (I)	35.49	0.67
Nippon MulAssetAllDP (G)	35.49	0.67
Nippon MulAssetAllDP (I)	35.49	0.67
HDFC ELSS TaxSaver (G)	101.40	0.65
HDFC ELSS TaxSaver (I)	101.40	0.65
HDFC ELSS TaxSaver (IDCWR)	101.40	0.65
HDFC ELSS TaxSaverDP (G)	101.40	0.65
HDFC ELSS TaxSaverDP (I)	101.40	0.65
HDFC ELSS TaxSaverDP (IDCWR)	101.40	0.65
HDFC DividendYield (G)	37.54	0.63
HDFC DividendYield (I)	37.54	0.63
HDFC DividendYieldDP (G)	37.54	0.63
HDFC DividendYieldDP (I)	37.54	0.63
Union EquSavings (G)	0.81	0.60
Union EquSavings (I)	0.81	0.60
Union EquSavings DP (G)	0.81	0.60
Union EquSavings DP (I)	0.81	0.60
HDFC Eq Savings DP (G)	30.42	0.56
HDFC Eq Savings DP (I)	30.42	0.56
HDFC Eq Savings DP (IDCWR)	30.42	0.56
HDFC EquitySavingsRP (G)	30.42	0.56
HDFC EquitySavingsRP (I)	30.42	0.56
HDFC EquitySavingsRP (IDCWR)	30.42	0.56
Sundaram MulAstAll (G)	13.83	0.56
Sundaram MulAstAll (I)	13.83	0.56
Sundaram MulAstAll (I-Rein)	13.83	0.56
Sundaram MulAstAllDP (G)	13.83	0.56
Sundaram MulAstAllDP (I)	13.83	0.56
Sundaram MulAstAllDP (I-Rein)	13.83	0.56
Axis Multicap (G)	37.45	0.55
Axis Multicap (I)	37.45	0.55
Axis Multicap DP (G)	37.45	0.55
Axis Multicap DP (I)	37.45	0.55
Sundaram Bal Adv DP (G)	8.11	0.54
Sundaram Bal Adv DP (I-Mont)	8.11	0.54
Sundaram Bal Adv DP (I-Mont)	8.11	0.54
Sundaram Bal Adv DP (MIDCWR)	8.11	0.54
Sundaram Balanced Ad (G)	8.11	0.54
Sundaram Balanced Ad (I-Mont)	8.11	0.54
Sundaram Balanced Ad (I-Mont)	8.11	0.54
Sundaram Balanced Ad (MIDCWR)	8.11	0.54
Mirae Aggr Hybrid (G)	46.48	0.54
Mirae Aggr Hybrid (I)	46.48	0.54
Mirae Aggr Hybrid (I-Rein)	46.48	0.54
Mirae Aggr Hybrid DP (G)	46.48	0.54
Mirae Aggr Hybrid DP (I)	46.48	0.54
Franklin Prima (G)	60.84	0.53
Franklin Prima (I)	60.84	0.53
Franklin Prima (IDCWR)	60.84	0.53
Franklin Prima DP (G)	60.84	0.53
Franklin Prima DP (I)	60.84	0.53
Axis Consumption (G)	20.81	0.53
Axis Consumption (I)	20.81	0.53
Axis Consumption DP (G)	20.81	0.53
Axis Consumption DP (I)	20.81	0.53
MiraeAsset ArbitraDP (G)	16.12	0.52
MiraeAsset ArbitraDP (I)	16.12	0.52
MiraeAsset Arbitrage (G)	16.12	0.52
MiraeAsset Arbitrage (I)	16.12	0.52
HDFC Multi Asset DP (G)	20.28	0.50
HDFC Multi Asset DP (I)	20.28	0.50
HDFC Multi Asset DP (IDCWR)	20.28	0.50
HDFC Multi Asset RP (G)	20.28	0.50
HDFC Multi Asset RP (I)	20.28	0.50
HDFC Multi Asset RP (IDCWR)	20.28	0.50
SBI Contra (G)	207.00	0.50
SBI Contra (I)	207.00	0.50
SBI Contra (IDCWR)	207.00	0.50
SBI Contra DP (G)	207.00	0.50
SBI Contra DP (I)	207.00	0.50
SBI Contra DP (IDCWR)	207.00	0.50
HDFC Hybrid Debt DP (G)	16.22	0.49
HDFC Hybrid Debt DP (I-Mont)	16.22	0.49
HDFC Hybrid Debt DP (I-Quar)	16.22	0.49
HDFC Hybrid Debt DP (MIDCWR)	16.22	0.49
HDFC Hybrid Debt DP (QIDCWR)	16.22	0.49
HDFC Hybrid Debt RP (G)	16.22	0.49
HDFC Hybrid Debt RP (I-Mont)	16.22	0.49
HDFC Hybrid Debt RP (I-Quar)	16.22	0.49
HDFC Hybrid Debt RP (MIDCWR)	16.22	0.49
HDFC Hybrid Debt RP (QIDCWR)	16.22	0.49
Mirae BSE200EqlETF (G)	0.07	0.49
MiraeAsset BalAdv (G)	8.56	0.48
MiraeAsset BalAdv (I)	8.56	0.48
MiraeAsset BalAdvDP (G)	8.56	0.48
MiraeAsset BalAdvDP (I)	8.56	0.48
Bandhan CoreEquity (G)	37.43	0.47
Bandhan CoreEquity (I)	37.43	0.47
Bandhan CoreEquity (IDCWR)	37.43	0.47
Bandhan CoreEquityDP (G)	37.43	0.47
Bandhan CoreEquityDP (I)	37.43	0.47
Nippon Bal Adv (B)	41.76	0.47
Nippon Bal Adv (G)	41.76	0.47
Nippon Bal Adv (I)	41.76	0.47
Nippon Bal Adv DP (G)	41.76	0.47
Nippon Bal Adv DP (I)	41.76	0.47
Nippon Multi Cap (B)	182.52	0.47
Nippon Multi Cap (G)	182.52	0.47
Nippon Multi Cap (I)	182.52	0.47
Nippon Multi CapDP (B)	182.52	0.47
Nippon Multi CapDP (G)	182.52	0.47
Nippon Multi CapDP (I)	182.52	0.47
HDFC Flexi Cap DP (G)	304.19	0.44
HDFC Flexi Cap DP (I)	304.19	0.44
HDFC Flexi Cap DP (IDCWR)	304.19	0.44
HDFC Flexi Cap RP (G)	304.19	0.44
HDFC Flexi Cap RP (I)	304.19	0.44
HDFC Flexi Cap RP (IDCWR)	304.19	0.44
Axis Arbitrage (G)	25.11	0.43
Axis Arbitrage (I-Mont)	25.11	0.43
Axis Arbitrage DP (G)	25.11	0.43
Axis Arbitrage DP (I-Mont)	25.11	0.43
ICICI Pru Bluechip (G)	274.71	0.42
ICICI Pru Bluechip (I)	274.71	0.42
ICICI Pru Bluechip (IDCWR)	274.71	0.42
ICICI Pru BluechipDP (G)	274.71	0.42
ICICI Pru BluechipDP (I)	274.71	0.42
ICICI Pru BluechipDP (IDCWR)	274.71	0.42
Bandhan MulAssAllo (G)	7.50	0.41
Bandhan MulAssAllo (I)	7.50	0.41
Bandhan MulAssAlloDP (G)	7.50	0.41
Bandhan MulAssAlloDP (I)	7.50	0.41
Nippon Vision (B)	22.31	0.41
Nippon Vision (G)	22.31	0.41
Nippon Vision (I)	22.31	0.41
Nippon Vision (I-Rein)	22.31	0.41
Nippon Vision DP (B)	22.31	0.41
Nippon Vision DP (G)	22.31	0.41
Nippon Vision DP (I)	22.31	0.41
Union ELSSTaxSaver (G)	3.55	0.41
Union ELSSTaxSaver (I)	3.55	0.41
Union ELSSTaxSaver (IDCWR)	3.55	0.41
Union ELSSTaxSaverDP (G)	3.55	0.41
Union ELSSTaxSaverDP (I)	3.55	0.41
Union ELSSTaxSaverDP (IDCWR)	3.55	0.41
Groww Multicap (G)	0.33	0.40
Groww Multicap (I)	0.33	0.40
Groww Multicap DP (G)	0.33	0.40
Groww Multicap DP (I)	0.33	0.40
HDFC Nif500MulticaDP (G)	1.61	0.39
HDFC Nif500Multicap (G)	1.61	0.39
Navi Nif500MulticaDP (G)	0.09	0.39
Navi Nif500Multicap (G)	0.09	0.39
SBI Balanced Adv (G)	131.48	0.39
SBI Balanced Adv (I)	131.48	0.39
SBI Balanced Adv DP (G)	131.48	0.39
SBI Balanced Adv DP (I)	131.48	0.39
Mirae Nif500MultiCap (G)	0.17	0.39
Axis Bluechip (G)	123.56	0.38
Axis Bluechip (I)	123.56	0.38
Axis Bluechip (I-Rein)	123.56	0.38
Axis Bluechip DP (G)	123.56	0.38
Axis Bluechip DP (I)	123.56	0.38
SBI BSE100 ETF (G)	0.03	0.38
WhiteoakLar&MidCap (G)	5.82	0.38
WhiteoakLar&MidCapDP (G)	5.82	0.38
Kotak MSCIIndiaETF (G)	3.79	0.37
Union Arbitrage (G)	1.03	0.34
Union Arbitrage (I)	1.03	0.34
Union Arbitrage DP (G)	1.03	0.34
Union Arbitrage DP (I)	1.03	0.34
Groww Nifty200ETF (G)	0.04	0.32
DSP Arbitrage (G)	18.27	0.31
DSP Arbitrage (I)	18.27	0.31
DSP Arbitrage (I-Mont)	18.27	0.31
DSP Arbitrage - DP (G)	18.27	0.31
DSP Arbitrage - DP (I)	18.27	0.31
DSP Arbitrage - DP (I-Mont)	18.27	0.31
WhiteOak Arbitrage (G)	1.12	0.30
WhiteOak ArbitrageDP (G)	1.12	0.30
ICICI Pru ElssTaxS (G)	40.56	0.30
ICICI Pru ElssTaxS (I)	40.56	0.30
ICICI Pru ElssTaxS (IDCWR)	40.56	0.30
ICICI Pru ElssTaxSDP (G)	40.56	0.30
ICICI Pru ElssTaxSDP (I)	40.56	0.30
ICICI Pru ElssTaxSDP (IDCWR)	40.56	0.30
Mirae MulAsseAllco (G)	5.39	0.29
Mirae MulAsseAllco (I)	5.39	0.29
Mirae MulAsseAllcoDP (G)	5.39	0.29
Mirae MulAsseAllcoDP (I)	5.39	0.29
UTI Arbitrage (G)	18.96	0.29
UTI Arbitrage (I)	18.96	0.29
UTI Arbitrage (I-Rein)	18.96	0.29
UTI Arbitrage DP (G)	18.96	0.29
UTI Arbitrage DP (I)	18.96	0.29
ICICIPru BSE500ETF (G)	0.96	0.28
Axis Nifty500Index (G)	0.61	0.28
Axis Nifty500IndexDP (G)	0.61	0.28
HDFC BSE500 ETF (G)	0.04	0.28
HDFC BSE500 Index (G)	0.59	0.28
HDFC BSE500 IndexDP (G)	0.59	0.28
SBI Nif500 Index (G)	2.29	0.28
SBI Nif500 Index (I)	2.29	0.28
SBI Nif500 IndexDP (G)	2.29	0.28
SBI Nif500 IndexDP (I)	2.29	0.28
Motilal Nifty500ETF (G)	0.32	0.28
Motilal Os Nif500 (G)	5.81	0.28
Motilal Os Nif500DP (G)	5.81	0.28
ICICI Pru Nifty500 (G)	0.06	0.27
ICICI Pru Nifty500 (I)	0.06	0.27
ICICI Pru Nifty500DP (G)	0.06	0.27
ICICI Pru Nifty500DP (I)	0.06	0.27
ICICI Pru EqArbit (G)	69.98	0.27
ICICI Pru EqArbit (I)	69.98	0.27
ICICI Pru EqArbit (IDCWR)	69.98	0.27
ICICI Pru EqArbit DP (G)	69.98	0.27
ICICI Pru EqArbit DP (I)	69.98	0.27
ICICI Pru EqArbit DP (IDCWR)	69.98	0.27
BandhanNifTotalMar (G)	0.10	0.27
BandhanNifTotalMarDP (G)	0.10	0.27
Groww NifTotalMar (G)	0.73	0.27
Groww NifTotalMar (I)	0.73	0.27
Groww NifTotalMarDP (G)	0.73	0.27
Groww NifTotalMarDP (I)	0.73	0.27
Mirae NifTotMarket (G)	0.10	0.27
Mirae NifTotMarket (I)	0.10	0.27
Mirae NifTotMarketDP (G)	0.10	0.27
Mirae NifTotMarketDP (I)	0.10	0.27
MiraeAssetEqSaving (G)	3.42	0.25
MiraeAssetEqSaving (I)	3.42	0.25
MiraeAssetEqSavingDP (G)	3.42	0.25
MiraeAssetEqSavingDP (I)	3.42	0.25
ICICI Pru EqSaving (G)	30.17	0.23
ICICI Pru EqSaving (I-Quar)	30.17	0.23
ICICI Pru EqSaving (QIDCWR)	30.17	0.23
ICICI Pru EqSavingDP (G)	30.17	0.23
ICICI Pru EqSavingDP (I-Quar)	30.17	0.23
ICICI Pru EqSavingDP (QIDCWR)	30.17	0.23
Edelw MultiAssetAl (G)	3.53	0.22
Edelw MultiAssetAl (I)	3.53	0.22
Edelw MultiAssetAlDP (G)	3.53	0.22
Edelw MultiAssetAlDP (I)	3.53	0.22
SBI Arbitrage Oppr (G)	66.76	0.21
SBI Arbitrage Oppr (I)	66.76	0.21
SBI Arbitrage Oppr (IDCWR)	66.76	0.21
SBI Arbitrage OpprDP (G)	66.76	0.21
SBI Arbitrage OpprDP (I)	66.76	0.21
SBI Arbitrage OpprDP (IDCWR)	66.76	0.21
Axis Balanced Adv (G)	5.31	0.20
Axis Balanced Adv (I)	5.31	0.20
Axis Balanced Adv DP (G)	5.31	0.20
Axis Balanced Adv DP (I)	5.31	0.20
Edelweiss EqSav (B)	1.14	0.20
Edelweiss EqSav (G)	1.14	0.20
Edelweiss EqSav (I)	1.14	0.20
Edelweiss EqSav (I-Mont)	1.14	0.20
Edelweiss EqSav DP (B)	1.14	0.20
Edelweiss EqSav DP (G)	1.14	0.20
Edelweiss EqSav DP (I)	1.14	0.20
Edelweiss EqSav DP (I-Mont)	1.14	0.20
Kotak Eq Arbitrage (G)	119.11	0.20
Kotak Eq Arbitrage (I)	119.11	0.20
Kotak Eq Arbitrage (IDCWR)	119.11	0.20
Kotak EquityArbit DP (G)	119.11	0.20
Kotak EquityArbit DP (I)	119.11	0.20
Nippon Nif500EqlWeDP (G)	0.74	0.20
Nippon Nif500EqlWeDP (I)	0.74	0.20
Nippon Nif500EqlWeig (G)	0.74	0.20
Nippon Nif500EqlWeig (I)	0.74	0.20
Sundaram EqSav DP (G)	1.55	0.16
Sundaram EqSav DP (HIDCWR)	1.55	0.16
Sundaram EqSav DP (I-Half)	1.55	0.16
Sundaram EqSav DP (I-Half)	1.55	0.16
Sundaram EqSav DP (I-Quar)	1.55	0.16
Sundaram EqSav DP (IDCWQS)	1.55	0.16
Sundaram EqSav DP (QIDCWR)	1.55	0.16
Sundaram EqSav QD (I)	1.55	0.16
Sundaram EqSav QD (IDCWQS)	1.55	0.16
Sundaram EqSav QD (IDCWR)	1.55	0.16
Sundaram EqSavDiv (HIDCWR)	1.55	0.16
Sundaram EqSavDiv (I-Half)	1.55	0.16
Sundaram EqSavGr (G)	1.55	0.16
ICICI Pru BalanceAdv (G)	92.58	0.15
ICICI Pru BalanceAdv (I)	92.58	0.15
ICICI Pru BalanceAdv (I-Mont)	92.58	0.15
ICICI Pru BalanceAdv (IDCWR)	92.58	0.15
ICICI Pru BalanceAdv (MIDCWR)	92.58	0.15
ICICI Pru BalnAdv DP (G)	92.58	0.15
ICICI Pru BalnAdv DP (I)	92.58	0.15
ICICI Pru BalnAdv DP (I-Mont)	92.58	0.15
ICICI Pru BalnAdv DP (IDCWR)	92.58	0.15
ICICI Pru BalnAdv DP (MIDCWR)	92.58	0.15
Kotak BalanceAdvan (G)	24.53	0.15
Kotak BalanceAdvan (I)	24.53	0.15
Kotak BalanceAdvanDP (G)	24.53	0.15
Kotak BalanceAdvanDP (I)	24.53	0.15
Bandhan Arbitrage (AIDCWR)	10.26	0.13
Bandhan Arbitrage (G)	10.26	0.13
Bandhan Arbitrage (I-Annu)	10.26	0.13
Bandhan Arbitrage (I-Mont)	10.26	0.13
Bandhan Arbitrage (MIDCWR)	10.26	0.13
Bandhan Arbitrage DP (AIDCWR)	10.26	0.13
Bandhan Arbitrage DP (G)	10.26	0.13
Bandhan Arbitrage DP (I-Annu)	10.26	0.13
Bandhan Arbitrage DP (I-Mont)	10.26	0.13
Tata Arbitrage (G)	14.15	0.11
Tata Arbitrage (I-Mont)	14.15	0.11
Tata Arbitrage (M)	14.15	0.11
Tata Arbitrage DP (G)	14.15	0.11
Tata Arbitrage DP (I-Mont)	14.15	0.11
Tata Arbitrage DP (M)	14.15	0.11
Edelweiss ArbitragDP (G)	13.96	0.10
Edelweiss ArbitragDP (I)	13.96	0.10
Edelweiss ArbitragDP (I-Mont)	13.96	0.10
Edelweiss Arbitrage (B)	13.96	0.10
Edelweiss Arbitrage (G)	13.96	0.10
Edelweiss Arbitrage (I)	13.96	0.10
Edelweiss Arbitrage (I-Mont)	13.96	0.10
Edelweiss Arbitrage (I-Rein)	13.96	0.10
Kotak Equity Savings (G)	7.41	0.09
Kotak Equity Savings (I-Mont)	7.41	0.09
Kotak Equity Savings (MIDCWR)	7.41	0.09
Kotak EquitySavingDP (G)	7.41	0.09
Kotak EquitySavingDP (I-Mont)	7.41	0.09
LIC MF Arbitrage (G)	0.26	0.08
LIC MF Arbitrage (I-Mont)	0.26	0.08
LIC MF Arbitrage (I-Week)	0.26	0.08
LIC MF Arbitrage DP (G)	0.26	0.08
LIC MF Arbitrage DP (I-Mont)	0.26	0.08
LIC MF Arbitrage DP (W)	0.26	0.08
ParagPar Arbitrage (G)	0.86	0.07
ParagPar ArbitrageDP (G)	0.86	0.07
InvescoInd ArbitraDP (B-Annu)	12.76	0.06
InvescoInd ArbitraDP (G)	12.76	0.06
InvescoInd ArbitraDP (I)	12.76	0.06
InvescoInd Arbitrage (G)	12.76	0.06
InvescoInd Arbitrage (I)	12.76	0.06
InvescoInd Arbitrage (I-Rein)	12.76	0.06
HDFC Arbitr WP DP (G)	5.00	0.03
HDFC Arbitr WP DP (I)	5.00	0.03
HDFC Arbitr WP DP (I-Mont)	5.00	0.03
HDFC Arbitrage - WP (G)	5.00	0.03
HDFC Arbitrage - WP (I)	5.00	0.03
HDFC Arbitrage - WP (I-Mont)	5.00	0.03
HDFC Arbitrage - WP (MIDCWR)	5.00	0.03
HDFC Arbitrage DP (G)	5.00	0.03
HDFC Arbitrage DP (I-Quar)	5.00	0.03
HDFC Arbitrage DP (QIDCWR)	5.00	0.03
HDFC Arbitrage RP (G)	5.00	0.03
HDFC Arbitrage RP (I-Mont)	5.00	0.03
HDFC Arbitrage RP (I-Quar)	5.00	0.03
InvescIndEqSavings (G)	0.09	0.02
InvescIndEqSavings (I)	0.09	0.02
InvescoIndEqSavingDP (G)	0.09	0.02
InvescoIndEqSavingDP (I)	0.09	0.02
AdityaBSL Arbit (G)	2.24	0.02
AdityaBSL Arbit (I)	2.24	0.02
AdityaBSL Arbit (IDCWR)	2.24	0.02
AdityaBSL Arbit DP (G)	2.24	0.02
AdityaBSL Arbit DP (I)	2.24	0.02
AdityaBSL Arbit DP (IDCWR)	2.24	0.02
Axis MulAsset All (G)	0.18	0.01
Axis MulAsset All (I-Mont)	0.18	0.01
Axis MulAsset All DP (G)	0.18	0.01
Axis MulAsset All DP (I-Mont)	0.18	0.01
Nippon Arbitrage (G)	1.21	0.01
Nippon Arbitrage (I)	1.21	0.01
Nippon Arbitrage (I-Mont)	1.21	0.01
Nippon Arbitrage (I-Rein)	1.21	0.01
Nippon Arbitrage (M)	1.21	0.01
Nippon ArbitrageDP (G)	1.21	0.01
Nippon ArbitrageDP (I)	1.21	0.01
Nippon ArbitrageDP (I-Mont)	1.21	0.01
ParagPar FlexiCap (G)	1.12	0.00
ParagPar FlexiCap DP (G)	1.12	0.00
SBI Eq SavingsFund (G)	0.27	0.00
SBI Eq SavingsFund (I-Mont)	0.27	0.00
SBI Eq SavingsFund (I-Quar)	0.27	0.00
SBI Eq SavingsFund (MIDCWR)	0.27	0.00
SBI Eq SavingsFund (QIDCWR)	0.27	0.00
SBI Eq SavingsFundDP (G)	0.27	0.00
SBI Eq SavingsFundDP (I-Mont)	0.27	0.00
SBI Eq SavingsFundDP (I-Quar)	0.27	0.00
SBI Eq SavingsFundDP (MIDCWR)	0.27	0.00
SBI Eq SavingsFundDP (QIDCWR)	0.27	0.00

Peers

Other companies within the same industry or sector that are comparable to Lupin Ltd

Company	Price	Price (% change)	pe(x)	EV/EBITDA(x)	ROE(%)	ROCE(%)
Albert David Ltd	840.85	0.23	11.87	1202.91	1321.50	1.37
Lotus Eye Hospital and Institute Ltd	81.36	2.94	339.00	4383.24	14.01	0.61
Vaishali Pharma Ltd	13.72	-0.15	457.33	2259.29	2.76	0.00
Astec Lifesciences Ltd	693.05	-1.61	0.00	4133.01	-687.11	0.00

Company Info

Lupin Chemicals Ltd (LCL) was promoted by Lupin Laboratories Ltd. The company was incorporated on 31.03.83 as a Private Ltd company and subsequently converted into a Public Ltd company with effect from 23.12.91. The company does not have any subsidary. The company is setting up a project for the manufacture of 93 tpa of Rifampicin, an essential anti-tuberculosis, anti-leprotic, life saving drug from a very basic stage of fermentation. It is an import substitute product. To finance the project the company is coming out with a PCD issue aggregating to Rs.45.6 crores. 2002 -Lupin Ltd has successfully introduced AkuriT, a revolutionary simplified therapy as per WHO's guidelines for treatment of tuberculosis -Crisil has upgraded the rating assigned to Lupin's non-convertible debentures from D to BB . -Lupin Ltd has enhanced its capacity of manufacturing various products at its formulations plants at Aurangabad and Manideep in Madhya Pradesh. 2007 - Lupin receives Final FDA Approval for Trandolapril. -Lupin Ltd inducted PricewaterHouseCoopers to implement SAP to faultlessly connect its 28 sales depot. -Lupin Ltd has cut down its debt by Rs.20cr . 2003 -Lupin Ltd has commissioned its facility at Mandideep near Bhopal, Madhya Pradesh for the manufacture of Lisinopril. -Lupin Ltd announces VRS for its employees in a bid to trim its wage bill. -Pharmaceutical major Lupin Ltd has divested about 12.55% of its equity holding in the company to CVC International, a private investment arm of the US based financial conglomerate Citigroup. -Lupin is closing down its South African Operations and is setting up two subsidiaries in Hongkong and the US. -Lupin Ltd has received the appproval of US Food and Drug Administration for cefuroxime axetil 250 mg and 500 mg tablets. Dr.Kamal K Sharma has been appointed as the Additional Director of the company. -The company has received USFDA's approval for cefotaxime sterile vials for injection. -Secured US FDA nod for generic Claforan marketing -Lupin receives USFDA approval for Caftriaxone Sterile Vials for injections -Lupin plans to list shares on NYSE -Lupin set up new herbal product division -Lupin submits INDA for psoriasis 2004 -Launches Ezedoc, a specialty drug for the cholesterol management segment -Lupin has appointed Vinod Dhawan as President - Business Development (Latin America, Japan, Australia, and New Zealand). Mr.Dhawan will be responsible for the development of Lupin's business strategy for these markets, with focus on, among others, product selection, entry strategy, marketing and sales, and regulatory compliance. -Lupin Limited has informed that at the EGM of the Company held on December 05, 2003, the members of the Company have by means of a special resolution determined to delist shares of the Company, from the following exchanges : 1) The Calcutta Stock Exchange Association Ltd. 2) The Stock Exchange, Ahmedabad, 3) Jaipur Stock Exchange Ltd., 4) The Delhi Stock Exchange Association Ltd. The Company has initiated action to secure de-listing of the equity shares of the Company, from the aforesaid exchanges. The Equity shares of the Company are listed on the NSE and BSE and will continue to be listed and traded on NSE and BSE. -Enters into an agreement with Baxter Healthcare Corporation, a global medical products company headquartered in the United States, whereby Baxter will exclusively distribute the Company's generic version of ceftriaxone sterile vials for injection in the USA - Floats new division - Lupin Herbal, dedicated to research-based phytomedicines. Unveiled nine herbal products in therapeutic areas, including diabetes, pediatrics, gastro intestinal, pain management and gynaecology 2004 -Delists Shares from Ahmedabad Stock Exchange. - Lupin Pharmaceuticals, Inc., wholly owned subsidiary of the Company has entered into an agreement with Allergan, Inc. in the United States to promote Zymar (gatifloxacin opthalmic solution) 0.3% in the pediatric specialty area. -Lupin Ltd has launched its anti-infective product Suprax (cefixime Oral Suspension) in the US market. -Shares of Lupin Ltd delisted from the Delhi Stock Exchange - Shares of Lupin Ltd delisted from Jaipur Stock Exchange - Ind Swift Ltd ties up with Lupin Ltd for a Co-marketing pact to launch Nitazoxanide, an anti-diarrhoeal / anti-helmintic drug for the first time in India under the brand name Netazox and Nizonide respectively. 2005 -Lupin launches Ceftriaxone vials in the US market -Lupin enters into co-operation agreement with Kyowa for Japanese market. -Lupin receives USFDA approvals for Cephalexin Oral Suspension -Lupin has entered into an agreement with GSK Philippines to manufacture and supply the 4 & 2 Drug FDCs for marketing in Philippines. -Lupin receives approval for conducting phase II clinical trials of Investigation New Drug candidate LLL-3348 (Desoris) from the Drug Controller General of India. 2006 -Lupin joins hands with ItalFarmaco to launch Lupenox in India -Lupin receives DCGI approval to conduct Phase II clinical Trials for Psoriasis NCE -Lupin & Aspen Pharmacare enters into MoU for establishment of JV -Lupin joins hands with ItalFarmaco to launch Lupenox in India -Lupin Ltd has announced that the Company has signed a MoU to acquire a 51% equity in Artifex Finance CVA, Belgium, along with its subsidiaries including Dafra Pharma Ltd (Dafra), a Belgian pharmaceutical Company focussed on anti-malaria -Lupin ties up with Italian co -Lupin has given the Bonus in the Ratio of 1:1 2007 - Lupin Receives US FDA Approval for Simvastatin Tablets - Lupin gets MHRA Approval for Lisinopril in UK - Lupin Ltd has announced that it has received Euro 20 million from Laboratoires Servier of France for the sale of additional patent rights for Perindopril. -Lupin receives DCGI Approval to conduct Combined Phase IIb/III Clinical Trials for it's herbal Psoriasis NCE -Lupin Ltd on April 27, 2007, has announced that theDepartment of Science and Technology (DST), Government of India and the Company have joined hands for the clinical development of the Company's Migraine and Psoriasis projects. -Lupin receives "Best New Manufacturer of the Year" Award from AmerisourceBergen 2008 -Lupin Limited has appointed Mr. R.V. Satam as Secretary & Compliance Officer of the Company w.e.f. May 01, 2008. -Lupin enters into agreement for Suprax 400 mg tablets -Lupin Launches SUPRAX r400 mg Tablets in the US -Lupin expands its product basket in JapanKyowa receives Ten product approvals 2009 -Lupin receives USFDA approval for Levetiracetam Tablets -Lupin ties up with leading Institutes for PhD Program -Lupin in Equity Partnership with Multicare Pharmaceuticals Philippines, Inc. -Lupin Expands Branded Play; Announces Acquisition of Worldwide Rights for its first NDA - AllerNaze 2010 - Lupin Limited has launched Ilyalganr (sodium hyaluronate), an osteoarthritis drug, available in the form of an injectable through leading orthopaedics and physiotherapists across the country. Hyalgan40 is the original research molecule of the Italian pharma giant I-'IDIA and is the world leader in HA therapy, marketed in over 60 countries globally. - Lupin Limited's U.S subsidiary, Lupin Pharmaceuticalss Inc. (LPT) has received the final approval for the company's Abbreviated New Drug Application (ANDA) for its Imipramine Pamoate capsules, 75 mg, 100 mg, 125 mg and 150 mg from the U.S. Food and Drug Administration (FDA). Commercial shipments of the product have already commenced. -Company has splits its Face value of Shares from Rs 10 to Rs 2 2011 - Lupin acquires Worldwide Rights for the Goannar Brand. -Lupin and Medicis Enter into Joint Development Agreement. -Lupin Acquires I'rom Pharmaceuticals through its Japanese Subsidiary. 2012 - "Lupin receives Tentative Approval for Generic Glumetza Extended-Release Tablets" -"LUPIN announces settlement with SANTARUS and DEPOMED for GLUMETZA Patent Litigation" -"Lupin launches Generic Geodon Capsules". -"Lupin launches Generic SEROQUEL Tablets". 2013 -Inauguration of new Plant at Nagpur. -Mahindra Samridhhi India Agri National Award for Bee keeping and Honey Production -NABARD's BEST NGO Award to MSGD, Alwar for promotion and linkages of Self Help Groups in the state 2014 -Lupin Acquires Laboratorios Grin S.A. De C.V., Mexico; Specialty Ophthalmic Company; Enters the Latin American Market. Lupin Acquires Nanomi B.V. - Enters Complex Injectables Space. -The Economic Times 500 rankings - India's 10 most resilient companies -Dun & Bradstreet Corporate Awards 2014 - Top Indian company in pharma sector -Great Place to Wok - Best companies to work for 2014 -American Society for Training & Development (ASTD)Best award - Winner for Employee Learning & Development -Lupin Receives FDA Approval for Generic Actosr Tablets. -Lupin Receives FDA Approval for Generic Celebrexr Capsules 2015 -Lupin Ltd launches Generic DIOVANr Tablets -Lupin Receives FDA Approval for Generic Vancocinr Capsules -Lupin and Celon Announce Strategic Development and Licensing Agreement for Generic Advair Diskusr -Lupin and Rotary Join Hands to Combat Tuberculosis in Mumbai -Lupin introduces generic hypertension drug in US -UBM India Pharma Awards 2015 -CNBC India Risk Management Awards -Lupin Ltd Acquires Biocom in Russia 2016 -Lupin Launches Generic Ortho Tri-Cyclenr Lo Tablets -Lupin gets USFDA nod for generic Generess tablets -Lupin Launches Generic Glumetzar HCI ER Tablets in the US -Lupin Completes its Acquisition of GAVIS -Lupin Launches Generic Intermezzor Sublingual Tablets in the US -Lupin Launches Generic Femhrtr Tablets in the US -Lupin Ltd has informed that the Registered Office of the Company shall be shifted from the present 159, C. S. T. Road, Kalina, Santacruz (East), Mumbai - 400 098 to Kalpataru Inspire, 3rd Floor, Off. Western Express Highway, Santacruz (East), Mumbai - 400 055 -Lupin receives EIR from US FDA for Goa, July 2015 Inspection -Lupin Launches Novel Injectable Iron Formulation Under Brand Names "ISOFER" and "JILAZO" in India 2017 - Lupin Launches Generic MS Continr ER Tablets in the US - Lupin Launches Generic Ortho-Cyclenr 28 Tablets in the US - Lupin Launches Generic Temovater Clobetasol Propionate Scalp Application in the US - Lupin Launches Generic Pristiqr Tablets in the US - Lupin launches Generic Paxil CRr tablets in the US - Lupin bags approval for Roxicodone tablets - Lupin gets USFDA approval for generic Crestor tablets 2018 -Lupin unveils generic Ancobon capsules in US. -Lupin bags approval for Tamiflu capsules. -Lupin gets USFDA nod to market its skin conditions cream. -Lupin launches Clobetasol Propionate Lotion. -Lupin launches ADHD treatment tablets in US market. -Lupin launches generic influenza treatment capsules in US. 2019 -Lupin gets USFDA nod to market hypothyroidism treatment drug. -Lupin launches generic antidepressant drug in US. -Lupin received approval from the US health regulator to market a generic version of Tadalafil tablets, used to treat pulmonary arterial hypertension. -Lupin launches generic Tadalafil tablets in US -Lupin launches seizures drug in US. -Lupin launches Minocycline Hydrochloride tablets in US. 2020 -Lupin's Pithampur facilities complete successful MHRA inspection. -Lupin launches generic arthritis relief tablet in US. -Lupin gets EIR from USFDA for Florida-based inhalation research centre. -Lupin gets EIR from USFDA for Nagpur plant. -Lupin receives USFDA approval for generic product. 2021 -Lupin gets USFDA nod to market generic anti-fungal cream in US market. -LupinLife launches ayurvedic energy supplement Be One. -Lupin launches Posaconazole delayed-release tablets. -Lupin launches generic drug to treat Wilson's disease in US mkt. -Lupin launches generic diarrhea drug in US market. 2022 -Lupin Receives Approval from U.S. FDA for Efinaconazole Topical Solution. -Lupin Launches its First Reference Laboratory in East India Establishing its Diagnostics Business in Kolkata. -Lupin Receives Approval from U.S. FDA for Vigabatrin for Oral Solution USP. -Lupin Completes Acquisition of Brands from Anglo-French. -Lupin Launches Merzeer Capsules in the United States. 2023 -Lupin Launches Softovac Liqui fibre, a first-of-its-kind liquid fibre."". -Lupin Launches Turqoz (Norgestrel and Ethinyl Estradiol) Tablets USP in theUnited States. -Lupin Launches Rocuronium Bromide Injection in the United States. -Lupin Launches Diazepam Rectal Gel in the United States. -Lupin inks pact to acquire 5 drug brands from Menarini for Rs 101 crore 2024 -Lupin and Slurrp Successfully Conclude Lupin Aptivate Achchi Bhookh Quiz. -Lupin Acquires Huminsulin from Lilly to Enhance Diabetes Portfolio. -Lupin Receives Approval from U.S. FDA for Emtricitabine and Tenofovir Alafenamide Tablets. -Lupin Acquires 3 Trademarks from Boehringer Ingelheim to Strengthen Diabetes Portfolio. -Lupin's R&D Facility in Pune Awarded LEED Platinum Certification. -Lupin Launches Bumetanide Injection, USP in the United States.

Parent Organisation

Lupin Ltd.

Founded

01/03/1983

Managing Director

Ms.Vinita Gupta

NSE Symbol

LUPINEQ

FAQ

The current price of Lupin Ltd is ₹ 2076.90. ₹ 2067.10.

The 52-week high for Lupin Ltd is ₹ 2115.90 and the 52-week low is ₹ 2053.20.

The market capitalization of Lupin Ltd is currently ₹ 94376.56. ₹ 94376.56. This value can fluctuate based on stock price movements and changes in the number of shares outstanding.

To buy Lupin Ltd shares, you need to have a brokerage account. First, choose a reputable brokerage firm, open an account, and complete the necessary KYC procedures.

To invest in Lupin Ltd, you need a brokerage account. After opening an account and completing the KYC process, you can fund your account and use the trading platform to purchase Lupin Ltd shares.

The CEO of Lupin Ltd is Ms.Vinita Gupta, who has been leading the company with a vision to expand its renewable energy portfolio and drive sustainable growth.

Sharekhan

Lupin Ltd

Lupin Ltd

Lupin Ltd

Lupin Ltd

Market Data

Essential tool: analyze, trade, manage, decide.

What’s Your Call?

Collective community sentiment on Lupin Ltd

Your Vote -

Market Depth

Buy Order Quantity

Sell Order Quantity

Option Chain

Analyzes market sentiment, predicts Lupin Ltd' movement.

News

Lupin Ltd. - Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS

Lupin Ltd. - Press Release

Lupin receives U.S. FDA approval for Tolvaptan Tablets

Lupin Ltd. - Announcement under Regulation 30 (LODR)-Press Release / Media Release

Lupin Ltd. - Press Release

Lupin Ltd. - Announcement under Regulation 30 (LODR)-Press Release / Media Release

Lupin Diagnostics secures NABL accreditation across all greenfield labs

Lupin Ltd. - Press Release

Lupin Ltd. - Announcement under Regulation 30 (LODR)-Press Release / Media Release

Lupin Ltd. - News Verification

Lupin Ltd. - The Company Has Informed The Exchange About Court Order In The Matter Of A Patent Case.

Lupin Ltd. - Pendency of Litigation(s)/dispute(s) or the outcome impacting the Company

Lupin Ltd. - Rumour Verification - Regulation 30(11)

Lupin Ltd. - Rumour verification - Regulation 30(11)

Lupin Ltd. - News Verification

Lupin Ltd. has submitted to BSE the Shareholding Pattern for the Period Ended March 31, 2025

Lupin Ltd. - Clarification sought from Lupin Ltd

Lupin Ltd. - Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure A

Lupin Ltd. - Certificate under SEBI (Depositories and Participants) Regulations, 2018

Lupin Ltd. - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018

Lupin Ltd. - Announcement under Regulation 30 (LODR)-Acquisition

Lupin Ltd. - Acquisition-XBRL

Lupin Ltd. - Acquisition

Lupin Ltd. - Update-Acquisition/Scheme/Sale/Disposal-XBRL

Lupin Ltd. - Slump Sale-XBRL

Lupin Ltd. - Announcement under Regulation 30 (LODR)-Restructuring

Lupin Ltd. - Other Restructuring

Lupin Ltd. - Announcement under Regulation 30 (LODR)-Restructuring

Lupin Ltd. - Other Restructuring

Lupin Ltd. - Board Meeting Outcome for Outcome Of The Board Meeting Held On March 31, 2025.

Lupin Ltd. - Outcome of Board Meeting

Lupin Ltd. - Trading Window-XBRL

Lupin Ltd. - Trading Window

Lupin Ltd. - Change in Directors/ Key Managerial Personnel/ Auditor/ Compliance Officer/ Share Transfer Agent

Lupin Ltd. - Retirement

Lupin Ltd. - Announcement under Regulation 30 (LODR)-Change in Management

Lupin Ltd. - Press Release

Lupin Ltd. - Announcement under Regulation 30 (LODR)-Press Release / Media Release

Lupin Ltd. - Announcement under Regulation 30 (LODR)-Press Release / Media Release

Lupin Ltd. - Press Release

Lupin Ltd. - Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS

Lupin Ltd. - Alteration Of Capital and Fund Raising-XBRL

Lupin Ltd. - ESOP/ESOS/ESPS

Lupin Ltd. - Shareholder Meeting / Postal Ballot-Scrutinizer\s Report

Lupin Ltd. - Shareholders meeting

Lupin Ltd. - Press Release

Lupin awarded EcoVadis silver medal for sustainability excellence

Lupin Ltd. - Announcement under Regulation 30 (LODR)-Press Release / Media Release

Lupin Ltd. - Update-Acquisition/Scheme/Sale/Disposal-XBRL

Lupin Ltd. - General Updates

Lupin Ltd. - Incorporation Of A Wholly Owned Subsidiary.

Lupin Ltd. - Press Release

Lupin Ltd. - Announcement under Regulation 30 (LODR)-Press Release / Media Release

Lupin launches Rivaroxaban Tablets USP, 2.5mg in the United States

Lupin Ltd. - Press Release

Lupin Ltd. - Announcement under Regulation 30 (LODR)-Press Release / Media Release

Lupin Ltd. - Alteration Of Capital and Fund Raising-XBRL

Lupin Ltd. - ESOP/ESOS/ESPS

Lupin Ltd. - Press Release

Lupin Ltd. - Announcement under Regulation 30 (LODR)-Press Release / Media Release

Lupin Ltd. - Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS

Lupin Ltd. - Announcement under Regulation 30 (LODR)-Press Release / Media Release

Lupin Ltd. - Press Release

Lupin Ltd. - Analysts/Institutional Investor Meet/Con. Call Updates